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Abstract: 
Introduction: Pigeon fanciers’ lung (PFL) is one of the most common forms of 
hypersensitivity pneumonitis (HP) in the UK. Generally it is considered that PFL is caused by 
immune complexes, however, this does not explain why some fanciers are asymptomatic 
despite the presence of high levels of anti-avian antigen antibodies in their serum. Pigeon 
intestinal mucin (PIM) is considered to be an important antigen in PFL. Thus this study was 
designed in order to understand the role of specific antibodies and T cells in the pathogenesis 
of PFL. 
Methods: Anti-avian IgG and IgG subclass responses among 50 symptomatic and 50 
asymptomatic pigeon fanciers were determined by ELISA and the functional affinity of IgG1 
and IgG2 against a range of pigeon antigens was determined by inhibition ELISA and 
microcalimetry. Mucin-specific T cell clones were also generated from pigeon fanciers and T 
cell phenotypes and cytokine profile of these cells were identified. 
Results: The median titres of IgG1 and IgG2 against all the pigeon antigens tested was 
always higher in asymptomatic than symptomatic fanciers and these differences were 
significant for anti-PS IgG1 (P=0.04), anti-PDF IgG2 (P=0.028), anti-PDO IgG2 (P=0.04) 
and anti-PIS IgG2 (P=0.03). The functional affinity of IgG1 and IgG2 against PDO was 
higher in symptomatic individuals as compared to asymptomatic fanciers (P=0.006 and 
P=0.002, respectively) whilst the functional affinity of anti-PDF IgG2 was also significantly 
higher in these patients (P≤0.001). Symptomatic fanciers were also significantly more likely 
to have high ΔH and thus had higher avidity antibodies against PDO (P=0.044). 12 T cell 
clones specific for t mucin also were generated from an asymptomatic fancier and 90-96% of 
clone 04, 22, 23 were CD4-CD8- double negative (DN). 
Conclusion: The data suggests that the magnitude of the serum antibody response cannot 
determine the development of the disease and as symptomatic fanciers had higher IgG 
antibody avidities and therefore immune complexes in individuals with PFL may have a 
stronger composition and bonds. In addition, this is the first demonstration of the use of ITC 
to measure antibody avidity in a clinical situation. This is a rapid and simple method of 
measuring antibody avidity and has a diagnostic potential in PFL. Finally t mucin-specific T 
cell clones with double negative phenotype may have a crucial role in immune regulation in 
asymptomatic fanciers and can be one of the reasons why these individuals do not have any 
symptoms in spite of having high antibody responses. 
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1: Introduction 
 
1.1: Hypersensitivity Pneumonitis: 
 
1.1.1: Definition: 
Hypersensitivity pneumonitis (HP) or extrinsic allergic alveolitis (EAA) is a group of 
inflammatory interstitial lung diseases resulting from hypersensitivity reactions after the 
repeated inhalation or ingestion of certain low molecular weight organic dusts or antigens 
derived from fungal, bacterial, animal protein or chemical sources (Fink et al., 1968; 
Kokkarinen, Tukiainen & Terho, 1993; Schuyler et al., 1997; Wahlstrom et al., 1997; 
Kurup, Zacharisen & Fink, 2006; Madison, 2008).  Provoking antigens associated with HP 
are usually less than 3 microns diameter which enable them to reach to the distal bronchial 
tree and alveoli in the lung where they may be transferred to the hilar nodes via the 
lymphatic system and therefore may induce an immune response including systemic IgG 
antibody production (Bourke et al., 2003). In contrast those antigens provoking asthma are 
larger and tend to be deposited in the proximal airways, stimulating an IgE response in 
atopic individuals (Calvert et al., 1999). However, even larger antigens may be able to 
reach the distal airways and alveoli after degradation and dissolving in lung secretions.  
Less than 10% of the individuals exposed to provoking antigens may develop HP (Bourke 
et al., 2003). In susceptible subjects hypersensitivity responses may result in a diffuse 
inflammation of the lung parenchyma and granulomatous inflammation of the distal 
bronchioles and alveoli (Fink, 1992; Kaltreider, 1993; Selman, 2004). 
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1.1.2: Epidemiology:  
Prevalence rates of HP are different throughout the world (Bourke et al., 2001). Different 
factors including climate, geographical conditions, smoking habit, local customs and 
working practices have been suggested to influence the prevalence rates (Terho, Husman 
& Vohlonen, 1987; Bourke et al., 2001; Takahashi et al., 2002; Fink et al., 2005; 
Solaymani-Dodaran et al., 2007). 
Overall the annual incidence of interstitial lung disease has been estimated to be 30:100000 
in the general population with HP accounting for almost 2% of these cases (Coultas et al., 
1994; Bourke et al., 2003). The incidence rate of HP was reported as approximately 
1:100000 in the UK per year between 1991 and 2003, and therefore about 600 new cases 
of HP may occur each year in the UK (Solaymani-Dodaran et al., 2007). Among different 
forms of HP, bird fanciers’ lung was reported as one of the most common forms in the UK 
due to the popularity of keeping budgerigars (Bourke et al., 2003) and the prevalence has 
been estimated to be 0.5-7.5% among bird owners (Hendrick, Faux & Marshall, 1978; 
Judson & Sahn, 2004). There are 80000 registered pigeon fanciers in the UK (McSharry et 
al., 2006a) and 5-6 million homes in Britain harbour budgerigars. Thus Hendrick et al 
suggested that budgerigar lung may be the most common type of HP in the UK (Hendrick, 
Faux & Marshall, 1978). On the other hand, the prevalence of pigeon fanciers’ lung (PFδ) 
was estimated to be 20-20000 cases per 100000 populations at risk in the US (Sharma, 
2006). 
 Another form of HP is farmer’s lung with an estimated prevalence of 10-200:100000 in 
population at risk in England (Staines & Forman, 1961) and more recently 420-3000 cases 
per 100000 populations at risk in the US (Sharma, 2006). 
The prevalence of farmer’s lung in exposed populations in some other European countries 
has been estimated at between 0.5- 3% (Lacasse & Cormier, 2006) depending on climatic 
19 
 
conditions and farming practice in harvesting and storage of hay and crops (Dalphin et al., 
1991). 
 
 
 
 
 
1.1.3: Aetiology: 
Over the last 3-4 decades a number of different antigens have been identified as causative 
antigens and provocative materials for HP (Fink, 1992; Guillon et al., 1992; Kaltreider, 
1993; Apostolakos, Rossmoore & Beckett, 2001; Bourke et al., 2003; Kurup, Zacharisen & 
Fink, 2006; Lacasse & Cormier, 2006).   
There are large number of different forms of HP and causative antigens and a number of 
them are shown in Table 1.1.  
 
 
 
 
 
 
 
 
 
 
 
20 
 
Disease Source of Exposure Antigens 
 
Animal handler lung 
 
 
Urine, serum, fur 
 
Animal proteins 
 
Bagassosis 
 
 
Mouldy bagasse (pressed 
sugarcane) 
 
Bacteria (Thermophilic 
actinomycetes saccharii, 
Thermoactinomyces vulgaris) 
 
 
Basement shower HP 
 
 
Mouldy basement shower, 
mouldy home 
 
 
Epicoccum nigrum, Fusarium 
napiforme 
 
Bird breeder lung such as 
pigeon fanciers’ lung ȋPFLȌ 
 
 
Bird droppings and feathers 
 
Avian glycoproteins 
 
Cheese washer lung 
 
 
Cheese casings 
 
Fungus (Penicillum casei or 
P.roqueforti) 
 
 
Chemical worker’s lung 
 
Manufacture of plastics, 
polyurethane foam, rubber 
 
 
Trimellitic anhydride, 
Diisocyanate, Methylene 
diisocyanate 
 
 
Coffee worker’s lung 
Tea grower’s lung 
 
 
Coffee bean dust, Tea leaves  
 
Coffee and tea dust 
 
Compost HP 
 
 
Compost 
 
Fungus (Aspergillus) 
 
Drug-induced HP 
 
 
Medication 
 
Amiodaron, Gold, Minocycline 
Hydrocholoride, Clozapine,  
Nitrofurantoin,  Fluoxetine, 
Beta blockers, Procarbazine, 
Cyclosporine 
 
 
Dry rot HP 
 
 
Mouldy rotten wood 
 
Fungus (Merulius lacrymans) 
 
El Nino lung 
 
Mouldy home from flooding 
 
Pezizia domiciliana 
 
Table 1.1: Some of the various types and the causative antigens of hypersensitivity 
pneumonitis (HP); Toluene diisocyate (TDI), Hexamethylene diisocyate (HDI), 
Methyenediphenyl diisocyate (MDI) and Trimelitic anhydride (TMA) (Fink, 1992; Guillon 
et al., 1992; Kaltreider, 1993; Apostolakos, Rossmoore & Beckett, 2001; Bourke et al., 
2003; Kurup, Zacharisen & Fink, 2006; Lacasse & Cormier, 2006). 
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Enzyme/detergent worker’s 
lung 
 
Enzyme dust, contaminated 
house dust 
 
 
Bacteria (Bacillus subtilis) 
 
Esparto grass HP 
 
 
 
Mouldy esparto used to produce 
ropes, canvas, sandals, mats, 
baskets, and paper paste; 
 
Fungus (Aspergillus fumigatus) 
 
Farmer's lung  
 
 
 
Mouldy hay 
 
Bacteria (Thermophilic 
actinomycetes, 
Saccaropolyspora rectivirgula) 
 
Fungus (Aspergillus species) 
 
 
Floor finisher’s lung 
 
 
Mouldy wood floor 
 
Cephalosporium acremonium 
 
Grain handler’s lung 
 
 
Mouldy grain 
 
Saccharopolyspora  
rectivirgula, 
Thermoactinomyces  vulgaris 
 
Greenhouse HP 
 
 
 
Mouldy soil 
 
Fungi (Aspergillus sp., 
Penicillium sp., Cryptostroma 
corticale) 
 
 
Hot tub HP 
 
 
Mist from hot tubs 
 
Bacteria (Mycobacterium avium 
complex) 
 
 
Humidifier lung 
 
 
 
 
 
 
 
 
Mist from standing water 
 
Bacteria (Thermoactinomyces 
candidus, Bacillus subtilis, 
Bacillus   cereus, Klebsiella 
oxytoca)  
Fungus (Aureobasidium 
pullulans ) 
Amoebae (Naegleria gruberi, 
Acanthamoeba polyhaga, 
Acanthamoeba castellani) 
 
 
Isocyanate HP 
 
 
Paints, resins, polyurethane 
foams 
 
TDI, HDI, MDI  
 
 
Japanese summer-type HP 
 
 
 
Damp wood and mats 
 
 
Fungus (Trichosporon 
cutaneum, Cryptococcus 
albidus, 
 Trichosporon  ovoides) 
 
 
Lifeguard lung 
 
 
Indoor swimming pool 
 
Bacteria (Endotoxin) 
Table 1.1: Continued. 
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Lycoperdonosis 
 
 
Puff ball spores 
 
Lycoperdon puff balls 
 
Malt worker lung 
 
 
Mouldy barley 
 
Fungus (Aspergillus clavatus) 
 
Maple bark HP 
 
 
Mouldy wood bark 
 
Fungus (Cryptostroma 
corticale) 
 
 
 
Metalworking fluids HP 
 
 
 
Mist from metalworking fluids 
 
 
Bacteria (Mycobacterium 
immunogenum,  
Pseudomonas fluorescens, 
Acinetobacter  lwoffili) 
 
 
Mollusc shell HP 
 
 
Mollusc shell dust 
 
Aquatic animal proteins 
 
Mushroom worker lung 
 
 
Mushroom compost  
 
Bacteria (Thermophilic 
actinomycetes) 
 
 
Oyster shell lung 
 
 
Shell dust 
 
Oyster shell proteins 
 
Paprika splitter’s lung 
 
 
Paprika dust 
 
Fungus (Mucor stolonifer) 
 
Pauli’s (P 
 
 
Laboratory reagent 
 
Pauli’s reagent 
 
Peat moss HP 
 
 
Peat moss 
 
Fungi (Monocillium sp,  
 
Penicillium citreonigrum) 
 
Pituitary snuff user’s lung 
 
 
Heterologous pituitary snuff 
 
Bovine and porcine proteins 
 
Salami worker’s lung 
 
 
Salami seasoning 
 
Penicillium camembertii, 
Penicillium nalgiouense, 
Penicillium          chrysogenum 
 
 
Saxophonist’s lung 
 
 
Mouldy reed 
 
Candida species 
 
Sequoiosis 
 
 
Mouldy wood dust 
 
Fungi (Graphium species,  
 
Pullularia species) 
 
Table 1.1: Continued. 
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Silk production HP 
 
 
Silk worm larvae 
 
Silk worm larvae proteins 
 
Soy sauce brewer lung 
 
 
Fermentation starter for soy 
sauce 
 
Fungus (Aspergillus oryzae) 
 
Suberosis 
 
 
Mouldy cork dust 
 
Fungus (Penicillum 
frequentans) 
 
 
 
TMA HP 
 
 
 
Plastics, resins, paints 
 
 
Trimellitic anhydride 
 
Tobacco worker lung 
 
 
Mouldy tobacco 
 
Fungus (Aspergillus sp.) 
 
Tree cutter lung 
 
Wood chips from living maple 
and oak trees 
 
Fungi (Penicillium (three 
species), Paecilomyces sp., 
Aspergillus niger, Aspergillus 
sp., Rhizopus sp.) 
 
 
 
Wheat weevil HP 
 
 
Infested flour 
 
Wheat weevil (Sitophilus 
granarius) 
 
 
Wine grower’s lung 
 
 
Mouldy grapes 
 
Botrytis cinerea 
 
Wood pulp worker lung 
 
 
Mouldy wood pulp 
 
Fungus (Alternaria species) 
 
 
Wood trimmer lung 
 
 
 
 
Mouldy wood trimmings 
 
 
Fungus (Rhizopus species) 
 
Table 1.1: Continued.  
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1.1.4: Host and Environmental Factors: 
The prevalence and incidence of HP seems to be less than 10% in population at risk, in 
spite of the large number of individuals who have contact with the causative antigens 
(Bourke et al., 2003; Fink et al., 2005). This may be due to various environmental and host 
cofactors such as duration and frequency of antigen exposure, the size of the antigenic 
particle, amount of rainfall, human leukocyte antigen (HLA) type, tumor necrosis factor-α 
(TNF-α) promoter gene polymorphisms and cytokine receptor mutations (Fink, 1992; 
Schaaf et al., 2001; Schuyler, 2001; Fink et al., 2005). The use of respiratory masks in the 
work environment may also influence the prevalence, onset and severity of HP (Bourke et 
al., 2003). It may reduce the level of circulating antibodies because of less exposure to 
provoking antigens. However, it may be difficult for many people to keep the mask on 
under strenuous physical activities (Bourke et al., 2003). It has been suggested that intense 
and intermittent antigen exposure in a susceptible individual usually results in an acute 
onset of disease whilst prolonged low level exposure causes chronic HP (Kaltreider, 1993; 
Perez-Padilla et al., 1993; Calvert et al., 1999; Bourke et al., 2001; Irifune et al., 2003). 
The best example of this can be seen in PFL and budgerigar’s lung in the UK. Low grade 
and prolonged exposure to the antigen tends to lead to the development of the chronic form 
of HP as mostly seen in budgerigar fanciers (Tanaka et al., 1995; Calvert et al., 1999; 
Bourke et al., 2003). On the other hand, intermittent high exposure to the bird antigens 
tends to result in the development of recurrent episodes of acute disease. Acute disease is 
mostly experienced by pigeon fanciers in the UK who typically keep 100-200 pigeons in a 
loft (Bourke & Boyd, 1997). This is accompanied with higher specific antibody titres 
during the pigeon sporting season in late summer and shedding feathers in the autumn 
(Dalphin et al., 1993; Tanaka et al., 1995; Bourke et al., 2003).  A seasonal variation was 
also suggested to be important in farmer’s lung. During rainy summers, stored damp hay 
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starts moulding which generate heat. This facilitates microbial proliferation and growth of 
Thermophilic actinomycetes and therefore farmer’s lung is most commonly seen in late 
winter (Takahashi et al., 2002; Bourke et al., 2003).  Summer type Japanese HP is another 
example of seasonal variation in the incidence of HP. This form of HP accounts for almost 
74% of all HP cases in Japan (Ando et al., 1991; Ohtani et al., 2000) and mainly appears 
during summer and mid-autumn when fungal growth in older wooden homes is stimulated 
by warm and moist air (Miyagawa, Hamagami & Tanigawa, 2000). 
Furthermore, it has been well established that other cofactors such as the presence of an 
additional lung inflammation and host smoking habit may also have some effect on the 
interaction between the relevant antigen and the host immune response (Kalra et al., 2000; 
Lahmouzi et al., 2000; Al-Ghamdi & Anil, 2007).  
Concomitant infection with various micro-organisms may enhance lung responses to the 
causative antigen in a sensitized subject resulting in the development of HP (Dakhama et 
al., 1999a; Cormier & Israel-Assayag, 2000). This may explain the reason of developing 
the disease after having contact with the causative antigen for many years. For instance, 
Cormier et al (1996) reported that Sendai virus infection in mice exposed to HP antigens or 
Saccharopolyspora rectivirgula may enhance their responses to them (Cormier et al., 
1996; Cormier & Israel-Assayag, 2000). They suggested that viral infection is generally 
the modulator of immune responses, as it will increase the antigen presenting capacity of 
alveolar macrophages, decreases phagocytosis and antigen clearance, and induces the 
proliferation of T helper1 lymphocytes. Dakhama et al showed that Influenza A viruses 
were positive in the nasopharyngeal secretions of the majority of patients with HP in their 
study group (Dakhama et al., 1999b). They suggested the important role of the lung 
inflammation caused by this virus on development of HP following antigen exposure. 
Finally additional lung inflammation due to Mycoplasma pneumoniae, Chlamydia psittaci, 
26 
 
and Bacille Calmette-Guerin (BCG) has been also suggested to influence the development 
of HP (Moore, Hensley & Fink, 1975; McGavin, 1986; Bourke et al., 1992). 
Smoking habits of individuals may also influence the host immune response.  It has been 
reported that smoking cigarette influences antigen presentation and antibody production, 
inhibits lymphocyte (Kalra et al., 2000) and fibroblast proliferation (Lahmouzi et al., 2000) 
and also compromises the function of natural killer cells (Mian et al., 2007). There is also a 
decrease in the secretion of interleukin-1 (IL-1), IL-6, IL-12, interferon- Ȗ (IFN-Ȗ) and 
TNF-α (McCrea et al., 1994; Sauty et al., 1994; Matsunaga et al., 2001). This may reduce 
antibody responses and affects macrophage function which decreases the risk of HP 
(Baldwin et al., 1998b; Blanchet, Israel-Assayag & Cormier, 2004). 
Host factors may also influence the prevalence, latency and severity of HP (Fink et al., 
2005). Overall HP has been reported to be more common in males than females although 
PFL particularly affects females in Mexico since they keep pigeons in their homes and 
Mexican females spend more time at home (Perez-Padilla et al., 1993). HP has been 
diagnosed in all ages including infants and children and 25% of affected children have a 
positive family history of HP which may indicate a link between genetic predisposition and  
HP or  suggest exposure to the same provoking antigen (Fan, 2002; Ratjen et al., 2003). 
Furthermore, several studies have indicated that genetic differences between individuals 
could be important in the occurrence and outcome of disease. The link between a particular 
HLA and HP has been supported by increased presence of HLA- DR7 in PFL in Mexican 
population (Selman et al., 1987), HLA- Bκ in farmer’s lung and PFδ in Caucasians (Rodey 
et al., 1979), HLA- DQw3 in Japanese summer- type HP (Ando et al., 1989), HLA-
DRB1*1305 and HLA-DQB1*0501 alleles in PFL (Mohr, 2004), and HLA-DRPhe47 in 
beryllium HP (Amicosante et al., 2005). For instance, Mexican pigeon fanciers with HLA-
DR7 tend to develop lung fibrosis with a poor prognosis whilst HP usually has a benign 
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clinical course in Caucasian populations (Chapela-Mendoza & Selman-Lama, 1999). There 
is some discussion on the role of genetic factors and the influence of environmental factors 
in HP. However, it is believed that HLA type may play an important role in binding and 
presentation of relevant antigen to T cell receptor (TCR) (Sospedra et al., 2006). It has also 
been suggested that the balance between proteolytic and antiproteolytic processes in the 
extracellular matrix of an individual’s lung is very important and polymorphisms in tissue 
inhibitors of metalloproteinases 3 (TIMP-3) may influence the susceptibility to idiopathic 
pulmonary fibrosis and PFL (Hill et al., 2004). Matrix metalloproteinases (MMPs) are 
highly regulated zinc dependent proteinases with an important role in turnover of the 
extracellular matrix which is vital in maintenance of the lung structure. They are induced 
during inflammatory responses and TIMP inhibits these proteinases in order to prevent 
excessive tissue damage (Ho et al., 2008). Recently it has been shown high levels of 
TIMP-3 are produced by peripheral blood mononuclear cells of asymptomatic pigeon 
fanciers (Lee, 2008).  
Finally, other combinations of polymorphisms of different genes may also influence the 
susceptibility to particular diseases. For instance, gene polymorphisms in TNF- α promoter 
with an increased frequency of TNF-2-308 allele in patients with HP were reported 
(Camarena et al., 2001; Schaaf et al., 2001; Schuyler, 2001). Since TNF-α is one of the 
more important mediators in HP, this polymorphism may be helpful to predict the 
susceptibility of individuals to HP.  
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1.1.5: Immunopathogenesis: 
HP is defined as an inflammatory interstitial lung disease resulting from hypersensitivity 
immune reactions against a range of antigens. This is a complex process which involves 
both arms, cellular and humoral, of the immune response (Kaltreider, 1993). 
Initially it was reported that HP was an immune complex mediated disease but 
subsequently studies have shown that T cells are important in the pathogenesis of disease 
and it has been suggested that the inflammatory cytokines may have even greater roles to 
play in the pathogenesis of disease than immune complexes (Moore et al., 1974; Fink, 
Moore & Barboriak, 1975; Schuyler, Thigpen & Salvaggio, 1978; Curtis et al., 1991; 
Ohkawa et al., 2001). 
In humans following antigenic stimulation of the respiratory tract, foreign antigens are 
engulfed by alveolar macrophages and subsequently these cells express high levels of class 
II MHC and the co-stimulatory B7 molecules which helps to transport antigens to the cell 
surface and to present the complex of MHC/antigen to T helper (Th) cells (Gordon et al., 
1995; Kaneko et al., 2000; Desombere et al., 2005). Following interaction between TCR 
and these complexes, Th cells become activated and produce inflammatory cytokines after 
interaction with B cells. As a consequence, B cells start dividing and differentiating into 
plasma cells which secrete antibodies (Jenkins et al., 2001). These interactions are 
explained in more detail in chapters 4 and 5.  
There is a number of animal models of HP using various animal species such as rats, 
rabbits, guinea pigs, mice, primates and calves (Fink et al., 2005). Schyler et al (1997) 
were able to adoptively transfer experimental HP by intravenous injection of a T helper 1 
(Th1) cell line that produced high levels of IFN- and low level of IL-4 to naive recipient 
mice (Schuyler et al., 1997). In a further study the role of cytokines such as IFN-was 
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emphasized as an essential factor for the development of granulomatous inflammation in 
IFN- (-/-) mice (Gudmundsson & Hunninghake, 1997).   
The reaction between antigen and antibody produces immune complexes (IC), which may 
become deposited in the basement membrane of the lungs and these will then activate the 
complement cascade by the classical pathway (Cunningham & Quigg, 2005; Wasowska et 
al., 2007). In addition to this, antigens associated with HP may provoke lung inflammation 
directly via activating complement through the alternative pathway together with 
stimulating alveolar macrophages (Berrens, Guikers & van Dijk, 1974; Calvert et al., 1999; 
Bourke et al., 2001). 
Complement activation leads to cell lysis, mast cell activation and neutrophil, monocyte 
and natural killer (NK) cell recruitment. It has also been suggested that pulmonary 
macrophages have an important role in the pathogenesis of disease. They secrete IL-8, a 
chemotactic factor for neutrophils, and macrophage inflammatory protein (MIP)-1α which 
is a chemotactic factor for CD8+ T cells (Denis, 1995; Kurup, Zacharisen & Fink, 2006). 
Neutrophils attracted to the site of inflammation try to phagocytose the IC deposited in the 
lung wall and also release lytic enzymes causing localized tissue damage. A transient 
neutrophilic alveolitis accompanies the symptoms of the acute phase of HP (Reynolds et 
al., 1993; Razin, Pecht & Rivera, 1995). 
Subsequently there is an influx of activated T cells with a predominance of CD8+ T cells 
(Kurup, Zacharisen & Fink, 2006) which can modulate granuloma formation. It has been 
suggested that CD8+ T cells may have a protective effect on the progress of pulmonary 
fibrosis (Costabel et al., 1984; Murayama et al., 1993). After long term exposure to the 
antigen and during the chronic phase of HP, there is an increase in activated CD4+ T cells 
(Barrera et al., 2008). These CD4+ T cells can be divided into Th1 or Th2 subset based on 
their pattern of cytokine secretion (Irifune et al., 2003). Th1 cells secrete IL-2, IFN- and 
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TNF- which help in activating resting macrophages, increase their phagocytic activity and 
are essential for development of disease (Nance et al., 2005). Th2 cells secret IL-4, IL-5, 
IL-6 and IL-10 which can activate B cells to produce antibodies and promote mast cell 
maturation and proliferation (Abbas, Murphy & Sher, 1996). Regulatory cytokines such as 
IL-10 may down regulate the inflammatory responses (Mosmann et al., 1986; Schuyler et 
al., 1997). During the chronic stage of HP the levels of IL-6 and TNF-α are higher as 
compared to the acute stage which emphasizes the importance of these cytokines in the 
development of pulmonary fibrosis (Needleman, Wigley & Stair, 1992; Ohtani et al., 
1999). On the other hand, the release of lytic enzymes from activated macrophages can 
cause a non-specific tissue damage and formation of granulomatous lesions (Squier & 
Cohen, 1994; Kinet, 1999). 
Further studies have been carried out in HP to understand the pathogenesis of disease. The 
presence of IgM rheumatoid factor (RF) is a frequent finding in HP (Martinez-Cordero, 
Negrete-Garcia & Mendoza, 1992; Aguilar Leon, Novelo Retana & Martinez-Cordero, 
2003; Araiza et al., 2007) suggesting IgM RF producing B cells may influence T cell 
activation and induce antibody differentiation and isotype switching of immunoglobulins 
(Araiza et al., 2007). High levels of nerve growth factor (NGF) have been found in culture 
of lymphocyte from pigeon fanciers. NGF can be secreted by lymphocytes and mast cells 
which shows a potential route between airway inflammation and production of this factor 
(McSharry et al., 2006a).  
Furthermore, the tracheobronchial mucociliary system is also very important in the 
clearance of inhaled antigens and it has been suggested that mucociliary clearance is 
compromised in symptomatic pigeon fanciers (Hasani et al., 1992). Finally, other cell 
populations have also been recovered from bronchoalveolar lavage (BAL) fluid in patients 
with PFL. Natural killer T (NKT) cells were recovered in increased numbers in BAL fluid 
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which are able to induce Th1 mediated immune response (Korosec et al., 2007) and also 
high numbers of Ȗį-T cells have been recovered in BAL fluid in PFL although their roles 
are not fully understood (Raulf et al., 1994). 
In summary, HP is a complex disease and both cellular and humoral aspects of immune 
system are involved in the immunopathogenesis of disease.  T cells, macrophages and NK 
cells together with different inflammatory cytokines and specific antibodies may contribute 
to protective immunity. However, many unsolved problems remain to be investigated in 
the pathogenesis of HP. 
 
  
 
1.1.6: Clinical Presentation: 
The clinical features of HP depend on the antigenicity and size of the antigen together with 
the frequency and intensity of antigen exposure and the amount of immunological response 
of host (Kaltreider, 1993; Calvert et al., 1999; Bourke et al., 2001; Irifune et al., 2003). 
Clinically HP can be classified as acute, subacute and chronic disease. 
Acute disease has a recurrent episodic nature and usually occurs within 4 to 8 hours after 
high level of exposure to the relevant antigen in a susceptible individual (Kaltreider, 1993). 
A flu-like syndrome starts abruptly with fever, chills, malaise, myalgia, severe dyspnoea, 
chest tightness and dry cough. Findings during physical examination of patients consist 
with fever, tachypnoea, cyanosis and basilar crackles in the lungs (Kaltreider, 1993; 
Bourke et al., 2001). Between attacks the patient may be completely normal (Kaltreider, 
1993; Kurup, Zacharisen & Fink, 2006). 
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The subacute form of HP is due to low level of exposure to the antigen and is more 
insidious. The progressive respiratory symptoms develop over weeks with hypoxemia and 
crackles in the lungs (Kurup, Zacharisen & Fink, 2006). 
Chronic HP usually occurs as a result of continuous and prolonged low level exposure to 
the provoking antigen resulting in  progressive, irreversible and debilitating fibrotic lung 
disease in susceptibility individuals with insidious onset (Kaltreider, 1993; Irifune et al., 
2003). As a consequence of interstitial inflammation and lung fibrosis the patient develops 
increasing dyspnoea, fatigue, anorexia, cough and general weight loss. During physical 
examination restricted ventilation, basilar crackles in the lungs and signs of right sided 
heart failure (Bourke et al., 2001; Patel, Ryu & Reed, 2001; Schuyler, 2002) may be seen. 
 
 
 
1.1.7: Laboratory Features: 
Routine laboratory tests for HP are often non-specific and no single laboratory test is 
diagnostic. There may be a neutrophilic alveolitis during acute episodes of disease 
(Navarro et al., 2006; Yoshikawa et al., 2006), whilst the bronchoalveolar lavage (BAL) 
fluid may be normal in chronic disease (Mohr, 2004). There is also a polyclonal increase in 
immunoglobulin level in HP, as shown by serum protein electrophoresis (Kaltreider, 
1993).  
It has been reported that KL-6 is significantly higher in the serum samples of individuals 
with PFL (McSharry et al., 2006b). KL-6 is a high-molecular-weight sialoglycoprotein 
secreted by proliferating alveolar type 2 epithelial cells which indicate lung inflammation 
in interstitial lung disease. 
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1.1.7.1: Serologic Studies: 
Specific serum precipitating IgG antibodies against the provoking antigen indicates intense 
exposure and are usually detectable in individuals with HP  (Lacasse et al., 2003; Morris, 
2003; Kampfer et al., 2005; McSharry et al., 2006b). IgG antibody against pigeon serum 
antigens has been quantified in pigeon fanciers by automated fluorimetry and levels above 
10 mg/L were associated with disease (McSharry et al., 2006b). However, precipitating 
antibodies are also present in 50% of asymptomatic susceptible individuals exposed to the 
relevant antigen (Kaltreider, 1993; Baldwin et al., 1998c).  
A positive Arthus Reaction can also be induced by a subcutaneous injection of the purified 
antigen which indicates the sensitization of B cells and T cells (Kaltreider, 1993; Calvert et 
al., 1999). 
Another serological finding is positive rheumatoid factor in PFL which seems to be the 
result of hypergammaglobulinemia and immune complex formation (Roosnek & 
Lanzavecchia, 1991). Positive RF reported in 52.8% of individuals with PFL and 4.2% of 
asymptomatic pigeon fanciers which can be useful together with high anti-avian antibodies 
in differentiating the diagnosis of disease (Aguilar Leon, Novelo Retana & Martinez-
Cordero, 2003). A possible pathogenic role of RF in HP has been suggested with immune 
complex formation and complement activation enhancing the inflammatory reaction (Leon 
et al., 2002). 
  
 
 
 
 
 
34 
 
1.1.7.2: Radiological Findings: 
A chest radiograph in acute HP may be either normal or reveal various degrees of 
reticulonodular infiltration and consolidation and ground glass attenuation at the middle 
and base of both lungs (Fink, 1992). Figure 1.1 shows patchy airspace consolidation 
throughout both lungs in a case of acute HP.  
A chest radiograph in chronic HP shows irregular linear opacities, bronchiectasis, 
bronchitis, diffuse interstitial fibrosis and honey comb appearance in 50% of the cases and 
progressive reduction in lung volume (Bourke et al., 2003; Fink et al., 2005).  Emphysema 
is another finding in chronic HP and it has been suggested that proteolytic enzymes 
produced by pathogens in organic dust may be a cause for development of the disease 
(Erkinjuntti-Pekkanen et al., 1998). Figure 1.2 shows a chest X-Ray of a chronic HP with 
honey comb pattern and lung volume reduction in the base of both lungs.  
High resolution computed tomographic scanning (HRCT) of the chest in acute HP is a 
sensitive method for the early detection of interstitial changes (Muller & Miller, 1990). 
Figure 1.3 shows patchy areas of consolidation and ground-glass attenuation in both lungs 
in acute HP.  
Micronodular infiltration and ground glass opacifications with interlobular septal 
thickening together with lobular areas with decreased attenuation, vascularity, centrilobular 
nodules, and absence of abnormalities in lower zone in HRCT represent a chronic type of 
HP (Silva et al., 2008) (Figure 1.4). 
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Figure 1.1: Acute hypersensitivity pneumonitis in a 36-year-old woman who presented 
with severe cough and dyspnoea. Chest radiograph shows diffuse small nodules (arrows) 
and normal lung volumes (Matar, McAdams & Sporn, 2000) 
 
 
 
 
 
 
 
Figure 1.2: Chest radiograph of a chronic type of hypersensitivity pneumonitis with lung 
fibrosis. Honey comb pattern and lung volume reduction in the base of both lungs (Matar, 
McAdams & Sporn, 2000) 
 
bilateral coarse reticulonodular 
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Figure 1.3: High-resolution CT (HRCT) in a 40 years old woman with pigeon fanciers’ 
lung; scan shows patchy areas of consolidation and scattered ground-glass attenuation in 
both lungs and well-defined centrilobular nodules (Matar, McAdams & Sporn, 2000). 
 
 
 
 
 
 
 
 
 
 
Figure 1.4:  HRCT in chronic HP shows basal honey combing, traction bronchiectasis and 
architectural distortion (Matar, McAdams & Sporn, 2000). 
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1.1.7.3: Pulmonary Function: 
Pulmonary function tests may show a restrictive pattern of disease with reduced lung 
compliance in HP. This test reveals a decreased lung volume, vital capacity, and total lung 
capacity and an elevated residual volume (Bourke et al., 2003). There is also a reduction in 
transferring of carbon monoxide (TL CO) in the lungs which is a sensitive measurement in 
detecting acute HP (Kokkarinen, Tukiainen & Terho, 1993; Bourke et al., 2003).  
Moderate hypoxia and mild hypocarbia may be detectable during the acute presentation of 
HP but return to normal between acute episodes (Kaltreider, 1993). Another measurement 
that can be useful in detection of lower respiratory tract inflammation and alveolitis is 
measurement of exhaled nitric oxide (NO) concentration which increases in alveolitis 
(Lehtimaki et al., 2001). 
 In chronic disease, after establishment of interstitial fibrosis, the abnormalities in 
pulmonary function test are progressive and show a severe restrictive pattern (Allen, 1976).   
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1.1.7.4: Broncho-alveolar Lavage: 
BAL may help to reveal the presence of lymphocytic and neutrophilic infiltrations of the 
interstitium and alveoli in HP. It has been reported that the presence of 30% lymphocytes 
in the BAL fluid cell profile of non-smokers and 20% in smokers can be used as a 
diagnostic sign in individuals with a history of exposure to provoking antigens (Sterclova 
et al., 2006).  
Analysis of BAL fluid in pigeon breeders 6 hours after inhalation challenge with pigeon 
antigen (pooled pigeon serum) revealed a significant increase in neutrophils (Reynolds et 
al., 1993; Ohtani et al., 2000). Neutrophil number decreases with time and they are 
gradually replaced by lymphocytes (Kurup, Zacharisen & Fink, 2006). Up to 80% of the 
cells recovered by BAL are lymphocytes with majority being CD8+ T cells in acute HP, 
causing an inversion of the CD4+/CD8+ ratio (Pardo et al., 2000; Kurup, Zacharisen & 
Fink, 2006). The CD4+/CD8+ ratio in normal lung varies by age, for instance the ratio is 
0.7 in children at 3-16 years old, 2.7 in young adult and 7.6 at age of 64-83 (Grigg & 
Riedler, 2000). Different pulmonary diseases may have different CD4+/CD8+ ratios. For 
instance the CD4+/CD8+ ratio is elevated in sarcoidosis (Reichenberger et al., 2007), 
bronchiectasis due to mustard gas inhalation (Emad & Emad, 2007) and idiopathic 
pulmonary fibrosis (Tabuena et al., 2005), and lower in asthma (Marguet et al., 1999). 
Sterclova M et al (2006) reported that there is a correlation between the continuous and 
intense exposure to the antigenic dusts in HP and the low CD4+/CD8+ ratio in BAL fluid. 
This could be due to the protective effect of CD8+ T cells against pulmonary fibrosis since 
it is believed that CD4+ T cells may have an important role in the pathogenesis of 
pulmonary fibrosis (Murayama et al., 1993; Sterclova et al., 2006). 
 Recently NKT cells have been identified as a unique subset of T cells with 
immunoregulatory function (Korosec et al., 2007) and they have been recovered from BAL 
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fluid of patients suffering from HP suggesting these cells may be involved in the 
pathogenesis of HP (Korosec et al., 2007). They produce large amount of various 
cytokines including IL-4 and IFN-Ȗ, and it has suggested that they play an important role in 
the induction of protective CD8+ T cells and the homeostatic proliferation of these cells 
(Ueda et al., 2006). 
 
 
 
 
1.1.7.5: Inhalation Provocation Studies: 
Inhalation provocation studies are a procedure used to definitively establish the role of a 
particular causative antigen in HP (Hage-Hamsten et al., 2007). This challenge usually 
induces a transient inflammation without long term complications and has been used for 
clinical and research purposes in the past by experienced investigators (Fink et al., 2005). 
Safety precautions are important and the challenge with suspected antigen is conducted at 
the hospital, laboratory or workplace. 
A highly purified suspension of suspected antigen is given as an inhalation challenge in 
order to limit the chance of any nonspecific irritant contamination to minimum. The 
clinical and laboratory responses such as blood count, PaO2 and pulmonary function tests 
are recorded. The reproduction of the signs and symptoms of acute HP in about 4-6 hours 
after the challenge should be considered as a positive response and this proves a strong 
relationship between the suspected antigen and acute HP, suggesting the important role of 
immune complexes, complement and neutrophils during disease (Kaltreider, 1993). 
For instance, pooled pigeon sera has been used by Ramirez-Venegas et al (1998) for 
inhalation challenge in an open space (hospital yard) through a jet nebulizer (Ramirez-
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Venegas et al., 1998). Also Ohtani et al (2000) have used fresh avian droppings extracts to 
carry out inhalation test through a hand nebulizer for their study subjects (Ohtani et al., 
2000). Inhalation provocation tests have also been useful in other diseases such as asthma 
(Brannan et al., 2005). 
 
 
 
 
1.1.7.6: Lung Biopsy: 
Lung biopsies can be carried out either as transbronchial (through bronchus) biopsy or 
open lung biopsy, nevertheless requesting an open lung biopsy must be balanced against a 
patient’s morbidity (Lacasse & Cormier, 2006). 
Acute HP is characterised by infiltrations of lymphocytes, plasma cells and 
polymorphonuclear leukocytes in alveolar walls together with oedema and poorly formed 
granuloma (Perez-Padilla et al., 1993; Fink et al., 2005; Lacasse & Cormier, 2006) (Figure 
1.5). 
A lung biopsy in a chronic HP reveals intense peribronchiolar lymphocytic infiltration, 
plasma cells and foamy macrophages in the alveoli and interstitial spaces. This may be 
accompanied by non-caseating granulomas, bronchiolitis, emphysema and lung fibrosis 
(Madison, 2008) (Figure 1.6).    
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Figure 1.5: Microscopic features of acute HP: interstitial inflammation accompanied by 
pneumonia (thick arrow) and  multinucleate giant cell (thin arrow) which is typical of HP 
(Matar, McAdams & Sporn, 2000). 
 
 
 
 
 
 
 
 
 
Figure 1.6: Microscopic features of chronic HP: biopsy specimen shows honeycomb 
pattern and moderate mononuclear interstitial infiltrate (Silva, Churg & Muller, 2007).  
 
 
 
 
Honeycomb pattern 
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1.1.8: Diagnosis: 
Clinical features and laboratory tests are not diagnostic for HP and the diagnosis of HP is 
usually established by a combination of clinical features, history of contact with provoking 
antigen, and exclusion of other similar conditions. The first step is having a strong 
suspicion of an environmental antigen being associated with disease. A detailed and 
accurate history of occupational or environmental exposure to the potential provoking 
antigens may suggest the aetiology of the disease (Kaltreider, 1993). However, it may be 
difficult to differentiate the acute type of HP from other respiratory diseases triggered by 
allergens or toxic organic dusts (Bourke et al., 2003).  
Diagnosis cannot be established based on single clinical feature or laboratory test and a 
combination of them together with radiographic changes must be used (Bourke et al., 
2001; Lacasse et al., 2003). Schuyler M et al (2002) described 6 major criteria and 3 minor 
criteria with the diagnosis of HP being made in patients fulfilling 4 major criteria together 
with 2 minor criteria (Schuyler, 2002).  
The major criteria are: 
1. Developing symptoms compatible with HP following exposure to provoking 
antigen. 
2. Confirmation of exposure to provoking antigen by history, positive specific 
precipitating antibodies and or BAL specific antibodies.  
3. Compatible chest radiograph or CT scan changes. 
4. Lymphocytosis observed from BAL fluid. 
5. Compatible histological changes in lung biopsy. 
6. Positive inhalation provocation test. 
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The minor criteria consist: 
1. Basilar crackles in chest auscultation. 
2. Reduced diffusion capacity. 
3. Arterial hypoxemia. 
However, establishing a diagnosis, especially in chronic HP in which the environmental 
offending antigen is not suspected and the patient’s condition deteriorates very slowly, 
may be a puzzle. In this situation a histological examination can provide some clue as to 
any further investigations required to establishing the diagnosis (Bourke et al., 2001; 
Schuyler, 2002; Lacasse et al., 2003).  
 
 
 
 
1.1.9: Therapy: 
 The most important aspect in the management of HP is the avoidance of the provoking 
antigen (Mohr, 2004; Venkatesh & Wild, 2005) with education being useful in the 
prevention of respiratory problems (Kaltreider, 1993; Kurup, Zacharisen & Fink, 2006). 
Unfortunately due to the financial and emotional commitment in some of the occupations 
or hobbies, individuals are reluctant to seek medical advice at an early stage. For instance, 
farmers should be educated about the risks of exposure to barns dust and preventive 
measures such as wearing a mask and better ventilation in the barn should be considered 
(Lacasse & Cormier, 2006). Also in pigeon fanciers, reducing the time spent with the birds, 
wearing suitable mask, hat and coat and ventilation measurements may be beneficial 
(McSharry, Anderson & Boyd, 2000). Other sources of exposure to the bird antigens 
(duvets, pillows) should also be considered (Inase et al., 2003). The antigenic dusts from 
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pigeon lofts can persist for 18 months after ceasing contact with birds which may even 
sensitise other family members or children (McSharry, Anderson & Boyd, 2000).  
A short course of treatment with corticosteroids such as prednisolone 0.5-1 mg/Kg/day or 
40 mg/day for 2-3 weeks can cause a rapid improvement in lung function in patients with 
acute episodes of disease (Kokkarinen, Tukiainen & Terho, 1992; Mohr, 2004; Venkatesh 
& Wild, 2005). Acute HP has also successfully been treated in a mushroom farm worker 
with an extra-fine aerosol corticosteroid (beclomethasone dipropionate (BDP) dissolved in 
hydrofluoroalkane-134a (HFA) (Tanaka et al., 1995).  
Corticosteroids inhibit Th2 cytokine synthesis and also enhance IL-10 production by T 
cells and airway cells which can inhibit IFN-production by CD4cells (Richards et al., 
2000). 
In chronic HP, treatment is supportive but higher doses of corticosteroids for a longer 
duration may be needed; however, the effectiveness of corticosteroids in long-term 
prognosis is still under debate (Lacasse & Cormier, 2006).  
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1.2: Pigeon Fanciers’ Lung: 
1.2.1: Introduction: 
PFL is a form of bird breeders’ lung which was first described by Reed et al in the mid 
1960s (Reed & Barbee, 1965). A large variety of birds may cause bird breeders’ lung and 
among them pigeons, lories, budgerigars, canaries, lovebirds, mynas, macaws, parakeets 
and parrots are the more common (Kurup, Zacharisen & Fink, 2006). PFL is one of the 
most common types of HP which is caused by the repeated inhalation of pigeon antigens in 
a sensitised subject (Bourke & Boyd, 1997). 
Pigeon racing is a competitive sport with large financial prizes and to be successful an 
individual needs to make a large financial and emotional commitment to this sport (Bourke 
& Boyd, 1997; McSharry, Anderson & Boyd, 2000). Pigeon fanciers spend extensive 
amounts of their time and money in order to train and breed their pigeons and such fanciers 
may be reluctant to cease their contact with the birds when symptoms start to appear since 
it is a way of life rather than just a hobby (McSharry, Anderson & Boyd, 2000). Exposure 
to pigeon antigens mostly happens while individuals spend times inside pigeon lofts and 
train their pigeons during the summer racing season (Calvert et al., 1999; McSharry, 
Anderson & Boyd, 2000). However, antigenic dust may be transferred to the home 
environment from the loft by hair and clothing of the fanciers and subsequently affects 
other family members (McSharry, Anderson & Boyd, 2000).  
  
 
 
 
 
 
46 
 
1.2.2: Antigen Exposure in Pigeon Loft: 
Antibodies against different sources of antigen in pigeons have been identified. Pigeon 
droppings, feathers, serum, egg yolk and white and gut wall contain a mixture of proteins, 
glycoproteins and polysaccharides which can be the sources of antigen (McSharry, 
Anderson & Boyd, 2000).  
The dust inside the pigeon loft contains desiccated pigeon droppings, feather dust (pigeon 
bloom as shown in figure 1.7) and the dust from grain feed. Routinely pigeon fanciers 
spend 20 hours or more per week in their lofts. The loft might be cleaned out daily, 
therefore, it does not generate great amounts of dust and in this situation pigeon feathers 
produce the most dust. On the other hand, the pigeon droppings might be accumulated on 
the floor as an absorbent for fresh droppings which is called the deep litter system as 
shown in figure 1.8 (McSharry, Anderson & Boyd, 2000). This can be a source of 
substantial amount of dust.  
Initially an acidic glycoprotein with a 200 KDa weight was extracted from pigeon 
droppings and identified as pigeon IgA (Edwards, Fink & Barboriak, 1969; McSharry, 
Anderson & Boyd, 2000) and it was suggested that this was the major pigeon antigen in 
PFL and is present in both pigeon bloom and droppings. Rodrigo et al (2000) compared the 
results of an inhibition ELISA for pigeon serum against bloom and they concluded that 
pigeon bloom is a stronger antigenic source than pigeon serum (Rodrigo et al., 2000).  
Pigeon bloom is a fine powder with a waterproofing nature on the flight feathers and is 
produced in copious quantities by healthy birds. These particles are one to three microns in 
size and contain the flattened squamous keratinised pigeon epidermal cells. Keratin is a 
highly hydrophobic protein and very resistant to enzymatic degradation. The bloom may 
act both as a carrier to take soluble antigens to the lower airways and as an irritant and 
foreign body causing granuloma in the lung (Longbottom, 1989; McSharry, Anderson & 
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Boyd, 2000). It can be deposited on hands and clothing of the fanciers. Therefore, pigeon 
bloom has been suggested as having high levels of antigenic potential (Baldwin et al., 
1998a; McSharry, Anderson & Boyd, 2000).  
In addition to sources described above, pigeon dropping extract and pigeon bloom also 
contain a large glycoprotein identified as pigeon intestinal mucin (PIM) (Fredricks, 1978). 
Mucin has a high carbohydrate content which has been reported to be disease-associated 
and relatively resistance to biochemical breakdown (Todd, Coan & Allen, 1991; Baldwin 
et al., 1998a; Baldwin et al., 1999; Thornton & Sheehan, 2004). PIM can stimulate very 
high antibody titres in pigeon fanciers and it has been suggested to be a major antigen in 
PFL (chapter 4) (Todd, Coan & Allen, 1991; Baldwin et al., 1998c).  
Although fungal spores have not been implicated in pigeon breeder's disease, pigeon 
feather mites; Diplaegidia columbae; may induce IgE antibody responses and these can be 
associated with significant asthma-like symptoms which can contribute to the symptoms of 
the disease (Colloff et al., 1997; McSharry, Anderson & Boyd, 2000). Finally, bacteria, 
fungi and their products may be spread in pigeon droppings (McSharry, Anderson & Boyd, 
2000). Therefore, the dust of the pigeon lofts will contain various bacterial and fungal 
products such as bacterial lipopolysaccharide, teichoic acid and fungal beta-glucan which 
may damage the lung tissue in fanciers (Cuthbert & Jeffrey, 1995; McSharry, Anderson & 
Boyd, 2000). Microorganisms that have been detected in pigeons or pigeon droppings are 
Chlamydia, Mycoplasma, Aspergillus fumigatus, Histoplasma capsulatum, Cryptococcus 
neoformans,  Influenza A and B (Springston, 1998; McSharry, Anderson & Boyd, 2000) 
and it has been suggested that co-infection with one or more of these organisms may 
influence the development of disease (Cormier et al., 1994; Dakhama et al., 1999b).  
Some of these antigens are highly resistant to degradation resulting in the production of 
persistent immune complexes which could be difficult to be cleared off the system, 
48 
 
therefore contribute to greater damage to the lungs (Bourke et al., 1990). Exposure to these 
antigens can start a series of pathological events which lead to the alveolitis together with 
an increase in the permeability of the alveolar capillary membrane in sensitised fanciers 
(section 1.1.5).  
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Figure 1.7: Pigeon Bloom (Photo curtesy of Dr CI Baldwin). 
 
 
 
 
 
 
 
            
 
 
 
 
Figure 1.8: Deep litter system in pigeon loft (Photo curtesy of Dr CI Baldwin). 
 
 
 
 
 
 
Pigeon 
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2: Hypothesis and Aims 
2.1: Hypothesis: 
Although many studies have been carried out on PFL, there are still many questions 
unanswered as to the underlying mechanisms of disease. Generally it is considered that the 
acute stage of disease is caused by immune complexes (Fink, Moore & Barboriak, 1975; 
Yoshizawa et al., 2001; Kurup, Zacharisen & Fink, 2006).  
Therefore the starting point for PFL is the generation of immune complexes. However, this 
does not explain why some fanciers are asymptomatic despite the presence of high levels 
of anti-avian antigen antibodies in their serum and why some symptomatic fanciers have 
low levels of these antibodies.  
The IgG subclass composition of the immune response to respective antigens is important 
in the composition of immune complexes and may influence the induction and 
development of disease. This IgG subclass distribution in the immune complexes will 
depend on both the quality and the functional affinity of each isotype. 
It has been shown that anti-mucin IgG1 responses have an important role in the 
development of disease although why different fanciers make such subclass responses is 
unknown. IgG1 is considered to be a T-dependent (TD) antibody and thus it has been 
suggested that T cell responses to mucin may also be important in the development of 
disease. 
Thus the hypothesis for this study is that pigeon anti-mucin IgG and T cell responses are 
critical in the development of PFL. 
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2.2: Aims: 
The aims of this study were: 
1) To study antibody responses in symptomatic and asymptomatic pigeon fanciers and 
to identify the functional affinity of specific anti-pigeon antigen IgG isotypes. 
2) To generate mucin-specific T cell clones from pigeon fanciers and to identify the T 
cell phenotype, cytokine profile and the antigen and epitope specificity of these 
cells.  
 
Therefore the objectives of this study were: 
1) Preparation of pigeon intestinal mucin from pigeon intestines. 
2) Quantification of the IgG and IgG subclasses against a series of pigeon antigens 
including pigeon serum (PS), PIM, trypsinised mucin (TM, t mucin), old pigeon 
droppings (PDO), fresh pigeon droppings (PDF) and pigeon intestinal scrapings 
(PIS).  
3) Comparison of these antibody responses between symptomatic and asymptomatic 
pigeon fanciers. 
4) Determination of the functional affinity of IgG subclasses in symptomatic and 
asymptomatic fanciers by chaotropic inhibition ELISA and isothermal 
microcalorimetry (ITC). 
5) Generation of EBV transformed B cell line (feeder cells) from pigeon fanciers. 
6) Generation of T cell clones from pigeon fanciers.  
7) Identification of antigen and epitope specificity, phenotype and cytokine profile of 
T cell clones generated from pigeon fanciers.  
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3: Materials and Methods:  
3.1: Preparation of Pigeon Intestinal Mucin: 
To prepare PIM, the intestines of freshly killed pigeons were washed carefully with water 
and the mucus gel that covers the mucosal surface of the intestines was scraped with a 
glass slide into phosphate buffer (PH: 6.5) containing the proteinase inhibitors (1 mM 
phenyl-methyl-sulphonyl-fluoride, 5mM EDTA and 5mM N-ethylmaleimide) (Mantle & 
Allen, 1981; Todd, Coan & Allen, 1991). The mixture was homogenised in a blender for 1 
minute, then centrifuged at 10000g for 1 hour. The supernatant (soluble mucus) was stored 
at -70˚ C in small aliquots and used as pigeon intestinal scrapings (PIS) in EδISA.  
The soluble mucus was also fractionated by caesium chloride (CsCl) density gradient 
centrifugation for 48 hours at 40000g (starting density: 1.42 g/ml) (Hutton DA, Clin Sci 
1990; 78). 9 fractions were collected and 1 ml of each fraction was weighed to determine 
the density of each fraction. Following 24 hours dialysis in water (minimum 8 changes), 
the carbohydrate (by PAS method) and protein (by Bio-Rad method) concentration of each 
fraction were determined (Mantle & Allen, 1978).  
The fractions with a higher content of carbohydrate (density: 1.47-1.58 g/ml) were pooled 
together and fractionated on a second CsCl density gradient (starting density: 1.47g/ml). 9 
equal fractions were collected again and the density, carbohydrate and protein contents of 
each were measured as previously described. The fractions with the highest amount of 
carbohydrate (density: 1.43-1.47 g/ml) were pooled as PIM and stored at –80˚ C. Samples 
were also freeze dried for further use. 
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3.2: Preparing the Trypsinised Mucin: 
To proteolytically digest the sparsely glycosylated region of the protein core of mucin, 
trypsin (Sigma, UK) was added to PIM at a ratio of one part trypsin to 100 parts mucin in 
PBS. This mixture was incubated at 37˚ C for 24 hours (professor J Pearson personal 
communication). Subsequently, one mole of phenyl methyl sulfonyl fluride (PMSF, Sigma, 
UK) was added to each mole of trypsin to inhibit the reaction of the enzyme. Finally this 
mixture was aliquoted and stored at – 20˚ C.    
 
 
3.3: Preparing Pigeon Droppings: 
Fresh (freshly voided and green) and old (dry and dusty) pigeon droppings were collected 
from a pigeon loft. They were vigorously stirred in 200 ml of 1% normal saline/ 1% phenol 
for 6 hours at room temperature and subsequently centrifuged at 900 g. The supernatant 
was dialysed against distilled water and freeze dried (Berrens & Maesen, 1972; Baldwin et 
al., 1998a).  
A proportion of these freeze-dried extracts were reconstituted in deionised water to make 
PDF and PDO at 1 mg/ml concentration for further experiments. 
 
 
 
3.4: Pigeon Serum: 
Lyophillised PS (Sigma, UK) was reconstituted at 5 mg/ml with distilled water, aliquated 
in 1 ml volumes and stored at - κ0˚ C for subsequent experiments. 
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3.5: Periodic Acid Schiffs for Carbohydrate Estimation: 
Periodic acid schiffs (PAS) method was used to measure the carbohydrate content of PIM 
and other pigeon antigens (Mantle & Allen, 1978). 
This test was carried out in a 96 well plate (Maxisorp, Nunc, Denmark). A range of 
standards of papain digested pig mucin (Todd, Coan & Allen, 1991) (A kind gift from 
Professor Jeff Pearson, Newcastle University) was prepared in PBS at concentrations 70 
g/ml to 10 g/ml. 
200 l of the standards were added to the plates and the pigeon antigens were double 
diluted across the plate into PBS.  
Subsequently, 10 l of solution 1 [10 l of 50% periodic acid (BDH, Bath, UK) in 5 ml of 
7% acetic acid (BDH, Bath, UK)] was added to each well and the plate was incubated at 
37˚ C for one hour.  
10 l of solution 2 [0.05 g of sodium metabisulfate (Sigma ,UK) in 3 ml of schiffs reagent 
(BDH, Bath, UK)] was then added into the wells and the plate was incubated at room 
temperature for a further 30 minutes. Finally, the plate was read on an ELISA Plate Reader 
(Bio-TEK, Vermont, USA) at 570 nm. The concentration of the unknowns was read from 
the standard curve. 
 
 
3.6: Bio-Rad Technique for Protein Estimation: 
The protein content of pigeon antigens were measured by the BioRad technique 
(Hempstead, UK). To begin with, bovine serum albumin (BSA) (Sigma, UK) was made up 
at a range of concentrations from 5g/ml to 100g/ml in distilled water.  
200 l of each concentration of BSA were placed into a 96 well plate (Maxisorp, Nunc, 
Denmark) in duplicate. 200 l of the samples were double diluted across the plate into 
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distilled water. Finally, 25 l Bio-Rad Dye Reagent was added to each well and the plate 
was incubated at room temperature for 5-30 minutes. The plate was read on ELISA Plate 
Reader (Bio-TEK, Vermont, USA) at 570 nm. The concentration of unknowns was read 
from the standard curve.   
 
 
 
3.7: Human Subjects: 
Approval for this project had been obtained from Ethical Committee of Joint Newcastle 
Health Authority in January 1994. Serum samples had previously been collected from 
pigeon fanciers who had participated in pigeon shows between 1997 until 2002. Plasma 
had also been collected from individuals who had no contact with pigeons or any other 
birds.  
The sera had been tested for precipitating antibodies to pigeon serum and pigeon droppings 
by counter current immunoelectrophoresis (CIE) and the sera had been considered positive 
when the precipitins were present to both pigeon serum and droppings (Baldwin et al., 
1998c). A clinical questionnaire had also been completed at the same time with 
information about the nature, frequency and severity of the symptoms together with the 
background details such as degree of pigeon contact and history of smoking being 
collected. A clinical diagnosis was made based on the presence of at least one respiratory 
symptom such as dry cough and at least one systemic symptom such as fever, following 
pigeon contact on at least 3 separate occasions. 
Based on the clinical findings and IgG titres of equal or greater than 10000, human 
subjects were classified into 4 clinical groups (A-D). One additional group was also 
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allocated as control negative group consisting individuals who did not have any contact 
with pigeons. These groups were: 
 Group Aμ Symptomatic with EδISA titres ≥ 10000 (nμ β5) 
 Group Bμ Asymptomatic with EδISA titres ≥ 10000 (n: 25) 
 Group C: Symptomatic with ELISA titres < 10000 (n: 25) 
 Group D: Asymptomatic with ELISA titres < 10000 (n: 25) 
 Group E: Control negative with no pigeon contact and ELISA titres < 1000 (n: 10) 
The serum samples were aliquoted and stored at –80˚ C. Data was coded for confidentiality 
and stored on Microsoft Office 2003. 
Peripheral blood mononuclear cells were separated from fresh blood taken from a number 
of asymptomatic pigeon fanciers (group B) for T cell cloning.  
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3.8: ELISA Checker Board Analysis: 
Optimal conditions and dilutions for ELISA of pigeon antigens including mucin, TM, PS, 
PDO, PDF and PIS for ELISA were established by checkerboard analysis (Boyd, 1975; 
McSharry et al., 2006a). 
Initially each antigen was diluted 1/100 in coating buffer (Appendix 2) and 100 l  were 
placed into the first column of 96 well plates (Maxisorp, Nunc, Denmark).  The antigens 
were double diluted across the plates into coating buffer (figure 3.1) and the plates were 
incubated overnight at 4˚ C.  
Subsequently, the plates were washed 3 times with PBS-T (Appendix 2) and tap water 
alternatively and dried on towel paper. Next 100 l PBS-T-BSA (Appendix 2) was added 
into each well and the plates were incubated for 1 hour at room temperature. After a further 
washing and drying step, positive control sera from an asymptomatic fancier with high titre 
of specific antibodies against pigeon antigens was diluted 1/500 in PBS-T-BSA and 100 l 
was placed into the first row of each plate as shown in figure 3.2. The positive control 
sample was subsequently double diluted into PBS-T-BSA and the plates were incubated at 
room temperature for 90 minutes. 
The plates were washed again a further 3 times, dried and 100 l of polyclonal rabbit anti-
human IgG/HRP (P0214, Sigma, UK) diluted 1/4800 was added to each well and 
incubated at room temperature for 1 hour.  
Finally after a further wash, 100 l of substrate solution (Appendix 2) was added to each 
well and the reaction was stopped within 30 minutes at room temperature with 100 l of 
12.5% sulphuric acid (Fisher Scientific, Leicestershire, UK). Absorbance was read in an 
ELISA reader (Bio-TEK, Vermont, USA) at 490 nm and the results were reported in 
optical density units (OD). 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A 100µl  
1/100 
Ag 
1/200  
Ag 
1/400 
Ag 
1/800 
Ag 
1/1600 
Ag 
1/3200 
Ag 
1/6400 
Ag 
1/12800 
Ag 
1/25600 
Ag 
1/51200 
Ag 
1/102400 
Ag 
1/204800 
Ag 
B 100µl  
1/100 
Ag 
1/200  
Ag 
1/400 
Ag 
1/800 
Ag 
1/1600 
Ag 
1/3200 
Ag 
1/6400 
Ag 
1/12800 
Ag 
1/25600 
Ag 
1/51200 
Ag 
1/102400 
Ag 
1/204800 
Ag 
C 100µl  
1/100 
Ag 
1/200  
Ag 
1/400 
Ag 
1/800 
Ag 
1/1600 
Ag 
1/3200 
Ag 
1/6400 
Ag 
1/12800 
Ag 
1/25600 
Ag 
1/51200 
Ag 
1/102400 
Ag 
1/204800 
Ag 
D 100µl  
1/100 
Ag 
1/200  
Ag 
1/400 
Ag 
1/800 
Ag 
1/1600 
Ag 
1/3200 
Ag 
1/6400 
Ag 
1/12800 
Ag 
1/25600 
Ag 
1/51200 
Ag 
1/102400 
Ag 
1/204800 
Ag 
E 100µl  
1/100 
Ag 
1/200  
Ag 
1/400 
Ag 
1/800 
Ag 
1/1600 
Ag 
1/3200 
Ag 
1/6400 
Ag 
1/12800 
Ag 
1/25600 
Ag 
1/51200 
Ag 
1/102400 
Ag 
1/204800 
Ag 
F 100µl  
1/100 
Ag 
1/200  
Ag 
1/400 
Ag 
1/800 
Ag 
1/1600 
Ag 
1/3200 
Ag 
1/6400 
Ag 
1/12800 
Ag 
1/25600 
Ag 
1/51200 
Ag 
1/102400 
Ag 
1/204800 
Ag 
G 100µl  
1/100 
Ag 
1/200  
Ag 
1/400 
Ag 
1/800 
Ag 
1/1600 
Ag 
1/3200 
Ag 
1/6400 
Ag 
1/12800 
Ag 
1/25600 
Ag 
1/51200 
Ag 
1/102400 
Ag 
1/204800 
Ag 
H 100µl  
1/100 
Ag 
1/200  
Ag 
1/400 
Ag 
1/800 
Ag 
1/1600 
Ag 
1/3200 
Ag 
1/6400 
Ag 
1/12800 
Ag 
1/25600 
Ag 
1/51200 
Ag 
1/102400 
Ag 
1/204800 
Ag 
 
 
 
 
Figure 3.1: Diagram showing the dilution of pigeon antigen in checker board ELISA.  
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 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control  
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
100 µl 
1/500 
positive 
control 
B 1/1000 D 1/1000 D 1/1000 
D 
1/1000 
D 
1/1000 
D 
1/1000 
D 
1/1000 
D 
1/1000 
D 
1/1000 
D 
1/1000 
D 
1/1000 
D 
1/1000 
D 
C 1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
1/2000 
D 
D 1/4000 D 1/4000 D 1/4000 
D 
1/4000 
D 
1/4000 
D 
1/4000 
D 
1/4000 
D 
1/4000 
D 
1/4000 
D 
1/4000 
D 
1/4000 
D 
1/4000 
D 
E 1/8000 D 1/8000 D 1/8000 
D 
1/8000 
D 
1/8000 
D 
1/8000 
D 
1/8000 
D 
1/8000 
D 
1/8000 
D 
1/8000 
D 
1/8000 
D 
1/8000 
D 
F 1/16000 D 1/16000 D 1/16000 
D 
1/16000 
D 
1/16000 
D 
1/16000 
D 
1/16000 
D 
1/16000 
D 
1/16000 
D 
1/16000 
D 
1/16000 
D 
1/16000 
D 
G 1/32000 D 1/32000 D 1/32000 
D 
1/32000 
D 
1/32000 
D 
1/32000 
D 
1/32000 
D 
1/32000 
D 
1/32000 
D 
1/32000 
D 
1/32000 
D 
1/32000 
D 
H 1/64000 D 1/64000 D 1/64000 
D 
1/64000 
D 
1/64000 
D 
1/64000 
D 
1/64000 
D 
1/64000 
D 
1/64000 
D 
1/64000 
D 
1/64000 
D 
1/64000 
D 
 
 
 
 
 
Figure 3.2: Diagram showing the dilution of positive control sera in checker board ELISA; 
D: dilution. 
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3.9: IgG ELISA: 
ELISA assays were based on that described by Baldwin CI et al (Baldwin et al., 1998c).  
96 well micro titre plates (Maxisorp, Nunc, Denmark) were coated with 100 l of pigeon 
antigens diluted at the optimal dilution as determined by checker board ELISA in coating 
buffer (Appendix 2), and incubated overnight at 4˚ C.  The plates were washed 3 times with 
PBS-T (Appendix 2) and tap water alternatively, dried on towel paper and blocked with 
100 l PBS-T-BSA (Appendix 2) for 1 hour at room temperature. 
Serum samples for groups A and B were diluted at 1/500 in PBS-T-BSA and serum 
samples from group C, D and E at 1/100 (since dilution at 1/500 for group C, D and E had 
a final results either negative or very low titres).  
After a further washing and drying step, 100 l of diluted test samples were added to the 
plates and double diluted across the plates into PBS-T-BSA and incubated for 90 minutes 
at room temperature (figure 3.3). The plates were washed a further time and 100 l of 
polyclonal rabbit anti-human IgG/HRP (P0214, Sigma, UK) at 1/4800 was added to each 
well and incubated at room temperature for 1 hour.  
Following 3 further washes 100 l of substrate solution (Appendix 2) was added into each 
well and the reaction was stopped within 30 minutes at room temperature with 100 l of 
12.5% sulphuric acid. Absorbance was read in a micro ELISA reader (Bio-TEK, Vermont, 
USA) at 490 nm.  
Absorbance was plotted against the reciprocal of the serum dilution and the dilution that 
gave an optical density of 0.2 was the antibody titre.  
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 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank 100 µl 1/500  
Positive 
control 
1/1000  
Positive 
control 
1/2000  
Positive 
control 
1/4000  
Positive 
control 
1/8000  
Positive 
control 
1/16000  
Positive 
control 
1/32000  
Positive 
control 
1/64000  
Positive 
control 
1/128000  
Positive 
control 
1/256000  
Positive 
control 
1/512000  
Positive 
control 
B Blank 100 µl 1/500  
Sample 
1 
1/1000  
Sample 
1 
1/2000  
Sample 
1 
1/4000  
Sample 
1 
1/8000  
Sample 
1 
1/16000  
Sample 
1 
1/32000  
Sample 
1 
1/64000  
Sample 
1 
1/128000  
Sample 1 
1/256000  
Sample 1 
1/512000  
Sample 1 
C Blank 100 µl 1/500  
Sample 
2 
1/1000  
Sample 
2 
1/2000  
Sample 
2 
1/4000  
Sample 
2 
1/8000  
Sample 
2 
1/16000  
Sample 
2 
1/32000  
Sample 
2 
1/64000  
Sample 
2 
1/128000  
Sample 2 
1/256000  
Sample 2 
1/512000  
Sample 2 
D Blank 100 µl 1/100  
Sample 
3 
1/200  
Sample 
3 
1/400  
Sample 
3 
1/800  
Sample 
3 
1/1600  
Sample 
3 
1/3200  
Sample 
3 
1/6400  
Sample 
3 
1/12800  
Sample 
3 
1/25600  
Sample 3 
1/51200  
Sample 3 
1/102400  
Sample 3 
E Blank 100 µl 1/100  
Sample 
4 
1/200  
Sample 
4 
1/400  
Sample 
4 
1/800  
Sample 
4 
1/1600  
Sample 
4 
1/3200  
Sample 
4 
1/6400  
Sample 
4 
1/12800  
Sample 
4 
1/25600  
Sample 4 
1/51200  
Sample 4 
1/102400  
Sample 4 
F Blank 100 µl 1/100  
Sample 
5 
1/200  
Sample 
5 
1/400  
Sample 
5 
1/800  
Sample 
5 
1/1600  
Sample 
5 
1/3200  
Sample 
5 
1/6400  
Sample 
5 
1/12800  
Sample 
5 
1/25600  
Sample 5 
1/51200  
Sample 5 
1/102400  
Sample 5 
G Blank 100 µl 1/500  
Sample 
6 
1/1000  
Sample 
6 
1/2000  
Sample 
6 
1/4000  
Sample 
6 
1/8000  
Sample 
6 
1/16000  
Sample 
6 
1/32000  
Sample 
6 
1/64000  
Sample 
6 
1/128000  
Sample 6 
1/256000  
Sample 6 
1/512000  
Sample 6 
H Blank 100 µl 
1/500  
Sample 
7 
1/1000  
Sample 
7 
1/2000  
Sample 
7 
1/4000  
Sample 
7 
1/8000  
Sample 
7 
1/16000  
Sample 
7 
1/32000  
Sample 
7 
1/64000  
Sample 
7 
1/128000  
Sample 7 
1/256000  
Sample 7 
1/512000  
Sample 7 
 
 
 
 
Figure 3.3: Diagrammatic set up of ELISA for IgG.   
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3.10: IgG Subclasses ELISA: 
100 l of pigeon antigen diluted appropriately in coating buffer (Appendix 2) was added to 
each well of a 96 well plate (Maxisorp, Nunc, Denmark). The plate was incubated at 4˚ C 
overnight.  The plate was washed 3 times with PBS-T (Appendix 2) and tap water 
alternatively, dried on towel paper and blocked with 100 l PBS-T-BSA (Appendix 2) for 
1 hour at room temperature. 
After a further washing and drying step, 100 l of appropriately diluted samples in PBS-T-
BSA (as described previously in section 3.9) was added to the plate, double diluted in 
PBS-T-BSA across the plates and incubated overnight at 4˚ C (figure 3.3).   
The plate was washed 3 times and 100 l monoclonal antihuman IgG1 (clone HP6001, 
Sigma, UK) or monoclonal antihuman IgG2 (clone HP6002, Sigma, UK) was added to 
each well for 90 minutes at room temperature. 
Subsequently, the plate was washed 3 times and 100 l of polyclonal rabbit anti-mouse 
immunoglobulin/HRP (P0260, Dako Cytomation, Denmark) was added to each well and 
incubated at room temperature for 1 hour. After a further 3 washes 100 l substrate 
solution (Appendix 2) was added into each well and the reaction was stopped within 30 
minutes at room temperature with 100 l of 12.5% sulphuric acid. Absorbance was read in 
an ELISA reader (Bio-TEK, Vermont, USA) at 490 nm.  
Absorbance was plotted against the reciprocal of the serum dilution, and the dilution factor 
that gave an optical density of 0.2 was the antibody titre.  
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3.11: Measurement of Antibody Avidity by Inhibition ELISA: 
100 l of antigen diluted in coating buffer (Appendix 2) at appropriate concentrations was 
added to each well of a 96 well plate (Maxisorp, Nunc, Denmark). The plates were 
incubated overnight at 4˚ C and washed 3 times in PBS-T (Appendix 2) and tap water 
alternatively, dried on towel paper and blocked with 100 l PBS-T-BSA (Appendix 2) for 
1 hour at room temperature. 
Serum samples for groups A and B were diluted in PBS-T-BSA (Appendix 2) at that 
dilution that gave an OD of 1 (based on the results of IgG1 and IgG2 ELISA) and 50 l of 
each sample was added in every well across the plate. 
The chaotropic reagent, ammonium thiocyanate (Sigma, UK) was made up at a range of 
concentrations (Appendix 3) from 1 to 10 M in PBS and 50 l of each concentration was 
added to each sample (figure 3.4). Plates were incubated overnight at 4˚ C. 
Following further washing and drying, 100 l monoclonal antihuman IgG1 (clone HP6001, 
Sigma, UK) or monoclonal antihuman IgG2 (clone HP6002, Sigma, UK) was added to 
each well for 90 minutes at room temperature. Subsequently, the plates were washed 3 
times, dried and 100 l of polyclonal rabbit anti-mouse immunoglobulin/HRP (P0260, 
Dako cytomation, Denmark) was added to each well and incubated at room temperature for 
1 hour.  
After a further 3 washes the plates were dried on towel paper and 100 l substrate 
(Appendix 2) was added into each well and the reaction was stopped within 30 minutes at 
room temperature with 100 l of 12.5% sulphuric acid. Absorbance was read in an ELISA 
reader (Bio-TEK, Vermont, USA) at 490 nm. The percentage of inhibition (as compared to 
sera without ammonium thiocyanate) was plotted against the concentration of ammonium 
thiocyanate and the concentration of ammonium thiocyanate required to reduce the OD by 
50% was calculated. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Sample A 
sample 
A+10M 
AT 
Sample 
A+9 M 
AT 
Sample 
A+8 M 
AT 
Sample 
A+7 M 
AT 
Sample 
A+6 M 
AT 
Sample 
A+5 M 
AT 
Sample 
A+4 M 
AT 
Sample 
A+3 M 
AT 
Sample 
A+2 M 
AT 
Sample 
A+1 M 
AT 
B Blank Sample A 
sample 
A+10M 
AT 
Sample 
A+9 M 
AT 
Sample 
A+8 M 
AT 
Sample 
A+7 M 
AT 
Sample 
A+6 M 
AT 
Sample 
A+5 M 
AT 
Sample 
A+4 M 
AT 
Sample 
A+3 M 
AT 
Sample 
A+2 M 
AT 
Sample 
A+1 M 
AT 
C Blank Sample A 
sample 
A+10M 
AT 
Sample 
A+9 M 
AT 
Sample 
A+8 M 
AT 
Sample 
A+7 M 
AT 
Sample 
A+6 M 
AT 
Sample 
A+5 M 
AT 
Sample 
A+4 M 
AT 
Sample 
A+3 M 
AT 
Sample 
A+2 M 
AT 
Sample 
A+1 M 
AT 
D Blank Sample A 
sample 
A+10M 
AT 
Sample 
A+9 M 
AT 
Sample 
A+8 M 
AT 
Sample 
A+7 M 
AT 
Sample 
A+6 M 
AT 
Sample 
A+5 M 
AT 
Sample 
A+4 M 
AT 
Sample 
A+3 M 
AT 
Sample 
A+2 M 
AT 
Sample 
A+1 M 
AT 
E Blank Sample 
B 
sample 
B+10M 
AT 
Sample 
B+9 M 
AT 
Sample 
B+8 M 
AT 
Sample 
B+7 M 
AT 
Sample 
B+6 M 
AT 
Sample 
B+5 M 
AT 
Sample 
B+4 M 
AT 
Sample 
B+3 M 
AT 
Sample 
B+2 M 
AT 
Sample 
B+1 M 
AT 
F Blank Sample 
B 
sample 
B+10M 
AT 
Sample 
B+9 M 
AT 
Sample 
B+8 M 
AT 
Sample 
B+7 M 
AT 
Sample 
B+6 M 
AT 
Sample 
B+5 M 
AT 
Sample 
B+4 M 
AT 
Sample 
B+3 M 
AT 
Sample 
B+2 M 
AT 
Sample 
B+1 M 
AT 
G Blank Sample 
B 
sample 
B+10M 
AT 
Sample 
B+9 M 
AT 
Sample 
B+8 M 
AT 
Sample 
B+7 M 
AT 
Sample 
B+6 M 
AT 
Sample 
B+5 M 
AT 
Sample 
B+4 M 
AT 
Sample 
B+3 M 
AT 
Sample 
B+2 M 
AT 
Sample 
B+1 M 
AT 
H Blank Sample 
B 
sample 
B+10M 
AT 
Sample 
B+9 M 
AT 
Sample 
B+8 M 
AT 
Sample 
B+7 M 
AT 
Sample 
B+6 M 
AT 
Sample 
B+5 M 
AT 
Sample 
B+4 M 
AT 
Sample 
B+3 M 
AT 
Sample 
B+2 M 
AT 
Sample 
B+1 M 
AT 
    
 
 
 
 
 
Figure 3.4: Diagram showing the set up of an inhibition ELISA plate; AT: ammonium 
thiocyanate. 
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3.12: Isothermal Microcalorimeter: 
VP-ITC Micro Calorimeter, one of the latest models produced by Microcal (MicroCal 
LLC, Milton Keyne, UK) (figure 3.5) was used to measure the heat produced in an 
antigen-antibody reaction (Sigurskjold, Altman & Bundle, 1991).The setting of  VP-ITC 
was as following:  
Total injection: 30 times, Cell temperature: 30˚ C, Reference power: 10 cal/sec, Initial 
delay: 60 second, Stirring speed: 300, Feedback mode: high, ITC equilibration option: fast, 
auto, Volume: 5 l, Duration: 10 second, Spacing: 240 second, Filter period: 2 second, 
Edit mode: all same. Figure 3.6 shows the setting page of VP-ITC.  
To begin with, the serum samples from group A and B were diluted 2 times in PBS 
(Appendix 2) and used as a ligand in the injection syringe. PDO was made at 2 mg/ml in 
PBS and used as a macro molecule in the sample cell.  In order to have a short equilibrium 
period, the serum sample and PDO were kept on ice. Before running the experiment, the 
sample and PDO were degassed for 5 minutes with stirring. 1.8 ml pigeon antigen was 
injected into the reaction cell by the glass syringe. The reference cell was filled with PBS. 
The injection pipette was placed in the pipette stand into the test tube containing the serum 
sample and filled with the sample slowly. The tip of the pipette was carefully placed into 
the reaction cell and the experiment was started. 
5 l of the antigen was injected into the reaction cell thirty times with a 240 second gap 
between each injection to give the reaction cell enough time to return to equilibrium. The 
heat generated by the antigen-antibody interactions (H) following each injection was 
measured by the system. A titration curve was obtained when the heat from each injection 
was plotted against the ratio of antigen and antibody in reaction cell by VP-ITC. H was 
extracted from the curve (Wiseman et al., 1989; Bundle & Sigurskjold, 1994).   
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           Figure 3.5: VP- ITC Machine. 
 
 
   
 
    Figure 3.6: VP- ITC setting page before running the experiment. 
 
Injection 
pipette 
The section containing 
reaction and reference cells 
Computer 
and soft 
ware 
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3.13: Isolation of Peripheral Blood Mononuclear Cells:  
Freshly heparinised peripheral blood from an asymptomatic fancier was diluted with an 
equal volume of sterile normal saline. 20 ml of this mixture was carefully layered onto 6 
ml Lympho-Prep (Nycomed Pharma As, Norway) in a sterile universal. The preparation 
was centrifuged at 900 g for 20 minutes at 20˚ C. The thin layer of peripheral blood 
mononuclear cells (PBMC) was located between the plasma at the top and Lympho-Prep 
underneath. Red blood cells and granulocytes centrifuged to the bottom of the tube as 
shown in figure 3.7.  
The PBMC layer was carefully removed by a plastic pipette, washed 2 times in RPMI 1640 
(Gibco, Invitrogen, UK) and cells were counted in a haemocytometer as described in 
section 3.14. 
 
                                                
 
           
 
 
 
  
   
 
 
 
 
 
 
Figure 3.7: Visualising the different layers of peripheral blood in the universal bottle. 
 
 
Plasma 
PBMC 
Lympho-Prep 
RBC/Granulocytes 
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3.14: Counting the Cells by Haemocytometer: 
To begin with, the hemocytometer slide was cleaned with 70% alcohol and a cover slip 
was placed carefully over the grooves and gridded area. 
After mixing the cell culture thoroughly to disperse any clumps, the suspension was 
transferred to the edge of the hemocytometer chamber allowing it to go under the cover 
slip by capillary action. By using a microscope and tally counter, the cells lying in 25 large 
squares in the gridded area (n) were counted. The cells that situated on the top and left 
hand lines of each large square were counted to avoid counting cells twice. Since the 
volume counted was 0.1 mm3 or 1 x 10-4 ml, the cell concentration in one millilitre (c) was 
calculated from the following formula:   
                                                                     c = n x 104 
 
                                                      
3.15: Culture Media: 
RPMI 1640 (Invitrogen, GIBCO, UK) was used for washing and preparing the cells for 
culture. RF 10 was used for cell culture and generating EBV transformed B cell lines and it 
contains: 
 inactivated foetal calf serum (FCS) (Invitrogen, UK ): 10% v/v (50 ml)  
 L- glutamine (200 mM) (Invitrogen, UK): 1% v/v (5 ml) 
 penicillin (100 unit/ml)/streptomycin (100g/ml) (Invitrogen, UK): 1% v/v (5 ml)  
 RPMI 1640 (Invitrogen, Gibco, UK): 500 ml 
Prior to use the foetal calf serum was placed in a water bath at 56˚ C for half an hour in 
order to inactivate complement components which may destroy cells.  
RH 10 is another type of fortified media which is similar to RF 10 except it contains 
inactivated human serum (Invitrogen, UK) instead of inactivated FCS and it was used for T 
cell cloning. 
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3.16: Generation of EBV transformed B cell lines: 
2 different methods were tested. The polymixin B method was faster, more efficient and 
successful. 
 
3.16.1: EBV/ Cyclosporin Transformed B cell lines: 
PBMC were separated from freshly heparinised peripheral blood from pigeon fanciers. 
1.2 ml of PBMC at 10 x 106 /ml was incubated with 2 ml supernatant of B958 cells (A kind 
gift from Dr Desa Lilic, Newcastle University) containing Epstein Barr Virus (EBV) in a 
humidified condition containing 5% CO2 at 37˚ C for 1-2 hours. Cyclosporin (Sandoz, 
Germany) at a final concentration of 1 g/ml was added to the mixture, which was 
incubated for a further 24 hours. This mixture was then transferred into 2 wells in a 12 well 
culture plate and 1 ml of RF 10/ cyclosporin (1 g/ml) was added to each well and 
incubated at 37˚ C for a week. Cells were monitored and each week 1 ml from each well 
was replaced with a fresh mixture of RF10 /cyclosporin. After about 3-4 weeks when small 
colonies of transformed cells were observed, the cells were transferred to small flask 
(figure 3.8). 
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Figure 3.8: The flow chart of cyclosporine method for generating of EBV 
transformed B cell lines. 
 
 
 
PBMC (10 x 10 6/ml) 
1.2 ml 
B958 supernatant 
2 ml 
Mixed and incubated for 
1-β hours at γ7 ˚ C 
Cyclosporin (1 µg/ml) 
added to above mixture, 
incubated for 24 hours 
at γ7 ˚ C 
Divided into 2 wells containing RF10 (1 ml) + 
cyclosporine (1 µg/ml), incubated at γ7 ˚ C for 1 week 
1 ml was replaced with fresh 
RF10 + cyclosporin every week 
Visible colonies were transferred to small 
flask containing RF10 for further grow 
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3.16.2: EBV/ Polymyxin B Transformed B cells: 
PBMC were separated from freshly heparinised peripheral blood from pigeon fanciers. 
2.5 – 5 x 106 PBMC were placed in 1.6 ml of transformation medium [containing 5 ml 
RPMI, 20% v/v inactivated FCS, 1% v/v 200 mM L-glutamine, 1% v/v 
phytohaemagglutinin (PHA, Sigma, UK), 100 units/ml penicillin/streptomycin and 100 
units/ml polymyxin B-sulphate (Sigma, UK)] and the EBV supernatant of B958 cell 
culture in the ratio of 4:1 (0.4 ml) ((Bass, Walters & Darke, 2004). 1 ml of that mixture 
was placed into 2 wells of the 24-well, flat-bottomed culture plate and incubated in 
humidified condition containing 5% CO2 at 37˚ C for 4-7 days until the visible B cell line 
was established. Every 3-4 days 1 ml from each well was replaced with a fresh mixture of 
RF 10. After about 3-4 weeks the cells were transferred to small flask (figure 3.9). 
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Figure 3.9: The flow chart of polymixin B method for generating of EBV  
transformed B cell lines. 
 
 
 
 
 
 
 
 
 
PBMC (2.5-5 x 10 6) 
 
B958 supernatant (0.4 ml) 
Mixed and divided between 2 wells and 
incubated at γ7 ˚ C for 4-7 days 
1 ml was replaced with 
fresh RF10 every 3-4 days 
Visible colonies were transferred to small flask 
containing RF10 for further grow 
 
Transformation 
medium (1.6 ml) 
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3.17: Irradiation of the Feeder Cells: 
To produce growth arrested feeder cell lines, the EBV transformed B cells were irradiated 
by “Gamma Cell 1000 Elite” (εDS Nordion, Ottawa, Canada) at 60 Gray ((Puck & 
Marcus, 1956). At this dosage of Gamma radiation, the cells survive but stop dividing (Dr 
Baldwin personal communication). 
 
 
 
 
 3.18: T cell cloning: 
The method choice for T cells cloning is dilution cloning in which a cell suspension is 
diluted to the point that a chance of having more than one cell in the inoculum’s volume is 
negligible (Newman, 1996).  
The process of cloning is shown in figure 3.10. Peripheral blood lymphocytes were made 
up at 5 x 105 /ml and seeded within 2 sets of 96 well cell culture plates as follow: 
 cells with antigen ( Ag positive cells): lymphocytes + t mucin (100 g/ml) + IL-2 
(20 ng/ml) 
 cells without antigen ( Ag negative cells): lymphocytes + IL-2 (20 ng/ml)  
Plates were incubated in a humidified incubator containing 5% CO2 at 37˚ C for one week. 
The cells were harvested into 2 separate tubes, washed three times with RPMI 1640, 
counted on a haemocytometer and diluted. 20 l of media containing Ag positive cells (1 
cell/20l), t mucin (100 g/ml), irradiated feeder cells (1 x 10 4 /well) and IL-2 (20 ng/ml) 
was aliquated into Terasaki plates (GBO, UK) (Figure 3.11).  
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Also 20 l of media containing Ag negative cells (1 cell/ 20l), irradiated feeder cells (1 x 
10 4 /well) and PHA (5 g/ml, Sigma, UK) was seeded onto a separate Terasaki plate. The 
plates were incubated in a humidified chamber at γ7˚ C in 5% CO2 for 2 weeks.   
After 2 weeks, colonies were selected and transferred into two 96 well round bottom 
culture plates. Subsequently, 180 l of irradiated feeder cells (5 x 105 /ml), t mucin  (100 
g/ml), and IL-2 (20 ng/ml) were added to the wells containing Ag positive cells or PHA 
(1 g/ml), Il-2 and irradiated feeder cells to the wells containing Ag negative cells. Every 2 
weeks 100 l of the media was replaced with the fresh mixtures.  
The cells were monitored regularly and when visible cell colonies were established, the 
cells were transferred into 2 wells. Cells were grown up into larger volumes when 
appropriate and after 4-6 months the clones were stored in liquid nitrogen (LN2) for further 
experiments. 
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 Figure 3.10: The flow chart of T cell cloning. 
 
 
 
PBMC (5 x 10 5/ml) 
96 well cell culture plate 
200 µl PBMC/well containing 
TM (100 µg/ml) + IL-2 (20 
ng/ml) 
96 well cell culture plate 
200 µl PBMC/well containing 
IL-2 (20 ng/ml) 
 
Incubation for 1 week 
Harvesting the cells of each plate separately 
20µl RH10 containing 1 Ag  
positive cell + TM (100 µg/ml) + 
irradiated feeder cell (1 x 104/well) 
+ IL-2 (20 ng/ml) onto Terasaki 
plate 
20µl RH10 containing 1 Ag  
negative cell + PHA (5 µg/ml) + 
irradiated feeder cell (1 x 
104/well) onto Terasaki plate  
 
         Incubation for 2 weeks 
Transferring Ag positive colonies to 96 
well plate containing 180 µl/well RH10 + 
irradiated feeder cells (5 x 105/ml) + TM 
(100 µg/ml) + IL-2 (20 ng/ml) 
Transferring Ag negative colonies to 
96 well plate containing 180 µl/well 
RH10 + irradiated feeder cells (5 x 
105/ml) + PHA (1 µg/ml) + IL-2 (20 
ng/ml) 
Replacing 100 µl of the media with fresh one every 2 week  
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          Figure 3.11: Terasaki plate; each well has 20 l volume. 
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3.19: Freezing down the Cells in Liquid Nitrogen: 
Cells were harvested and washed twice with RPMI 1640 and then made up to 1-2  x 106 
/ml in inactivated FCS  containing 10% Dimethyl Sulfoxide (DMSO, Pharmingen, UK).                  
Cells were aliquoted into the cryovials (Sigma, UK) and then placed at –80˚ C in a 
polysterene container for 24 hours and subsequently transferred into liquid nitrogen.  
 
 
 
3.20: Proliferation Assay: 
Cell proliferation was determined by the use of radiolabeled DNA precursors, in this case 
tritiated thymidine  (3H-thymidine) (Merion, Howell & Bromberg, 1998; Laughlin et al., 
2007). The amount of radiation detected in the cells is proportional to proliferative 
response of the cells (Merion, Howell & Bromberg, 1998; Laughlin et al., 2007).    
T cell clones and irradiated feeder cells were made up at 2.5 x 105 /ml and 200 l of this 
was added into the wells of a 96 well plate as shown in figure 3.12. Cells were incubated 
with IL-2 (20 ng/ml), PHA or t mucin (at 200, 50, and 10 g/ml) respectively in triplicate 
at γ7˚ C for 4 days. On the 4th day of incubation, 0.0185 MBq 3H-thymidine was added to 
each well. After 6 hours incubation, the T cell clones were harvested into a glass fibre filter 
by Packard Filter mate Harvester (Packard Instrument Company, Meriden, CT, USA) 
(Figure 3.13). The next day the filters were processed for counting in a flat beta plate 
counter (Packard Instrument Company, Meriden, CT, USA). Following calculation of 
mean values of each triplicate, the stimulation index (SI) which is the ratio of the counts 
per minute of radioactivity in cells stimulated by t mucin, IL-2 or PHA divided by the 
counts per minute for unstimulated cells was determined.   
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(20ng/ml) 
    RPMI 
RPMI RPMI RPMI RPMI RPMI RPMI RPMI RPMI RPMI RPMI RPMI RPMI 
 
 
Figure 3.12: Diagram of preparation of the plate for proliferation assay. 
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                                Figure 3.13: Packard Filter mate Harvester   
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3.21: Cytokine Profile: 
2 x 10 5 T cell clones were incubated with and without the stimulators; Ionomycin (2 
g/ml, Sigma, UK) and Phorbol 12 Myristate 13- Acetate (PMA, 10 ng/ml, Sigma, UK); in 
triplicate at 37˚ C for one to five days as shown in figure 3.14.  Each day the supernatant of 
the clones were collected and stored at –20˚ C. Finally the supernatant was analysed for 
different cytokines by ELISA. 
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Figure 3.14: Diagram of preparing the plate for cytokine profile. 
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3.22: Cytokine ELISA: 
The supernatants collected after stimulation with PMA and Ionomycin were tested for 
different cytokines (Appendix 5) by ELISA. 
96 well plates (Maxisorp, Nunc, Denmark) were coated with 100 l of specific anti-
cytokine antibody (Pharminogen, BD Bioscience, UK) diluted appropriately (Appendix 4) 
in the coating buffer (Appendix 2) and incubated in a humidified chamber at 4˚ C 
overnight. The following day the content of the wells was discarded and the plate was 
dried on tissue paper. 100 l PBS-T-BSA (Appendix 2) was added into the wells, 
incubated at room temperature for one hour. Subsequently the plate was washed 3 times in 
PBS-T (Appendix 2) and dried.  
The top standard (NIBSC, Hertfordshire, UK) (concentration of the top standards are 
shown in section Appendix 5) was double diluted down in the plate in PBS-T-BSA 
(Appendix 2) and 100 l of ½ diluted supernatant in PBS-T-BSA (Appendix 2) was added 
to the rest of the wells and the plate was incubated at 37˚ C for one hour (figure 3.15). 
Following a further 3 washes, the plate was dried and 100 l of diluted biotinylated anti-
cytokine antibody (Pharminogen, BD Bioscience, UK) in PBS-T-BSA (dilution of each 
biotinylated antibody are shown in Appendix 6) was added to each well and the plate was 
incubated at 37˚ C for one hour. 
Subsequently after a further washing and drying step, 100 l of substrate solution 
(Appendix 2) was added to each well and the plate was incubated for 30 minutes in the 
dark. Finally 100 l of 12.5% sulphuric acid was added to each well to stop the reaction 
and OD was read by using an ELISA Ultra Microplate Reader (Bio-TEk, Vermont, USA) 
at 490 nm. The standard curve was determined by plotting the concentrations against the 
OD of the standard. 
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Figure 3.15: Diagram showing the set up of cytokine ELISA; (S+): supernatants with 
stimulator, (S-): supernatant without stimulator, D: day. 
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3.23: Fluorescence- Activated Cell Sorting (FACs) Analysis: 
 
Each T cell clone was stained with a range of specific antibodies (Bioscience, UK) to 
determine the phenotype of the cells. These antibodies were attached to T lymphocytes as a 
single color direct immunofluorescence reagent detected when the flow cytometer light 
excited the fluorochrome.   
For each clone 2 tubes were prepared. 5 l anti- CD3 (FITC, Fluorescein Isothiocyanate, 
producing green fluorescence), 5 l of anti- CD4 (PE, Phycoerythrin) were added to the 
first test tube. The second test tube contained 5 l anti- CD3 (FITC), 5 l of anti- CD8 
(PE). Subsequently 2.5 x 10 5 of T cell clone were added to each tube and the total volume 
was made up to 300 l with RPMI 1640. Tubes were incubated in a dark place at room 
temperature for 20 minutes and finally the tubes were analyzed by a Becton Dickinson 
FACs machine (Becton Dickinson Company, San Diego, USA). 
 
 
 
3.24: Safety Statement: 
Pigeon antigens were considered to be class 2 substances and were handled appropriately. 
Human products were also handled as following class 2 health and safety guidelines. 
Tritiated thymidine or 3H-thymidine emits  particle and was handled as prescribed by the 
Northumbria University Radiation Safety code. The operator attended in the radiation 
safety training course (Northumbria University, 2003). 
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3.25: Statistical Analysis: 
Statistical analysis was performed using Mann Whitney U test, multiple regression and 
Chi-square where the data was nonparametric and student t test where the data was 
parametric. All statistical calculation was carried out on SPSS version 15. A P value  0.05 
was considered significant. 
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4: The Role of Serum Antibodies in Pigeon Fanciers’ Lung 
4.1: Introduction: 
4.1.1: Antibody: 
 
4.1.1.1: The Structure of Antibodies: 
 
The humoral immune response plays an effective role in protection against foreign 
antigens (Boes et al., 1998; Rogers  et al., 2006). Antibodies are produced by B cells and 
exist as either membrane bound immunoglobulin which interacts with antigen, or secreted 
antibodies.  
A schematic diagram of an IgG molecule is presented (Figure 4.1) as this molecule 
demonstrates the shared basic structure of all antibodies. The IgG molecule contains four 
different polypeptide chains: 2 identical heavy (H) and 2 identical light (L) polypeptide 
chains. The chains are linked together by interchain disulfydryl bonds (S-S) between 
cysteine residues. The light chains are β identical kappa (ț) or lambda (Ȝ) and the heavy 
chains are alpha (α), gamma (Ȗ), delta (į), epsilon (İ), or mu (ȝ) (Clark, 1997). The amino 
terminal domains of both the H and L chains have different amino acid sequences which 
form the variable regions (VH, VL) or domains. These variable domains allow antibodies to 
recognise a huge diversity of antigens. The Ȗ heavy chain has γ domains (CH1, CH2, and 
CH3) whilst the light chain has one constant domain. The constant domain of the H chains 
has limited variability and determines the biological functions of each isotype.  
The hypervariable regions within the VH and VL domains show a high level of amino acid 
sequence variability between different antibodies whilst the framework regions show less 
variability. A cleft formed by a folded VH and VL domains brings the hypervariable regions 
together and this is the antigen-binding site. The complementary determining regions of 
antibodies (CDR) are the sites of closest contact between antigen and antibody. The CH2 
domain of FC section interacts with the complement cascade, and the CH2 and CH3 
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domains bind phagocyte via FC receptors (FCRs) to stimulate the antigen uptake 
(Michaelsen, Garred & Aase, 1991).   
Antibodies are classified as different isotypes based on their heavy chain. There are 
structural variations in the quaternary structure and the hinge length between isotypes. 
There are different quaternary arrangement including monomers such as IgG, IgD and IgE, 
dimmers such as secretary IgA and pentamers such as IgM. This structure determines the 
isotype size and therefore its distribution in the body. IgG can be further divided into the 
subclasses IgG1, IgG2, IgG3 and IgG4 and IgA can be divided into IgA1 and IgA2. 
Biological preparations of the immunoglobulin are shown in Table 4.1. 
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Figure 4.1: Schematic diagram of an IgG molecule. It has 2 identical heavy (H) and 2 
identical light (L) chains. Each heavy chain has one variable domain (VH) and 3 constant 
domains (CH1, CH2 and CH3). Each light chain has one variable (VL) and one constant 
(CL) domain. Antigen binding fragment (Fab) contains one entire L chain and about half 
of H chain. The other half of H chain is crystalizable fragment (Fc) which contains FC 
receptor-binding sites (Mayer, 2008). 
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Isotype Molecular 
Weight 
(kDa) 
% of total 
Ig  
(adult 
serum) 
Biological  
half-life 
(days) 
Trans- 
placental 
transfer 
Complement 
activation via 
classical 
pathway 
Biological 
properties 
IgA1  160-300 11-14 5.9 - - Toxin neutralizing, 
agglutinating, 
bacteriolytic 
IgA2  160-350 1-4 4.5 - - Toxin neutralizing, 
agglutinating, 
bacteriolytic 
IgD  175 0.2 2-8 - - Mature B cell 
marker 
IgE  190 0.004 1-5 - - Mediate changes in 
vascular 
permeability 
IgG1  150 45-53 21-24 + +++ Toxin neutralizing, 
opsonising, 
agglutinating, 
bacteriolytic 
IgG2  150 11-15 21-24 + + Toxin neutralizing, 
opsonising, 
agglutinating, 
bacteriolytic 
IgG3  160 3-6 7-8 + ++++ Toxin neutralizing, 
opsonising, 
agglutinating, 
bacteriolytic 
IgG4  150 1-4 21-24 + - Toxin neutralizing, 
opsonising, 
agglutinating, 
bacteriolytic 
IgM  950 10 5-10 - ++++ Primary antibody 
response, toxin 
neutralizing, 
agglutinating, 
bacteriolytic,  
                                    
Table 4.1: The details about the half-life of different antibodies, the longest half-life 
belongs to IgG subclasses (Paul, 2003). 
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4.1.1.2: IgG Fc Receptors: 
Receptors for immunoglobulin interact with the FC domains of antibodies and link 
humoral and cellular aspects of the immune responses (Salmon & Pricop, 2001). IgG Fc 
receptors are termed FcȖR which exist on macrophages, monocytes, neutrophils, 
eosinophils, NK cells and B cells (Table 4.2) (Sarfati et al., 1992; Bazilio et al., 2004; 
Selvaraj et al., 2004). They are encoded by members of the immunoglobulin superfamily 
of genes which are present on the long arm of chromosome 1 (1q21–23) (Salmon & 
Pricop, 2001).  
Three main subclasses of IgG Fc receptors have been identified with FCȖRI (CD64) 
having a high affinity for human IgG1 and IgG3 (Akerley, Guyre & Davis, 1991) and 
FCȖRII (CDγβ) and FCȖRIII having a low affinity for IgG (Hogg, 1988; Bazilio et al., 
2004). FCȖRII has been classified into 3 isoforms of A, B and C based on their cell 
distribution and stimulatory or inhibitory functions which depends on the presence of 
immunoreceptor tyrosine-based activation/inhibition motif (ITAM/ITIM) in their 
intracytoplasmic domain (Salmon & Pricop, 2001; Bazilio et al., 2004).  
Stimulatory FCȖR initiates phagocytosis, antibody-dependent cell mediated cytotoxicity 
(ADCC) and the release of cytokines such as TNF-α, IFN-Ȗ, Iδ-2, IL-6 and IL-12 (Bazilio 
et al., 2004). These receptors have an important role in type II and type III hypersensitivity 
reactions. On the other hand, inhibitory FCȖR (FcȖRIIb) can abolish cellular signalling and 
play a central role as negative regulators of immune complex-triggered activation 
(Wasowska et al., 2007).  
Following interaction of stimulatory FCȖR with its ligand (Fc region), FCȖR are clustered 
and cross-linked at the cell surface by multivalent antigen-antibody complexes which 
induce phosphorylation of ITAM by tyrosine kinases (Salmon & Pricop, 2001; Bazilio et 
al., 2004). As a consequence, SyK kinase is recruited which activates phospholipase C and 
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therefore production of phosphoinositol messengers and increases cytoplasmic calcium. 
This signalling pathway triggered by FCȖR reaches the nucleus leading to activation of 
transcription factors (Salmon & Pricop, 2001; Pan & Pei, 2003; Swanson & Hoppe, 2004). 
On the other hand, interaction of inhibitory FCȖR with FC domain can lead to the 
phosphorylation of ITIM, recruitment of SH2-containing inositol polyphosphate 59-
phosphatase (SHIP) and prevention of calcium influx (Salmon & Pricop, 2001).  
One of the host defence mechanisms triggered by the humoral immune response is ADCC, 
a lytic attack on antibody tagged cells. This triggers the release of cytokines such as TNF-α 
and IFN-Ȗ, and cytotoxic granules containing perforin (cytolytic protein) and granzymes 
(serine protease) from NK cells resulting in elimination of antibody covered target cells 
(Sun, 2003; Niwa et al., 2005). The structure of the oligosaccharides linked to the CH2 
domain of the FC region of antibody may also influence ADCC. It has been reported that 
removal of fucose from IgG1 oligosaccharides can enhance ADCC activity in vitro (Niwa 
et al., 2005).  
It has been suggested that FCȖR polymorphisms may play an important role in an 
individual’s susceptibility to immune complex-mediated diseases (Zuniga et al., 2003; 
Bazilio et al., 2004). For instance, FCȖRIIa has β expressed alleles, R1γ1 and H1γ1 
(arginine or histidine at position 131, respectively), in the extracellular domain of the 
molecule (Bazilio et al., 2004).). FCȖRIIa-H131 binds to IgG2 efficiently and has been 
shown to have an essential role in the handling and clearance of IgG2 immune complexes 
(Bazilio et al., 2004). Polymorphisms in FCȖRIIa have been associated with the 
development of a number of diseases such as SLE (Yuan et al., 2008), severe Falciparum 
malaria (Sinha et al., 2008) and invasive Streptococcus pneumonia infection (Yuan et al., 
2008).  
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Receptor 
name 
Principal 
antibody 
ligand 
Affinity for 
ligand 
Cell 
distribution 
Effect following binding to 
antibody 
FcγRI 
(CD64) 
IgG1 and IgG3 High  Macrophages 
Neutrophils 
Eosinophils 
Dendritic cells 
Phagocytosis 
Cell activation 
Activation of respiratory burst 
Induction of microbe killing 
FcγRIIA 
(CD32) 
IgG Low  Macrophages 
Neutrophils 
Eosinophils 
Platelets 
Langerhans 
cells 
Phagocytosis 
Degranulation (eosinophils) 
FcγRIIB1 
(CD32) 
IgG Low  B Cells 
Mast cells 
No phagocytosis 
Inhibition of cell activity 
FcγRIIB2 
(CD32) 
IgG Low  Macrophages 
Neutrophils 
Eosinophils 
Phagocytosis 
Inhibition of cell activity 
FcγRIIIA 
(CD16a) 
IgG Low  NK cells Induction of antibody-dependent 
cell-mediated cytotoxicity 
(ADCC) 
FcγRIIIB 
(CD16b) 
IgG Low  Eosinophils 
Macrophages 
Neutrophils 
Mast cells 
Follicular 
dendritic cells 
Induction of microbe killing 
 
Table 4.2: IgG FC receptors and their antibody ligands, affinity, cell distributions and 
functions (Fridman, 1991; Indik et al., 1995).   
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4.1.1.3: Antibody Isotype Switching: 
Following genomic rearrangement of the immunoglobulin gene using V(D)J 
recombination, membrane IgM and IgD molecules are expressed on naive mature B cells 
(Maizels, 2005). These membrane expressed antibodies are critical in primary antibody 
production and their expressions are independent of both antigen and T cells. Three 
lymphoid specific proteins are involved in this rearrangement are recombination activation 
genes (RAG1, RAG2) and terminal deoxynucleotidyl transferase (Neuberger et al., 2000). 
The first 2 are involved in recognition and cutting of rearrangement signal sequences and 
the third is responsible in adding nucleotides to the junctions of V, D and J segments 
(Neuberger et al., 2000).  
The secondary antibody repertoire is shaped in the lymph nodes, mainly in germinal 
centres, tonsils and spleen and is an antigen and T cell dependent process which involves 
class-switch recombination (CSR) and somatic hypermutation (SHM) in the 
immunoglobulin gene (Imai et al., 2003). Both require successful transcription of target 
DNA sequences, DNA cleavage, and DNA repair (Notarangelo et al., 2006). CSR is a 
DNA recombination event in the immunoglobulin gene which replaces the CȖ exon with 
different CȖ, Cα, or Cİ resulting in the production of different isotypes (Bransteitter et al., 
2006). The V region and therefore the antibody specificity and affinity stay intact (Zarrin 
et al., 2005).  
On the other hand, SHM generates high frequency mutations downstream from the 
transcription start site in the V region and therefore, leads to the selection of B cells with 
higher affinity for an antigen although the specificity will not change (Bransteitter et al., 
2006; Notarangelo et al., 2006).  
Cell to cell contact, such as the interaction between B and T lymphocytes, together with 
different cytokines plays a crucial role in the maturation of antibody responses 
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(Notarangelo et al., 2006). Following antigenic stimulation, TD antigen is presented to T 
cells via class II MHC which leads to MHC-TCR interactions and the expression of CD40 
ligand (CD40L or CD154) on T cells. CD40L is important in the induction of the CSR and 
is a member of the TNF superfamily (Sitati et al., 2007). CD40L- CD40 interactions result 
in cross-linking of CD40 on the surface of B cells leading to B cell proliferation, 
generation of plasma cells, formation of germinal centres, and finally triggers CSR and 
SHM (Figure 4.2). T cells secrete cytokines such as IL-2, IL-4 and IL-10 which also 
promote B cell activation (Quezeda et al., 2004).  Several signalling pathways are triggered 
by CD40L-CD40 interactions resulting in the activation of several genes responsible for B 
cell proliferation and antibody production (Thusberg & Vihinen, 2007). One of these genes 
is activation-induced cytidine deaminase (AID) which deaminates cytidine in DNA and 
has a crucial role in CSR and SHM (Imai et al., 2003). Nuclear AID deaminates the V(D)J 
region and converts cytosine to uracil (Ta et al., 2003). Uracil is then removed by uracil 
DNA glycosylase (UNG) in order to protect DNA from mutational damage which leads to 
an abasic site. As a result, this abasic site can be attacked by endonucleases generating 
DNA breaks which are the key for CSR (Imai et al., 2003; Begum et al., 2004). These 
signalling cascades also stimulate T cells to produce cytokines that determine the antibody 
class in B cells  (Finkelman et al., 1990).  
Following ligation CD40 forms clusters at the B cell membrane and signalling pathways 
start with the interaction of the cytoplasmic domain with TNF receptor-associated factors 
(TRAFs) 2, 3 and 6 (Harigai et al., 2004). This clustering and TRAFs initiate the signalling 
cascade involving nuclear factor (NF)-țB-inducing kinases, and protein serine/threonine 
kinases that activate transcription factors which regulate gene expression (Thusberg & 
Vihinen, 2007). In addition, TRAF-independent pathways may also be triggered following 
CD40L-CD40 interaction. For instance, Janus-associated kinases (JAKs) and signal 
95 
 
transducers and activators of transcriptions (STATs) might also be involved which are 
important in CD40-mediated functions (Hanissian & Geha, 1997). Isotype switching is 
also regulated by cytokines such as IL-4, IL-10, IL-13, IFN-Ȗ and TGF-ȕ (Tangye et al., 
2002). IFN-Ȗ has stronger effects on this process than Iδ-4 and both IFN-Ȗ and Iδ-4 are 
dominant over TGF-ȕ (Deenick, Hasbold & Hodgkin, 2005). In the presence of IL-4 and 
IL-13, CD40-stimulated B cells undergo isotype switching to IgG4 and IgE (Gascan et al., 
1991) or to IgG1 and IgG3 in the presence of IL-10 (Malisan et al., 1996). Furthermore, 
IL-10 and TGF-ȕ are necessary for switching to IgA1 and IgAβ (Defrance et al., 1992).  
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Figure 4.2: Schematic figure of CD40L-CD40 interaction. Activated T cells in germinal 
centre of lymph nodes interact with B cells and therefore, secrete interleukins (IL) which 
interact with IL receptors on B cells. As a result of CD40L-CD40 interaction, NFțB 
pathway is activated and as consequences AID and uracil N-glycosylase (UNG) are 
expressed which are crucial in CSR and SHM and therefore in isotype switching of 
antibody (Myers & Swanson, 2002).  
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4.1.2: Complement Activation: 
An important component of both the innate and adaptive immune response is the 
complement system which is involved in both activation and regulation of the immune 
system (Nonaka & Miyazawa, 2002). The major functions of complement system are the 
recognition and elimination of pathogens through opsonisation and stimulation of 
phagocytosis to the immunoregulatory roles such as enhancing humoral immunity and 
modifying T cell immunity (Thurman & Holers, 2006). 
The complement system contains approximately 35 heat-labile proteins that, once 
triggered, activate each other in a strict order (Nonaka & Miyazawa, 2002; Mueller-Ortiz, 
Drouin & Wetsel, 2004). It consist of three major pathways: the classical pathway, 
activated by antibodies; the lectin pathway, initiated by engagement of mannan-binding 
lectin; and the alternative pathway, triggered directly by surface molecules on a pathogen 
surface (Mueller-Ortiz, Drouin & Wetsel, 2004; Thurman & Holers, 2006).  
Some of the complement components are serine protease in nature which are crucial for the 
proteolytic activation of the whole system, among them C1r and C1s from the classical 
pathway and mannan-binding-protein-associated serine proteases (MASPs) from the lectin 
pathway (Cunningham & Quigg, 2005). They all share a common lytic pathway resulting 
in the formation of the membrane attack complex (MAC). At least 12 proteins are known 
to regulate and limit the complement activity and prevent sudden spontaneous complement 
activation which may lead to anaphylaxis (Cunningham & Quigg, 2005). Complement 
activation is also important for processing and limiting the size of circulating immune 
complexes (Alexander et al., 2001) and therefore, transferring the immune complexes to 
Fc R-bearing cells of the mononuclear phagocyte system.  
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4.1.2.1: The Classical Pathway: 
The classical pathway is triggered by the binding of complement component C1q to 
complexes of IgG/antigen or IgM/antigen (Cunningham & Quigg, 2005). C1 contains 6 
molecules of C1q, 2 molecules of C1r and 2 molecules of C1s. A binding site for C1q is 
present on the constant region of the antibodies. Activated C1 activates C4 and then C2, 
which form the C3 convertase (C4b2a) (Cunningham & Quigg, 2005). This catalyzes C3 to 
the C3a (anaphylatoxin) and C3b which binds to the growing immune complex. Following 
the formation of the C5 convertase (C4b2a3b), circulating C5 is cleaved into C5a 
(anaphylatoxin) and C5b. Similar to C3b, C5b joins to the immune complex, where it 
activates C6, C7, C8, and C9 and forms the C5b-9 complex (Figure 4.3). The hydrophobic 
domains of C7, C8, and C9 can insert into the lipid cell membranes of bacteria, 
erythrocytes, and nucleated cells and may lead to the changes in lipid layers of plasma 
membrane allowing the exchange of ions and water which results in the cell lysis. They 
may also activate a range of signaling pathways and induce the active process of 
endocytosis (Cunningham & Quigg, 2005; Wasowska et al., 2007).  
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Classical Pathway                                  Lectin Pathway 
(Antigen +Antibody)  C1q/C1r/C1s                      MBL/MASP-1/MASP-2 
 
 
                                  C4                            C4b + C2 
                                                 C4a                                  C4b2a (C3 convertase) 
                                                                                                      C4b2a3b (C5 convertase)  
                                                                                                                   C6-9 
       C3                               C3b + C3a       C5      C5b                C5b-9 (MAC)  
                      C5a 
                               C3Bb3b 
                    (Amplification loop) 
                                                                      C3bBb-P (Amplification C3 convertase) 
                              C3               C3b + B      P,D 
Alternative Pathway 
   C3 (H2O) or C3b + B                             C3(H2O)Bb (Intiation C3 covertase)         
                                        D          Ba 
 
 
 
Figure 4.3: Adopted figure of complement activation pathways. The classical, lectin, or 
alternative pathways can activate complement system. The proinflammatory mediators 
such as C3a and C5a, C3b can interact with complement receptors and the C5b-9 
membrane attack complex (MAC). B, Factor B; D, Factor D; P, Properdin; MBL, 
mannose-binding lectin; MASP-1, MBL-associated serine protease-1; MASP-2, MBL-
associated serine protease-2 (Cunningham & Quigg, 2005). 
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4.1.2.2: The Alternative Pathway: 
The complement system can also be activated spontaneously through the alternative 
pathway. Three unique components of the alternative pathway are factor B, factor D, and 
properdin which have crucial roles in this process (Thurman & Holers, 2006).  
The alternative pathway is activated through a process referred as tickover of C3 (Thurman 
& Holers, 2006). As a result of the spontaneous hydrolysis of C3 in plasma, C3(H2O) is 
generated (Figure 4.3). C3(H2O) associates with Factor B resulting in the generation of 
C3(H2O)Bb. Factor B can be cleaved by an active serum protease, factor D, which leads to 
the generation of Ba and Bb. The Bb fragment remains with the complex and can cleave 
additional C3 molecules and therefore generate more C3Bb which is a C3 convertase. The 
serum protein properdin (P) stabilizes protein-protein interactions during the process. The 
“amplification loop” of the alternative pathway can also be initiated when C3b, generated 
by classical or the lectin pathway, binds factor B which leads to the process as described 
above. The C3 and C5 convertases of the alternative pathway (C3bBb and C3bBb3b) also 
trigger and generate C3a, C3b, C5a, and C5b-9 (Cunningham & Quigg, 2005; Thurman & 
Holers, 2006). Since the alternative pathway is able to be activated spontaneously, it 
requires continuous active control by cell-bound complement regulatory proteins (CRP) 
(Rose et al., 2008). CRP may influence the complement activation cascades resulting in the 
prevention of C1 activation by C1 inhibitor and blocking formation of C5b-9 by CD59.  
There is a further group of proteins which are contained within the regulators of 
complement activation gene family and these include the C4-binding protein, factor H, 
decay accelerating factor (DAF; CD55), membrane co-factor protein (CD46), and 
complement receptor 1 (CR1; CD35) (Cunningham & Quigg, 2005). In humans DAF and 
CR1 lower C3 and C5 activation and CD59 restricts C5b-9 formation.  
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4.1.2.3: The Lectin Pathway: 
The lectin pathway plays a crucial role in innate immunity particularly between the first 6 
and 18 months of age when the adaptive immune system is still immature (Turner, 2003). 
This pathway is an antibody-independent pathway triggered by the binding of mannose-
binding lectin (MBL) ficolins to a range of sugars including N-acetyl-D-glucosamine, 
mannose, N-acetyl-mannosamine, fucose and glucose found on the surface of 
microorganisms (Krarup et al., 2007; Takahashi et al., 2007). MBL is structurally similar 
to C1q, and activates the complement system through MBL-associated serine protease 
(MASP) which is similar to C1r and C1s of the classical pathway (Nonaka & Miyazawa, 
2002). The binding of ficolin and MASPs molecules to pathogen surface leads to 
conformational changes in these complexes resulting in autoactivation of the MASPs 
which initiates antibacterial activity by the terminal, lytic complement components.  
Three types of MASPs, referred to as MASP-1, MASP-2 and MASP-3 have been 
identified. MASP-2 can autoactivate and cleaves C4 and C2 to make a C3 convertase, 
C4b2a. MASP-1 has an ability to cleave C3 directly (Takahashi et al., 2007).  
 
 
 
4.1.2.4: IgG subclasses and the Complement System: 
Although the C domains of IgG subclasses share almost identical amino acid sequences, 
their ability to activate complement are different (Tan et al., 1990; Sitaru, Mihai & 
Zillikens, 2007). Various studies have shown that IgG3 is the most efficient at activating 
complement followed by IgG1, with IgG2 being a weak activator, whilst IgG4 seems to be 
unable to activate complement (Doekes, van Es & Daha, 1984; Garred, Michaelsen & 
Aase, 1989; Saeland et al., 2003; Sitaru, Mihai & Zillikens, 2007). Some of the other 
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factors which may affect complement activation are the segmental flexibility of the hinge 
region (Redpath et al., 1998; Hezareh et al., 2001), antigen specificity and density (Da 
Silveira  et al., 2002) and high antibody concentration (Bard et al., 2003).  
It has been suggested that the hinge region determines the difference between IgG isotypes 
partly since the hinge regions have diverse sequences (Tan et al., 1990) and the IgG3 hinge 
has the highest flexibility (Redpath et al., 1998). In addition the density and distribution of 
antigen epitope influences C1 activation by creating a suitable angle of the IgG Fab arms 
(Lucisano Valim & Lachmann, 1991; Da Silveira  et al., 2002). Complement activation 
through the classical pathway is also triggered more efficiently at high antibody 
concentration which is markedly influenced by antibody affinity (Bard et al., 2003).  
IgG1 activates C4 and C3 better than IgG3 and IgG2 at high antigen concentrations whilst 
at low epitope density IgG3 is the best inducer of complement activation followed by IgG1 
and IgG2. On the other hand, at high epitope density and complement concentration IgG2 
is able to trigger the alternative pathway efficiently in contrast to IgG1 and IgG3 (Garred, 
Michaelsen & Aase, 1989; Lucisano Valim & Lachmann, 1991; Sitaru, Mihai & Zillikens, 
2007).  
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4.1.3: Hypersensitivity: 
The term of hypersensitivity is used to describe exaggerated or inappropriate immune 
responses to an allergen or antigen that result in tissue damage. 
Hypersensitivity reactions have been classified to 5 types as follows: 
 Type I or immediate hypersensitivity which develops when antigen-antibody 
complexes, in this case IgE, cause the degranulation of mast cells with the release 
of histamine and other mediators (Marshall & Bienenstock, 1994; Wigginton et al., 
2008). Anaphylaxis and hay fever are the examples of this type of hypersensitivity 
reaction.      
 Type II or antibody-mediated hypersensitivity involves IgG or IgM bound to the 
antigens with subsequent complement fixation (Jewett et al., 1997; Niwa et al., 
2005). Examples of this mechanism are Haemolytic Anaemia, Good Pasture’s 
Syndrome and Rheumatic Fever.  
 Type III or immune complex-mediated hypersensitivity (described in section 
4.1.3.1) 
 Type IV or delayed-type hypersensitivity (described in section 4.1.3.2) 
 Type V or stimulatory hypersensitivity in which antibody (IgG) binds to the cell 
surface receptors which mimic the effects of the ligand and have a stimulatory 
effect on its target. This type is seen in Myasthenia gravis, Graves disease and 
Thyrotoxicosis due to TSH autoantibodies (Rajan, 2003).  
HP is considered to be a mixture of type III and Type IV responses (Yi, 2002) which I will 
discuss further. 
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4.1.3.1: Type III Hypersensitivity Reaction: 
 
Type III hypersensitivity reactions can be triggered by exposure to soluble antigens and 
clinical presentation may happen after 3-10 hours. The pathology starts by the deposition 
of IC at the basement membrane of blood vessels, kidneys or in the lungs in the case of 
HP. IC then can bind to FC receptors on leukocytes, leading to tissue injury. The 
pathogenic potential of IC is determined by their size and concentration, affinity, and 
isotype of the antibody in the IC. Clinically type III hypersensitivity reaction has 2 types of 
presentation including localized and generalized types (Riedl & Casillas, 2003; Ghaffar, 
2004; Ellsworth et al., 2008).   
The arthus reaction is an example of a localised reaction. Following injection an antigen 
into the skin of a sensitized individual, circulating IgG antibody forms IC locally which 
can bind to FCȖ RIII (CD16) on mast cells and other leukocytes. This initiates 
degranulation of mast cells and a local inflammatory response with increased vascular 
permeability which leads to the retention of fluid and influx of leukocytes to the site 
(Figure 4.4.a) (Razin, Pecht & Rivera, 1995). These IC can also activate complement 
through the classical pathway. C3a and C5a not only cause localized mast cell 
degranulation and increased vascular permeability but also can bind to C5a receptors on 
leukocytes. 
On the other hand, the systemic type of reaction can be described in serum sickness as a 
result of the injection of large quantities of foreign soluble antigens and deposition of IC 
throughout the body. The clinical features are chills, fever, rash, arthritis, and 
glomerulonephritis. The ligation of IC with FCȖ RIII triggers mast cells degranulation 
(Figure 4.4.b) (Ellsworth et al., 2008). These IC also activate complement and bind to 
leukocytes bearing Fc and complement receptors which can cause widespread tissue injury. 
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Anti-lymphocyte globulin, which is an immunosuppressive agent used in transplant 
recipients, can cause serum sickness (Cuzic et al., 2001).  
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Figure 4.4.a: The local type III hypersensitivity reaction (Arthus Reaction). 
Following injection of the antigen into the skin of sensitized individual and formation 
of immune complexes, they bind to FCȖ RIII on mast cells and other leukocytes which 
initiates mast cell degranulation and increased vascular permeability. This leads to the 
retention of fluid and influx of leukocytes to the site (Janeway, 2008). 
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Figure 4.4.b: Development of systemic type III hypersensitivity reaction. Immune 
complexes initiate the complement cascade. The complement intermediates 
stimulate (i) mast cell degranulation, (ii) neutrophil recruitment, and (iii) releasing 
lytic enzyme from neutrophil in order to help in phagocytosis of C3b-coated 
immune complexes. 
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4.1.3.2: Type IV Hypersensitivity Reaction: 
 
Type IV hypersensitivity reactions are mediated by antigen-specific effector T cells and are 
an important mechanism in host defence against intracellular bacteria and parasites. It has 
2 phases including the sensitisation phase and effector phase.  
As seen in cutaneous hypersensitivity, the sensitizing chemicals react with self proteins 
and create protein-hapten complexes which bind to MHC class II molecules which are 
recognised as foreign antigens by T cells. These antigens are processed by cutaneous 
δangerhans’ cells during the sensitization phase and migrate to regional lymph nodes to 
activate T cells and generate memory T cells. The activated T cells are mostly CD4+ and 
Th1 cells but CD8+ T cells may also be activated (Czarnobilska, Obtulowicz & Wsolek, 
2007).  
Following further exposure, the antigen is presented to memory T cells in the dermis which 
triggers the production of T cell cytokines such as IFN-Ȗ and Iδ-17. This stimulates the 
keratinocytes of the epidermis and they release cytokines such as IL-1, IL-6, TNF-α and 
GM-CSF (Squier & Cohen, 1994; Kinet, 1999). These cytokines activate resting 
macrophages and increase their phagocytic potential. These activated macrophages also 
express higher level of class II MHC molecules, and therefore have more effective function 
as APCs (Figure 4.5.a). In the case of EAA, the release of the lytic enzymes from activated 
macrophages can initiate non-specific tissue damage and create granulomatous lesions (Yi, 
2002).  
Another example of type IV hypersensitivity is seen after immunization with BCG when a 
local T cell-mediated inflammatory reaction begins over 24–72 hours (Figure 4.5.b) 
(Umemura et al., 2007). Following injection complexes of peptide/MHC class II molecules 
on APCs are recognised by Th1 cells leading to release of inflammatory cytokines such as 
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IFN-Ȗ and TNF-ȕ. The cytokines can increase local vascular permeability which causes a 
visible swelling at this site. This process takes 24-48 hours to develop. 
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Figure 4.5.a: Type IV hypersensitivity reaction. During the first 1-2 weeks 
following primary contact between antigen (ie: intracellular bacteria, chemicals) 
and antigen presenting cells (APCs, ie: macrophage), T helper cells proliferate. 
After secondary contact with antigen, T cells secrete a variety of cytokines which 
lead to activation of macrophages. These cells express higher level of class II MHC 
molecules and increased level of phagocytosis.   
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Figure 4.5.b: The local presentation of type IV hypersensitivity. Following subcutaneous 
injection of the antigens, APCs pick up the antigens and present them via class II MHC to 
Th1 cells. This stimulates Th1 cells to release cytokines which cause an increase in 
vascular permeability and therefore swelling at the site of injection (Janeway, 2008). 
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4.1.4: Evidence of Type III and IV Hypersensitivity reactions in PFL: 
As previously described (sections 4.1.3.1, 4.1.3.2), the acute form of disease usually occurs 
4-6 hours after exposure to the relevant antigen in susceptible individuals (Kaltreider, 
1993; Bourke et al., 2001). Basically alveolar macrophages engulf foreign antigens, 
transport them to the cell surface and present the complex of MHC/antigen to Th cells 
(Kaneko et al., 2000; Desombere et al., 2005).  This leads Th cells to become activated and 
interact with B cells. As a consequence, B cells start differentiating into plasma cells which 
secrete antibodies (Jenkins et al., 2001). The reaction between antigen and antibody 
produces IC, which may become deposited in the basement membrane of the lungs and 
these will then activate the complement cascade by the classical pathway (Cunningham & 
Quigg, 2005; Wasowska et al., 2007). Neutrophils attracted to the site of inflammation try 
to phagocytose the IC and also release lytic enzymes causing localized tissue damage and 
neutrophilic alveolitis (Razin, Pecht & Rivera, 1995).  
These findings support the initial report of HP being an immune complex mediated 
(Hypersensitivity reaction type III) disease but subsequently studies have shown that T 
cells and inflammatory cytokines may have even greater roles to play in the pathogenesis 
of disease than immune complexes (Curtis et al., 1991; Ohkawa et al., 2001; Curtis et al., 
2002). This is supported by adoptive transfer of experimental HP by intravenous injection 
of a Th1 cell line in animal models (Schuyler et al., 1997).  
During the chronic phase of HP, activated CD4 + T cells  can be divided into either Th1 or 
Th2 cells based on their pattern of cytokine secretion (Irifune et al., 2003; Barrera et al., 
2008). Th1 cells secrete IL-2, IFN- and TNF- which help in activating resting 
macrophages and their phagocytic activities which are responsible for cell mediated 
immunity reactions. Lytic enzymes from activated macrophages can cause a non-specific 
tissue damage and the formation of granulomatous lesions (Kinet, 1999). IL6 and TNF-α 
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also are higher in the chronic stage of disease as compared to the acute stage and this 
emphasizes the importance of these cytokines in the development of pulmonary fibrosis 
(Ohtani et al., 1999).  
 
 
 
 
4.1.5: Pigeon Intestinal Mucin as an Antigen in PFL: 
PIM is a complex high molecular weight glycoprotein with a high carbohydrate 
composition of 70-80% (Hounsell, Davies & Renouf, 1996; Baldwin et al., 1999; Thornton 
& Sheehan, 2004).  
PIM is produced by goblet cells in the intestine of pigeon and has been shown to be highly 
antigenic in humans (Todd, Coan & Allen, 1991). It has been detected in pigeon droppings 
and pigeon bloom collected from pigeon lofts (Fredricks, 1978; Todd, Coan & Allen, 
1991; Baldwin et al., 2000b) and thus pigeon fanciers have been shown to be exposed to 
high levels of the antigen. The carbohydrates in pigeon intestinal mucin may be O or N- 
linked with the majority being O-linked. Based on the resistance to proteolytic digestion, 
there are 2 regions on the mucin protein core: the highly glycosylated (bottle brush) region 
which is shown in figure 4.6.a and the regions susceptible to proteolysis where 
glycosylation is little or absent (Baldwin et al., 1999). Following proteolysis, the heavily 
glycosylated and antigenic mucin fragments are produced which are resistant to further 
breakdown, thus they may persist in the pigeon loft for long periods of time. These highly 
glycosylated regions are rich in serine, threonine and proline which are the sites for sugar 
attachment. The glycosylation of PIM was investigated by enzyme-linked lectin assay 
(ELLA). High levels of α-2, 3 N-acetyl neuraminic acid (α-2, 3 NeuNAc), N-acetyl 
galactosamine (GalNAc) and N-acetyl glucosamine (GlcNAc) and low levels of fucose 
(Fuc) and galactose (Gal) were detected. Very high levels of α-2, 3 NeuNAc in PIM  
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Figure 4.6.a: Generic structure of a mucin monomer; the heavily glycosylated and 
antigenic fragment of mucin molecule (Bowen, 1998).                 
 
 
 
 
       GalNAc(ȕ1-γ)GalcpNAc(ȕ1-4)Gal(ȕ1-γ)Gal(α/ȕ) 
                                       3                            
                                     Fucα1 
 
      Figure 4.6.b: The terminal structure of side chains in mucin molecule; N-acetyl 
galactosamine (GalNAc), N-acetyl glucosamine (GlcNAc), fucose (Fuc) and galactose 
(Gal) (Baldwin et al., 2005). 
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suggest that a large proportion of the oligosaccharide chains are sialylated (Baldwin et al., 
1999; Thornton & Sheehan, 2004). The terminal structure of these side chains are shown in 
figure 4.6.b (Baldwin et al., 2005).  
The antibody positive fanciers have high titres of anti-mucin IgG (Todd, Coan & Allen, 
1991; Baldwin et al., 1998a; Baldwin et al., 1998c). Although IgG titres are similar in 
symptomatic and asymptomatic fanciers, a significant difference in the IgG subclass 
against PIM has been identified.  All 4 subclasses of IgG antibody against PIM are present 
in the pigeon fanciers’ serum, however, it has been demonestrated that anti-PIM IgG1 is 
significantly higher in symptomatic individuals and this correlates with the development of 
disease (Baldwin et al., 2000b). It has been suggested that the immune complexes 
containing IgG1 are able to bind to a range of FC receptors more effectively than the 
immune complexes containing other IgG antibodies and thus they may have more 
significant pathological effects (Burton, Gregory & Jefferis, 1986; Todd, Coan & Allen, 
1993; Baldwin et al., 1998c).  Furthermore, IgG2 levels are high in both symptomatic and 
asymptomatic fanciers whilst IgG3 and IgG4 are much lower in both groups (Baldwin et 
al., 1998a; Baldwin et al., 1998c; Baldwin et al., 2000a).  
      High levels of anti- proteolytically digested mucin- IgG1 and IgG2 have been detected, 
suggesting that these antibodies are carbohydrate-specific. On the other hand, IgG3 
reactivity was significantly reduced in proteolytically digested mucin, suggesting that IgG3 
reacts against the protein portion of the molecule (Baldwin et al., 1999).  
Thus, PIM may stimulate both T-dependent (TD) and T-independent (TI) antibody 
responses due to the highly glycosylated nature of this molecule. TI responses are found 
against carbohydrate (CHO) antigens whilst TD responses are typically found against 
protein antigens (Obukhanych & Nussenzweig, 2006). Interestingly, in this case IgG1 is 
generated against the CHO region of the PIM, which is an unusual observation as generally 
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IgG1 is considered to be a TD antibody and is almost exclusively active against protein 
antigens whilst IgG2 is a TI antibody and is produced against carbohydrate antigens 
(Hammarstrom & Smith, 1986).  
 
    
 
4.1.6: Antibody Affinity: 
The strength of binding between a monovalent antibody molecule and an antigenic 
determinant is called the affinity (Steward, 1979; Rosleos et al., 2007). It is under 
polygenic control and is important in providing an effective and protective immunity. The 
fit of the antigen into the binding grove of a Fab, the size of contact area, hypervariable 
loop conformation changes (Rini, Schulze-Gahmen & Wilson, 1992), rotation of VH-VL 
interface (Stanfield et al., 1993) and the distribution of hydrophobic groups influence the 
antibody affinity. The reduced flexibility of the antibody binding pocket has also been 
reported to be important in the generation of high affinity antibody (lock-and-key model) 
(Thorpe & Brooks, 2007).  
On the other hand, functional affinity or avidity is defined as the multivalent binding of an 
antibody to a complex antigen and shows the overall binding strength in an immune 
complex. Increasing antibody affinity over the lifetime of an immune response is referred 
to as affinity maturation and depends on SHM in the variable region of the antibody 
molecule mainly in the CDR which increases the surface complementarity (Furukawa et 
al., 2001; Acierno et al., 2007). It is triggered when an antigen enters the body and is 
presented to T cells via class II MHC which leads to MHC-TCR interaction and expression 
of CD40L on T cells. CD40 cross-linking on the surface of B cells leads to B cell 
proliferation, generation of plasma cells and also triggers CSR and SHM which previously 
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discussed in section 4.1.1.3  (Imai et al., 2003; Zarrin et al., 2005; Notarangelo et al., 
2006). Since low affinity antibody may not be able to eliminate the antigen effectively, the 
formation of immune complexes in an antigen excess situation may cause immune 
complex disease (Devey, Beckman & Kemeny, 1993). On the other hand, it has been 
suggested that infection with high antigen load even in the presence of high level of high 
affinity antibodies may result in the deposition of immune complexes (Steward, 1979).  
The structural difference in the constant region of the antibodies may also determine the 
affinity of the antibody (McCloskey et al., 1996). Carbohydrate groups on antibodies also 
have important roles in solubility, stability, immune complex clearance, antibody 
dependent cellular cytotoxicity and macrophages recognition through FC Receptor.  For 
instance, the absence of glycosylation, mutation in the COOH-terminal of HC region and 
fucose depletion can influence the antibody affinity (Bazin et al., 1992; Okazaki et al., 
2004).  
 
 
 
4.2: Aims: 
The aim of this section was to study antibody responses in symptomatic and asymptomatic 
pigeon fanciers and to identify the functional affinity of specific anti-pigeon antigen IgG 
isotypes. 
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4.3: Results: 
4.3.1: Human Subjects: 
Human subjects were classified into one of the following 5 groups based on clinical 
findings and IgG titres of equal or greater than 10000 as measured by ELISA. It has been 
shown that an ELISA titre of 10000 or more correlated with the detection of precipitating 
antibodies as measured by CIE (Baldwin personal communication). 4 of these groups were 
pigeon fanciers and one group was control negative individuals: 
 Group A: Symptomatic with EδISA titres ≥ 10000 (nμ β5) 
 Group Bμ Asymptomatic with EδISA titres ≥ 10000 (nμ β5) 
 Group C: Symptomatic with ELISA titres < 10000 (n: 25) 
 Group D: Asymptomatic with ELISA titres < 10000 (n: 25) 
 Group E: Control negative with no pigeon contact with ELISA titres < 1000 (n: 10) 
 
Table 4.3 shows the details of the background of individuals in group A-D. 
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 Group A Group B Group C Group D Group E 
Age (mean) 
     (range) 
 
Sex (number) 
 Male 
 Female 
Years spent with  
pigeon (mean) 
 
Number of pigeons 
           (mean) 
 
 
Hours of contact/wk 
          (mean) 
 
 
 
Smoking  Non/Ex-
smoker  current 
smoker 
 
 
50 
(21-73) 
 
 
23 
2 
29 
 
83 
 
25 
 
 
22 
3 
 
50 
(25-77) 
 
 
25 
0 
33 
 
87 
 
29 
 
 
24 
1 
46 
(23-77) 
 
 
25 
0 
24 
 
101 
 
23 
 
 
13 
12 
40 
(14-60) 
 
 
25 
0 
20 
 
74 
 
29 
 
 
7 
18 
34 
(24-47) 
 
 
8 
2 
0 
 
0 
 
0 
 
 
8 
2 
 
 
 
Table 4.3: Details of the human subjects classified in group A-E.  
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There were no significant age differences between groups A and B, and group C and D. All 
fanciers included in this study were males except 2 females in group A. Group B had the 
longer history of contact with pigeons than group A, however, the difference was not 
significant. This difference was not also significant when group C was compared with 
group D. 
When smoking habit of fanciers was compared between groups, there was no significant 
difference between group A and B, and group C and D. 
  
 
4.3.2: Preparation of Antigens: 
4.3.2.1: Pigeon Intestinal Mucin (PIM): 
Soluble mucin was prepared as described in section 3.1. The results of the first and the 
second CsCl density gradient centrifugations are shown in figure 4.7.  
After the first CsCl density gradient centrifugation, high concentrations of protein were 
found in the earlier, low density fractions and low concentrations of protein were detected 
in the later fractions (4.7.A). 
On the other hand, high concentrations of carbohydrate were found in the later, high 
density fractions, whilst low concentrations of carbohydrate were detected in the earlier 
fractions (4.7.A). 
Fractions 6-9 (density: 1.476-1.582 g/ml) of the first CsCl density gradient centrifugation 
had the highest concentrations of carbohydrate and were pooled and underwent a second 
run of centrifugation. After the second CsCl centrifugation, the highest concentrations of 
carbohydrate were recovered from fractions 6-9 (density: 1.40-1.466 g/ml) and very little 
protein was present in any of the removal fractions (4.7.B). 
Fractions 6-9 were pooled and designated as PIM, freeze dried and used for future studies. 
121 
 
 
 
 
 
(A) Carbohydrate (CHO) and protein concentration (ȝg/ml) and density 
(g/ml) after the first CsCl centrifugation. Fractions 6-9 (density: 
1.476-1.582) had the highest concentrations of CHO. 
(B) CHO and protein concentrations (ȝg/ml) and density (g/ml) after 
second CsCl centrifugation. Fractions 6-9 (density: 1.40-1.466) had 
the highest concentrations of CHO. 
 
 
A
 
1 2 3 4 5 6 7 8 9
Fraction
0
1
2
3
4
Concentration (ug/ml)
1
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2
Density (g/ml)
Density
CHO
Protein
 
 
   
B
 
1 2 3 4 5 6 7 8 9
Fraction
0
2
4
6
8
10
12
Concentration (ug/ml)
1
1.2
1.4
1.6
1.8
2
Density (g/ml)
Density
CHO
Protein
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4.3.2.2: Trypsinised Mucin: 
TM was prepared as described in section 3.2. The final mixture was aliquoted and stored at 
– 20°C.   
4.3.2.3: Fresh Pigeon Droppings (PDF) and Old Pigeon Droppings (PDO):  
Fresh (PDF) and old (PDO) pigeon droppings had previously been collected from a pigeon 
loft (supplied by Dr Christopher Baldwin). They were prepared as described in section 3.3. 
A proportion of freeze-dried extracts were reconstituted in deionised water to make PDF 
and PDO at 1 mg/ml concentration for further experiments. 
4.3.2.4: PIS:  
The supernatant of the pigeon intestinal scrapings was prepared as described in section 3.1 
and used as one of the pigeon antigens called PIS. This antigen contains soluble mucus and 
is different from PIM with respect to the high concentration of protein in this sample. 
4.3.2.5: Pigeon serum: 
PS was commercially supplied by Sigma (Sigma, UK). 
 
 
 
4.3.3: Measurement of Protein and Carbohydrate concentrations of Pigeon Antigens: 
The carbohydrate and protein concentrations of each pigeon antigen were measured by the 
PAS and Bio-Rad methods as described previously (sections 3.5 and 3.6). 
The results are presented in table 4.4.  PIS had the highest (44κ0 ȝg/ml) carbohydrate 
concentration whilst mucin and PDO had a much lower (βκ0 ȝg/ml) carbohydrate 
concentration. On the other hand, mucin and Tε had the lowest (<5 ȝg/ml) protein 
concentration whilst PS contained the highest (640 ȝg/ml) concentration of protein.     
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Pigeon Antigens Protein Concentration (g/ml) Carbohydrate Concentration (g/ml)  
Mucin 
TM 
PDF 
PDO 
PIS 
PS 
 5 
 5 
240 
10 
400 
640 
280 
400 
1600 
280 
4480 
1600 
 
 
 
Table 4.4: The ptotein and carbohydrate concentrations of the pigeon antigens used in this 
study. 
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4.3.4: Checker Board ELISA: 
To establish the optimal concentration and dilution of each pigeon antigen a checkerboard 
ELISA was performed as described in section 3.8. 
Examples of individual antigen checker board for PDO, PIS and PIM can be seen in 
figures 4.8- 4.10. Data for PDF, PS and TM are not shown. The optimal antigen 
concentration for coating the ELISA plates for each antigen is shown in table 4.5. 
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Figure 4.8: The checker board ELISA graph for PDO, the optimal dilution of PDO was 
1/500. 
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 Figure 4.9: The checker board ELISA graph for PIS, the optimal dilution of PIS was 
1/7000. 
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Figure 4.10: The checker board ELISA graph for PIM, the optimal dilution of PIM was 
1/2000. 
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Pigeon 
Antigen 
Optimal dilution for 
ELISA 
[CHO] μg/ml at the 
optimal dilution 
[protein] μg/ml at the 
optimal dilution 
PIM 
TM 
PS 
PDF 
PDO 
PIS 
1/2000 
1/500 
1/2000 
1/1000 
1/500 
1/7000 
0.14 
0.8 
0.8 
1.6 
0.6 
0.64 
0.003 
0.01 
0.32 
0.24 
0.02 
0.06 
 
 
 
 
 
Table 4.5: The optimal dilution and concentration of pigeon antigens as determined by 
checker board ELISA for coating ELISA plates. 
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The ELISA plates were coated with the pigeon antigens with carbohydrate concentrations 
of 0.14- 0.κ ȝg/ml. The diluted PIM used for coating the ELISA plates had the lowest 
carbohydrate concentration 0.14 ȝg/ml whilst the highest concentration belonged to PS and 
Tε (0.κ ȝg/ml). The protein concentration of the coating antigens varied 0.00γ ȝg/ml 
(PIε) to 0.β4 ȝg/ml (PDF). 
 
 
 
 
4.3.5: IgG ELISA: 
ELISA was used to determine the titre of IgG against the pigeon antigens including PIM, 
TM, PS, PDF, PDO and PIS as previously described in section 3.9. 
Absorbance at 490 nM was plotted against the reciprocal of the serum dilution.  
The reciprocal of the dilution of each serum sample that gave an optical density of 0.2 
(approximately 3 times of the background) was considered to be the end point titre of the 
test serum. An example of an ELISA test plate for each antigen is shown in figures 4.11- 
4.16. 
Note that as the samples were tested in different ELISA plates on different days, the same 
positive control serum sample was always included on each plate. This enables the results 
from different plates on different days to be compared. The positive control sample was 
from an asymptomatic fancier with high specific antibody titres against pigeon antigens. 
The median and the range of IgG titres for each clinical group are shown in Table 4.6 and 
figure 4.17 shows the level of IgG against all pigeon antigens in the 5 study groups. 
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Figure 4.11: Anti-mucin IgG graph of 7 pigeon fanciers’ serum sample; PB900 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered to 
be the titre of the serum. 
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Figure 4.12: Anti-TM IgG graph of 7 pigeon fanciers’ serum sample; PBλ00 was control 
positive sample. Absorbance was plotted against the reciprocal of the serum dilution and 
the value of each sample that gave an optical density of 0.2 was considered to be the titre 
of the serum. 
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Figure 4.13: Anti-PS IgG graph of 7 pigeon fanciers’ serum sample; PBλ00 was control 
positive sample. Absorbance was plotted against the reciprocal of the serum dilution and 
the value of each sample that gave an optical density of 0.2 was considered to be the titre 
of the serum. 
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Figure 4.14: Anti-PDF IgG graph of 7 pigeon fanciers’ serum sample; PBλ00 was control 
positive sample. Absorbance was plotted against the reciprocal of the serum dilution and 
the value of each sample that gave an optical density of 0.2 was considered to be the titre 
of the serum. 
 
131 
 
10 100 1000 10000 100000 1000000
Titre
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
OD at 490 nM
PB900
PB18
PB19
PB141
PB108
PB140
PB349
PB666
 
Figure 4.15: Anti-PDO IgG graph of 7 pigeon fanciers’ serum sample; PBλ00 was control 
positive sample. Absorbance was plotted against the reciprocal of the serum dilution and 
the value of each sample that gave an optical density of 0.2 was considered to be the titre 
of the serum. 
 
10 100 1000 10000 100000 1000000
Titre
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
OD at 490 nM
PB900
PB18
PB19
PB141
PB108
PB140
PB349
PB666
 
Figure 4.16: Anti-PIS IgG graph of 7 pigeon fanciers’ serum sample; PBλ00 was control 
positive sample. Absorbance was plotted against the reciprocal of the serum dilution and 
the value of each sample that gave an optical density of 0.2 was considered to be the titre 
of the serum. 
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Group Anti- mucin 
IgG Titres 
Median 
(range) 
Anti- TM 
IgG Titres 
Median 
(range) 
Anti- PS 
IgG Titres 
 
Median 
 
(range) 
Anti- PDF 
IgG Titres 
Median 
(range) 
Anti- PDO 
IgG Titres 
Median 
(range)  
Anti- PIS 
IgG Titres 
Median 
(range) 
 
A 
n:25 
 
 
B 
n:25 
 
 
C 
n:25 
 
D 
n:25 
 
E 
n:10 
 
84000 
(10000- 
375000) 
 
112000 
(24000-
245000) 
 
500 
(5-8400) 
 
900 
(20-8400) 
 
120 
(20-2000) 
 
 
291000 
(8700-1160000) 
 
 
464000 
(145500-
1750000) 
 
1700 
(5-50000) 
 
1700 
(70-12800) 
 
300 
(40-3500) 
 
 
21000 
(470-245000) 
 
 
31600 
(470-230000) 
 
 
340 
(5-4500) 
 
930 
(20-27900) 
 
40 
(8-2200) 
 
 
134400 
(7500-
735000) 
 
145000 
(42000-
655000) 
 
1300 
(5-13500) 
 
1600 
(20-21600) 
 
300 
(60-7500) 
 
 
145000 
(77000-
525000) 
 
275000 
(66000-
800000) 
 
1300 
(60-36000) 
 
2000 
(200-77000) 
 
700 
(100-2600) 
 
 
56400 
(4000-
784000) 
 
87000 
(15000-
400000) 
 
470 
(5-8700) 
 
700 
(20-22500) 
 
100 
(50-700) 
 
 
 
Table 4.6: The median and interquartile range of IgG titres against pigeon antigens in each 
study group; anti-PS IgG had the lowest median and range among pigeon antigens. 
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Figure 4.17: IgG titres against pigeon antigens in all study groups; 1: IgG anti- PIM, 2: 
IgG anti- TM, 3: IgG anti- PDF, 4: IgG anti- PDO, 5: IgG anti- PIS, 6: IgG anti- Pigeon 
serum.  
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Overall, groups A and B had significantly higher IgG titres than groups C, D and E 
(P≤0.001). Interestingly, individuals in group B had higher IgG titres against all pigeon 
antigens as compared to group A (figure 4.17). Although only anti- TM and anti-PDO IgG 
titres were significantly higher (P= 0.02 and P= 0.03, respectively).  
Also the median and range of anti-TM responses were the highest followed by anti-PDO, 
anti-PDF, anti-PIM, anti- PIS and anti-PS responses.  However, the lowest IgG titres were 
anti-PS.   
 
 
 
 
4.3.6: IgG Subclass ELISA: 
ELISA was used to determine the titre of IgG1 and IgG2 against the pigeon antigens as 
described in section 3.10. The positive control sample was from an asymptomatic fancier 
with high specific antibody titres against pigeon antigens. 
Absorbance at 490 nM was plotted against the reciprocal of the serum dilution.  
The reciprocal of the dilution of each serum sample that gave an optical density of 0.2 
(approximately 3 times of the background) was considered to be the end point titre of the 
test serum. An example of an ELISA test plate for each antigen is shown in figures 4.18- 
4.29. 
The median and the range of IgG1 and IgG2 titres for each clinical group are shown in 
Table 4.7 and 4.8. Also figure 4-30 and 4.31 show the level of IgG1 and IgG2 against all 
pigeon antigens in all study groups. 
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Figure 4.18: Anti-mucin IgG1 graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered to 
be the titre of the serum. 
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Figure 4.19: Anti-Tε IgG1 graph of 7 pigeon fanciers’ serum sample; PBλ00 was control 
positive sample. Absorbance was plotted against the reciprocal of the serum dilution and 
the value of each sample that gave an optical density of 0.2 was considered to be the titre 
of the serum. 
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Figure 4.20: Anti-PS IgG1 graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.21: Anti-PDF IgG1 graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.22: Anti-PDO IgG1 graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.23: Anti-PIS IgG1 graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.24: Anti-mucin IgGβ graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.25: Anti-Tε IgGβ graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.26: Anti-PS IgGβ graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.27: Anti-PDF IgGβ graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.28: Anti-PDO IgGβ graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Figure 4.29: Anti-PIS IgGβ graph of 7 pigeon fanciers’ serum sample; PBλ00 was 
control positive sample. Absorbance was plotted against the reciprocal of the serum 
dilution and the value of each sample that gave an optical density of 0.2 was considered 
to be the titre of the serum. 
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Group Anti- mucin 
IgG1 
Median  
(range) 
Anti- TM 
IgG1  
Median 
(range) 
Anti- PS 
IgG1  
 
Median 
 
(range) 
Anti- PDF 
IgG1 
Median 
(range) 
Anti- PDO 
IgG1 
Median  
(range)  
Anti- PIS 
IgG1 
Median  
(range) 
 
A 
n:25 
 
 
B 
n:25 
 
 
C 
n:25 
 
D 
n:25 
 
E 
n:10 
 
 
6300 
(100-253800) 
 
 
13600 
(200-358700) 
 
 
30 
(7-1000) 
 
350 
(2-2800) 
 
30 
(7-400) 
 
 
24900 
(110-420000) 
 
 
25700 
(500-250000) 
 
 
150 
(6-5000) 
 
400 
(10-3700) 
 
70 
(10-300) 
 
 
11400 
(200-243000) 
 
 
22800 
(4100-228000) 
 
 
30 
(4-5.1000) 
 
300 
(5-5700) 
 
30 
(4-200) 
 
 
30000 
(500-860000) 
 
 
36900 
(1700-553900) 
 
 
50 
(9-4400) 
 
200 
(5-6900) 
 
20 
(9-700) 
 
 
88500 
(4300-2160000) 
 
 
360000 
(11800-1780000) 
 
 
2100 
(30-17800) 
 
170 
(100-64200) 
 
200 
(10-1300) 
 
 
68000 
(1800-1200000) 
 
 
72000 
(5700-952000) 
 
 
100 
(6-12300) 
 
400 
(6-33600) 
 
40 
(6-800) 
 
 
 
Table 4.7: The median and interquartile range of IgG1 titres against pigeon antigens in 
each study group. 
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Group Anti- mucin 
IgG2 
Median  
(range) 
Anti- TM 
IgG2 
Median  
(range) 
Anti- PS 
IgG2 
 
Median 
 
(range) 
Anti- PDF 
IgG2 
Median 
(range) 
Anti- PDO 
IgG2 
Median  
(range)  
Anti- PIS 
IgG2 
Median  
(range) 
 
A 
n:25 
 
B 
n:25 
 
 
C 
n:25 
 
D 
n:25 
 
E 
n:10 
 
 
22500 
(500-275000) 
 
38500 
(5800-242000) 
 
 
100 
(3-10000) 
 
300 
(0.02-5.8) 
 
100 
(0.001-2) 
 
 
66000 
(300-375000) 
 
66000 
(4600-438000) 
 
 
100 
(5-9900) 
 
300 
(0.02-219) 
 
35 
(0.005-3.7) 
 
 
7300 
(100-49200) 
 
11200 
(500-294000) 
 
 
100 
(3-11700) 
 
200 
(0.01-4.2) 
 
30 
(0.01-0.2) 
 
 
150000 
(200-500000) 
 
249000 
(99600-
780000) 
 
900 
(4-25000) 
 
900 
(0.04-75) 
 
200 
(0.05-3.8) 
 
 
199000 
(200-800000) 
 
226000 
(93100-
1120000) 
 
1600 
(2-66500) 
 
200 
(0.1-53.2) 
 
400 
(0.02-2.4) 
 
 
124500 
(200-625000) 
 
300000 
(56200-625000) 
 
 
300 
(4-31200) 
 
2400 
(0.02-156) 
 
100 
(0.03-3.2) 
 
 
 
Table 4.8: The median and interquartile range of IgG2 titres against pigeon antigens in 
each study group. 
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Figure 4.30: IgG1 levels against pigeon antigens in all study groups; A: IgG1 anti- PIM, 
B: IgG1 anti- TM, C: IgG1 anti- PDF, D: IgG1 anti- PDO, E: IgG1 anti- PIS, F: IgG1 anti- 
Pigeon serum.  
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Figure 4.31: IgG2 titres against pigeon antigens in all study groups; 1: IgG2 anti- PDF, 2: 
IgG2 anti- PDO, 3: IgG2 anti- PIS, 4: IgG2 anti- PIM, 5: IgG2 anti- TM, 6: IgG2 anti- 
Pigeon serum.  
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It should be emphasized that the comparison between antibodies titres were made within 
the IgG subclasses of the group of pigeon fanciers and not between different subclass 
responses due to differences in the sensitivity of the IgG subclass ELISAs.  
Firstly the median and range of IgG1 titres against PIM, TM, PDO, PDF and PIS was 
higher than the IgG1 titres against PS in both group A and B individuals. This may suggest 
that either those antigens are more effective in B cell stimulation and antibody production 
than PS or it may be that individuals are exposed to higher concentration of those antigens 
thus triggering higher responses. Groups A and B also had significantly higher titres of 
IgG1 against pigeon antigens compared to groups C, D and E (P≤0.001). However, there 
were no significant differences between IgG1 titres against pigeon antigens in groups C 
and D except for IgG1 anti-mucin (P=0.02). IgG1 titres against all pigeon antigens in 
group B were higher than group A, but it was only significant for anti-PS IgG1 (P=0.04). 
Secondly the median and range of IgG2 titres against PIM, TM, PDO, PDF and PIS was 
also higher than the IgG2 titres against PS in both group A and B individuals. Groups A 
and B also had significantly higher titres of IgG2 against pigeon antigens compared to 
groups C, D and E (P≤0.001). However, there were no significant differences between 
IgG2 titres against pigeon antigens in groups C and D. Also the IgG2 titres against all 
pigeon antigens in group B were higher than group A. These differences were significant 
for anti-PDF IgG2 (P=0.02), anti-PDO IgG2 (P=0.04) and anti-PIS IgG2 (P=0.03). IgG2 
titres against PS had the lowest median and range compared to other pigeon antigens 
suggesting the presence of high carbohydrate content of these antigens, since IgG2 is 
associated with responses to polysaccharide antigens (Hammarstrom & Smith, 1986; 
Obukhanych & Nussenzweig, 2006).  
Finally the antibody titres (IgG, IgG1 and IgG2) against all pigeon antigens were compared 
with the smoking status of pigeon fanciers by Multiple Regression test.  
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There was a significant association between antibody titres and smoking status, with those 
fanciers who smoked having significantly lower antibody titres than non-smokers 
(P<0.05). 
 
 
 
4.3.7: Inhibition ELISA to Measure Antibody Avidity: 
Antibody avidity is an important aspect of a protective immune response and can be 
assessed by chaotropic or inhibition ELISA. This technique utilizes a chaotropic reagent 
such as ammonium thiocyanate which disrupts antigen-antibody binding by interfering 
with the electrostatic, hydrophobic bounds in immune complexes. It also chelates the 
proton of the hydrogen bonds which stabilize immune complexes (Macdonald, Hosking & 
Jones, 1988; Giovannoni, Chapman & Thompson, 2006). The avidity index (AI) is 
determined as the concentration of ammonium thiocyanate that inhibits antibody binding 
by 50% in an ELISA (Richmond et al., 2001). Thus the higher avidity of an antigen-
antibody complex the higher the concentration of chaotropic reagent needed to disrupt the 
complex.    
This experiment was carried out as previously described in section 3.11 and AI was 
defined as the concentration of ammonium thiocyanate required to reduce the OD by 50% 
in comparison to sample without chaotropic reagent. This is determined from a graph 
plotting the percentage inhibition against the concentration of ammonium thiocyanate. 
Individual data for each IgG subclass tested the six pigeon antigens ie presented in figures 
4.32- 4.43. The mean and range of AI for IgG1 and IgG2 against pigeon antigens are 
shown in Table 4.9 and 4.10. Figure 4.44 shows AI levels for IgG1 and IgG2 against PDO 
and PDF in group A and B. 
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Considering these data, group A generally had a higher mean and range of AI for IgG1 
against pigeon antigens as compared to group B, however, the differences were only 
significant For IgG1 against PDO (P=0.006). Group A also had higher AI for IgG2 against 
5 antigens, with significant differences being seen for IgG2 against PDO and PDF 
(P=0.00β and P≤0.001, respectively) as shown in figure 4.44. This data showed that higher 
AI for IgG1 and IgG2 could be used as a diagnostic tool. The AI for IgG2 against mucin 
was higher in group B than group A but it was not significant (P>0.05). Interestingly, the 
mean and range of AI for IgG2 were higher than IgG1 in both groups A and B which may 
suggest the presence of more IgG2 in the immune complexes. 
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Figure 4.32: Inhibition ELISA for IgG1 against mucin; percentage inhibition was plotted 
against the concentration of ammonium thiocyanate. AI is defined as the concentration of 
ammonium thiocyanate that reduces the OD by 50%. 
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Figure 4.33: Inhibition ELISA for IgG1 against TM; percentage inhibition was plotted 
against the concentration of ammonium thiocyanate. AI is defined as the concentration 
of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 4.34: Inhibition ELISA for IgG1 against PS; percentage inhibition was plotted 
against the concentration of ammonium thiocyanate. AI is defined as the concentration 
of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 4.35: Inhibition ELISA for IgG1 against PDF; percentage inhibition was 
plotted against the concentration of ammonium thiocyanate. AI is defined as the 
concentration of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 3.36: Inhibition ELISA for IgG1 against PDO; percentage inhibition was 
plotted against the concentration of ammonium thiocyanate. AI is defined as the 
concentration of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 3.37: Inhibition ELISA for IgG1 against PIS; percentage inhibition was plotted 
against the concentration of ammonium thiocyanate. AI is defined as the concentration 
of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 3.38: Inhibition ELISA for IgG2 against mucin; percentage inhibition was 
plotted against the concentration of ammonium thiocyanate. AI is defined as the 
concentration of ammonium thiocyanate that reduces the OD by 50%. 
 
 
 
0 1 2 3 4 5 6 7 8 9 10
Molar Ammonium Thiocyanate
0
10
20
30
40
50
60
70
80
90
100
%  Inhibition
114
143
154
159
160
169
171
192
 
 
Figure 3.39: Inhibition ELISA for IgG2 against TM; percentage inhibition was plotted 
against the concentration of ammonium thiocyanate. AI is defined as the concentration 
of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 4.40: Inhibition ELISA for IgG2 against PS; percentage inhibition was plotted 
against the concentration of ammonium thiocyanate. AI is defined as the concentration 
of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 4.41: Inhibition ELISA for IgG2 against PDF; percentage inhibition was 
plotted against the concentration of ammonium thiocyanate. AI is defined as the 
concentration of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 4.42: Inhibition ELISA for IgG2 against PDO; percentage inhibition was 
plotted against the concentration of ammonium thiocyanate. AI is defined as the 
concentration of ammonium thiocyanate that reduces the OD by 50%. 
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Figure 4.43: Inhibition ELISA for IgG2 against PIS; percentage inhibition was plotted 
against the concentration of ammonium thiocyanate. AI is defined as the concentration 
of ammonium thiocyanate that reduces the OD by 50%. 
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Groups Mucin TM PS PDF PDO PIS 
 
Group A 
(n=25)         
*Mean 
*Range 
*SD 
 
Group B 
(n=25) 
*Mean 
*Range 
*SD 
 
 
 
2.21 
(0.6-5) 
1.29 
 
 
 
1.59 
(0.5-4) 
0.9 
 
 
 
 
1.72 
(0.6-4.2) 
0.95 
 
 
 
1.27 
(0.5-3.5) 
0.7 
 
 
 
2.31 
(0.8-4) 
1.10 
 
 
 
2.15 
(0.6-5.4) 
1.19 
 
 
 
2.76 
(0.6-5.5) 
1.45 
 
 
 
2.61 
(1-4.5) 
0.95 
 
 
 
2.69 
(0.5-6) 
1.52 
 
 
 
1.59 
(0.4-5) 
1.14 
 
 
 
1.21 
(0.6-2.5) 
0.58 
 
 
 
1.06 
(0.6-3) 
0.52 
 
 
 
 
 
 
Table 4.9: The mean, range and standard deviation (SD) of avidity index (AI) of IgG1 
against pigeon antigens in group A and B (95% Confidence Interval); Group A had 
higher AI for IgG1 against all pigeon antigens than group B. 
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Groups Mucin TM PS PDF PDO PIS 
 
Group A 
(n=25) 
*Mean 
*Range 
*SD 
 
Group B 
(n=25) 
*Mean 
*Range 
*SD 
 
 
 
 
4.51 
(1.2-7.5) 
1.6 
 
 
 
5.12 
(2-8) 
1.5 
 
 
 
3.57 
(1.5-7.5) 
1.34 
 
 
 
3.24 
(0.5-6) 
1.29 
 
 
 
3.59 
(0.6-7.5) 
1.61 
 
 
 
3.22 
(1-7) 
1.54 
 
 
 
 
6.12 
(2.2-10) 
1.63 
 
 
 
4.05 
(0.7-8.5) 
1.82 
 
 
 
 
3.66 
(1.8-8.5) 
1.6 
 
 
 
2.39 
(0.6-4.8) 
0.94 
 
 
 
 
2.67 
(1.2-5.5) 
1.26 
 
 
 
2.09 
(0.5-4.6) 
0.96 
 
 
 
 
 
 
 
Table 4.10: The mean, range and standard deviation (SD) of avidity index (AI) of IgG2 
against pigeon antigens in group A and B (95% Confidence Interval); Group A had higher 
AI for IgG2 against all pigeon antigens except mucin compared to group B. 
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Figure 4.44: AI levels for anti- PDO IgG1 (1), anti- PDO IgG2 (2), anti- PDF IgG1 (3) 
and anti-PDF IgG2 (4) in group A and B; Group A had much higher AI of IgG2 against 
both antigens and higher AI of IgG1 against PDO. 
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4.3.8: Microcalorimetry: 
In order to achieve a better understanding of the interaction between antigen and antibody 
(avidity of the antibody), the thermodynamics of the antigen-antibody reaction were 
measured by microcalorimetry. In this series of experiments an injection syringe (pipette) 
containing a ligand (antibody) was titrated against a binding partner or macro molecule 
(antigen) at a constant temperature. The temperature difference between the reference cell 
and the sample cell was measured by VP-ITC (MicroCal LLC, Milton Keyne, UK) 
(section 3.12).  
The heat generated by antigen-antibody interactions (H) following each injection was 
measured by the system. The signal diminishes as the antigen binding sites in the sample 
cell became saturated with added ligand. Differential power (DP) in µcal/sec is the 
difference in power between the sample cell and the reference cell. A positive DP value 
means the reference cell is hotter than the sample cell. Thus, an endothermic reaction needs 
more feedback heat to maintain the same temperature, resulting in a positive deflection in 
the DP values. On the other hand, a negative DP value means the sample cell is hotter than 
the reference cell.  In an exothermic reaction the feed back heat provided to the sample cell 
to maintain the temperature equilibrium between the sample and the reference cell is 
decreasing, which causes the DP to deflect in a negative direction.  
A titration curve is obtained when the heat from each injection is plotted against the ratio 
of antigen and antibody in the reaction cell. H can then be extracted from the curve 
(Wiseman et al., 1989; Bundle & Sigurskjold, 1994).  
PDO was used as the tested antigen in this experiment since it was shown that fanciers in 
group A have a significant higher AI for IgG1 and IgG2 against PDO in comparison with 
group B (P=0.006 and P=0.002, respectively).  To determine the optimal concentration of 
ligand and macromolecule, in order to have a sigmoid slope in the final graph, one sample 
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from group A and B diluted 1/2 and 1/10 into PBS and were tested against PDO at 
concentrations of 1 mg/ml and 2 mg/ml. The results are shown in figures 4.45 and 4.46. 
The best sigmoidal slopes were achieved with both samples at a 1/2 dilution with antigen 
concentration of 2 mg/ml.  
10 serum samples from group A and 11 from group B were selected for this series of 
experiments. The aim was to choose the samples with almost similar anti-PDO IgG titres 
in order to minimise any effects of antibody concentration that may be seen between 
samples. Thus any differences in ∆H detected would be as a result of differences in 
avidity/affinity of the antibody in the serum sample and not concentration. 
The group A and group B serum samples are shown in table 4.11 with the IgG titres. 
Results for the samples with similar antibody titres to PDO were compared.  
Each serum sample was tested against PDO and PBS as a control. The final graph (∆H) 
was the result of subtracting the control graph from the main graph since the interaction 
between the ligand and the buffer (PBS) produces some heat. Figures 4.47 and 4.48 show 
this process for sample 143 (group A) and sample 37 (group B). The other graphs are not 
shown.                               
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Figure 4.45: Initial ITC experiments for sample 143 (group A) in order to find the optimal 
concentration of the ligand and macromolecule; the results show that a 1/2 dilution of 
serum (ligand) and PDO at 2mg/ml (macromolecule) gives the best sigmoidal slope. 1) 
1/10 diluted serum into PBS and PDO at 1 mg/ml; 2) 1/2 diluted serum into PBS and PDO 
at 1 mg/ml; 3) 1/2 diluted serum into PBS and PDO at 2 mg/ml.  
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Figure 4.46: Initial ITC experiments for sample 25 (group B) in order to find the optimal 
concentration of the ligand and macromolecule; the results show that a 1/2 dilution of 
serum (ligand) and PDO at 2mg/ml (macromolecule) gives the best sigmoidal slope. 1) 
1/10 diluted serum into PBS and PDO at 1 mg/ml; 2) 1/2diluted serum into PBS and PDO 
at 1 mg/ml; 3) 1/2diluted serum into PBS and PDO at 2 mg/ml.  
 
 
161 
 
 
 
       Group A 
    Serum Samples 
     Anti-PDO IgG  
Titres 
       Group B 
      Serum Samples 
160, 114 
143, 216 
225 
213 
229, 269 
192 
261 
400,000 
250,000-275,000 
150,000 
110,000 
60,000-100,000 
80,000 
35,000 
25, 37, 125 
31, 116 
167 
120 
129 
23, 26 
218 
  
 
Table 4.11: The list of serum samples from groups A and B with related IgG titres 
against PDO used for ITC experiments 
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Figure 4.47: 1) The comparison results of ITC for sample 143 against PDO at 2 mg/ml 
and sample 143 against PBS buffer as control test. 2) The final graph for sample 143 after 
subtraction of control from the main graph. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PDO 
 
PBS 
163 
 
 
1)                                                                      2) 
0.00 0.02 0.04 0.06 0.08 0.10 0.12
-32
-30
-28
-26
-24
-22
-20
-18
-16
-14
-12
-10
-8
-6
-4
-2
0
2
-5.0
-4.5
-4.0
-3.5
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
-10 0 10 20 30 40 50 60 70 80 90 100110120
Time (min)
µc
a
l/s
e
c
Molar Ratio
kc
al
/m
o
le
 o
f i
n
je
c
ta
n
t
                   
0.00 0.02 0.04
-24
-22
-20
-18
-16
-14
-12
-10
 Z37doubleP_NDH
Molar Ratio
kc
a
l/m
o
le
 
o
f i
n
jec
ta
n
t
 
 
 
 
 
 
 
 
 
Figure 4.48: 1) The comparison results of ITC for sample 37 against PDO at 2 mg/ml and 
sample 37 against PBS buffer as control test. 2) The final graph for sample 37 after 
subtraction of control from the main graph. 
 
 
 
 
  
 
 
 
PDO 
 
PBS 
164 
 
The slope of each graph represents the avidity of the anti-PDO antibody in each serum 
sample, with a sigmoid slope showing a higher avidity of antibody.  
Figure 4.49 is a schematic diagram which gives a better understanding of ∆H and how the 
shape and height of the graph can represent the strength of the reactions and the antibody 
avidity. ∆H is the difference between the 2 plateaux. 
The slope of the graph and the ΔH of each serum sample from group A were compared 
against the related serum sample from group B and the results are shown in figures 4.50 - 
4.57 whilst table 4.1β shows the ΔH calculated for each sample. γ arbitrarily cut off points 
were selected for ∆H in order to calculate the sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV), and also group A and B were compared 
by Chi- square Test (Table 4.13). 
Interestingly, the results showed that the majority of tested serum samples from group A 
had a higher avidity as measured by ∆H than the related serum samples from related 
samples from group A. In addition, when ∆H ≥γβ was considered in order to compare the 
antibody avidity of serum samples from group A with group B, it seems that samples from 
group A had a significant higher ∆H as compared to group B (P=0.044) with sensitivity of 
κ0% and specificity of 6γ%. Both ∆H > γ0 and ∆H ≥ γ5 were not significant as samples 
from group A were compared with samples from group B.  
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Figure 4.49: Schematic graphs showing how to define ∆H; ∆H is the difference between 
the 2 plateaux. Serum A has a higher avidity, binding enthalpy and ∆H compared to serum 
B.  
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Figure 4.50: Comparison between the results of ITC for sample 192 (group A) against 
PDO at concentration of 2 mg/ml with samples 23 and 26 (group B) against the same 
pigeon antigen; Sample 1λβ had a higher ∆H compared to samples βγ and β6.  
 
0.00 0.02 0.04 0.06 0.08 0.10 0.12
-55
-50
-45
-40
-35
-30
-25
-20
-15
-10
-5
0
5
10
 Z125double_NDH
 Z37doubleP_NDH
 Z25doubleP_NDH
 Z114bouble_NDH
 Z160double_NDH
Molar Ratio
kc
al/
mo
le 
of 
inje
cta
nt
 
 
Figure 4.51: Comparison between the results of ITC for samples 114 and 160 (group A) 
against PDO at concentration of 2 mg/ml with samples 25, 37 and 125 (group B) against 
the same pigeon antigen; Samples 1β5 and β5 had higher ∆H compared to the other 
samples.  
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Figure 4.52: Comparison between the results of ITC for samples 143 and 216 (group A) 
against PDO at concentration of 2 mg/ml with samples 31 and 116 (group B) against the 
same pigeon antigen; Sample 14γ had a higher ∆H compared to the other samples.  
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Figure 4.53: Comparison between the results of ITC for sample 225 (group A) against 
PDO at concentration of 2 mg/ml with sample 167 (group B) against the same pigeon 
antigen; Sample ββ5 had a higher ∆H compared to sample 167.  
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Figure 4.54: Comparison between the results of ITC for sample 213 (group A) against 
PDO at concentration of 2 mg/ml with sample 120 (group B) against the same pigeon 
antigen; Sample 1β0 had a higher ∆H compared to sample β1γ.  
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Figure 4.55: Comparison between the results of ITC for samples 229 and 269 (group A) 
against PDO at concentration of 2 mg/ml with sample 129 (group B) against the same 
pigeon antigen; Samples β6λ and ββλ had higher ∆H compared to sample 1βλ. 
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Figure 4.56: Comparison between the results of ITC for sample 261 (group A) against 
PDO at concentration of 2 mg/ml with sample 218 (group B) against the same pigeon 
antigen; Samples β61 had higher ∆H compared to sample β1κ. 
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Samples 
(Group A) 
      ∆( Samples 
(Group B) 
          ∆( 
*192 
 
 
*114 
*160 
 
 
*143 
*216 
 
*225 
 
*213 
 
*229 
*269 
 
*261 
35 
 
 
35 
33 
 
 
51 
18 
 
46 
 
32 
 
36 
44 
 
16 
*26 
*23 
 
*125 
*25 
*37 
 
*31 
*116 
 
*167 
 
*120 
 
*129 
 
 
*218 
27 
25 
 
49 
33 
27 
 
47 
28 
 
31 
 
45 
 
27 
 
 
14 
 
 
 
Table 4.12: ΔH for each serum sample 
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∆H sensitivity specificity PPV NPV Chi-square 
P value 
 
>30 
 
≥32 
 
≥35 
 
 
80% 
 
80% 
 
60% 
 
54% 
 
63% 
 
72% 
 
61% 
 
66% 
 
66% 
 
75% 
 
77% 
 
66% 
 
1.04 
 
0.044 
 
0.13 
 
 
 
 
 
Table 4.13: The results of sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for γ different cut off points of ∆H. 
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4.4: Discussion: 
Bird fanciers’ lung is one of the most common forms of HP in the UK (Bourke et al., 
2003). There are 80000 registered pigeon fanciers in the UK (McSharry et al., 2006a) and 
an estimated 5-6 million homes with caged birds such as budgerigars and canaries 
(Hendrick, Faux & Marshall, 1978; Bourke et al., 2003; Judson & Sahn, 2004). Although 
the mechanisms involved in the pathogenesis of PFL are unclear, it is generally accepted 
that the early acute stages of the disease are mediated by immune complexes in the 
alveolar epithelial surface (Kaltreider, 1993; Razin, Pecht & Rivera, 1995; Bourke et al., 
2001). A factor supporting the role of immune complexes in early disease is that the 
majority of individuals with acute PFL have high levels of systemic and local anti-avian 
antibodies (Todd, Coan & Allen, 1993; Baldwin et al., 1998b). However, this does not 
explain why a large number of pigeon fanciers are asymptomatic despite the presence of 
high levels of anti-avian antibodies in their serum and why a small number of fanciers 
develop symptoms while having low levels of these antibodies. 
 It has been suggested that the ability of immune complexes to induce disease will be 
influenced by all or a number of the following: i) the IgG isotype responses against the 
causative antigens; ii) the functional affinity of each isotype; and iii) the biochemical 
nature of the offending antigens (Baldwin et al., 1998c; 1999). A major theme of the study 
was therefore to investigate antibody responses in PFL. The aim of this section being to 
investigate anti-avian IgG and IgG subclasses responses among symptomatic and 
asymptomatic pigeon fanciers and particularly to determine the functional affinity of anti-
pigeon antigen IgG isotypes by both inhibition ELISA and isothermal titration calorimetry 
(ITC). The purpose was to investigate whether there is a significant difference in the 
functional affinity of specific antibodies between these 2 groups of pigeon fanciers.  
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PIM is a very large highly glycosylated molecule containing epitopes recognised by the 
major IgG subclasses and has been previously implicated as a major antigen in the 
development of PFL (Todd, Coan & Allen, 1991; Todd, Coan & Allen, 1993; Baldwin et 
al., 1999; Baldwin et al., 2000b). Specific glycosidases of microbial origin are necessary 
for degradation of oligosaccharide chains of mucin molecules in humans (Corfield et al., 
1996) and therefore immune complexes containing mucin may be persistent and 
problematic in the lung.  PIM is present in a various materials inside the pigeon lofts 
including pigeon droppings and pigeon bloom (Baldwin et al., 1998a; McSharry, Anderson 
& Boyd, 2000). Therefore, a range of different pigeon antigens containing pigeon mucin 
i.e. TM, PDO, PDF and PIS together with pigeon mucin itself and PS, which may contain 
glycoproteins with terminal sugar groups similar to that found in pigeon mucin (Baldwin et 
al., 1999; Suzuki et al., 2003) have been used in this study. This was the first study looking 
at IgG subclass responses to TM, PDO, PDF and PIS in PFL.  
Firstly the IgG, IgG1 and IgG2 titres against these pigeon antigens have been determined 
in the five clinical groups (groups A-E). Each group contained 25 pigeon fanciers except 
group E which included 10 individuals with no previous history of pigeon contact. IgG3 
and IgG4 responses were not measured against these antigens as previous studies have 
shown that IgG3 and IgG4 responses against a range of pigeon antigens are negligible 
(Todd, Coan & Allen, 1993; Baldwin et al., 1998c).  
Previous studies have shown that both symptomatic and asymptomatic antibody positive 
pigeon fanciers have similarly high IgG titres to both PS and PIM, however, in this study 
the median titres of IgG against pigeon antigens were always higher in group B than group 
A and these differences were significant for anti-TM IgG (P=0.026) and anti-PDO IgG 
(P=0.036). This suggests that the magnitude of the total IgG response cannot determine the 
development of the disease although it may be that high levels of antibodies (particularly 
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some isotypes) are protective as previously reported that measles neutralising antibodies 
>500 mIU/ml may prevent symptomatic measles infection (Lee et al., 2000). 
Also IgG, IgG1 and IgG2 titres against TM, PDO, PDF, PIM and PIS in both groups A and 
B were much higher than those responses to PS (P ≤ 0.001). The results for TM and PIM 
suggest that mucin is a more effective molecule in stimulating B cells and the production 
of antibodies than PS. Mucin is highly glycosylated with previous studies showing that 
most anti-mucin IgG1 and IgG2 responses are anti-carbohydrate in nature (Baldwin et al., 
1998c; 1999) indicating that the biochemical nature of this antigen may affect the ability of 
B cells to respond. Pigeon droppings contain a wide variety of materials such as intestinal 
secretions, mucin and infectious microorganisms ie Chlamydia, Mycoplasma and Influenza  
which will not be present in pigeon serum (Calvert et al., 1999; Curtis et al., 2002). They 
may also have a role as adjuvant effect and influence the antibody production in pigeon 
fanciers (McGee, Elson & McGhee, 1993; Blom & Hilgers, 2004). Baldwin et al (1998) 
also reported higher antibody titres against PIM as compared to PS (Baldwin et al., 1998c).  
The lowest median and range of IgG2 titres was seen against PS as compared to the other 
pigeon antigens, containing pigeon mucin, which may be explained by the fact that mucin 
has a high polysaccharide content and IgG2 is generally associated with responses to 
polysaccharide antigens (Hammarstrom & Smith, 1986; Obukhanych & Nussenzweig, 
2006) in contrast to IgG1 which is generally generated against T cell-dependent protein 
antigens (Rubinstein et al., 1998).  
It has been suggested that IgG1 may be of greater pathological significance in the 
development of PFL as immune complexes containing higher levels of this antibody will 
be more effective in the activation of the classical complement pathway and binding to 
FCȖR (Baldwin et al., 1998c). Surprisingly, in contrast to previous studies, group A did not 
have significantly higher IgG1 titres to any of the tested antigens (Baldwin et al., 1998c; 
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Baldwin et al., 2000b). These differences may be explained by the fact that this study used 
a different study population, smaller group numbers, or the serum samples were collected 
at a different time of year. For instance, higher specific antibody titres due to intensive 
contact with pigeon antigens are seen during the pigeon sporting season in late summer and 
during the period that pigeons shed feathers in the autumn (Dalphin et al., 1993; Tanaka et 
al., 1995; Bourke et al., 2003). It could also be explained by the fact that IgG1 may not be 
as important as first thought in the pathogenesis of disease and further studies about the 
role of mucin and IgG1 responses to mucin in PFL are urgently needed. The median titres 
of IgG1 and IgG2 against all the pigeon antigens tested was always higher in group B than 
group A and these differences were significant for anti-PS IgG1 (P=0.04), anti-PDF IgG2 
(P=0.028), anti-PDO IgG2 (P=0.04) and anti-PIS IgG2 (P=0.03). This is very interesting 
since it is generally expected to detect higher antibody titres in symptomatic patients with 
an immune complex mediated disease (Obwaller et al., 1998; Messias-Reason et al., 
2002), however this data emphasizes the fact that the magnitude of the IgG subclasses 
responses cannot determine the development of PFL.  
Furthermore, IgG2 titres against all the tested pigeon antigens were higher than IgG1 in 
both group A and B although these differences were only significant for TM and PDF (P= 
0.0γ and P ≤ 0.001, respectively). This may be due to the non-identical sensitivity of 
subclass-specific monoclonal antibodies used in the IgG1 and IgG2 assays (Falconer et al., 
1993). It can also be explained by the fact that very large highly glycosylated mucin 
molecules (carbohydrate composition of 70-80%) are present in all the tested antigens 
except PS and IgG2 is generally associated with responses to polysaccharide antigens 
containing multiple repeating epitopes (Todd, Coan & Allen, 1993; Obukhanych & 
Nussenzweig, 2006) and thus mucin may elicit high titres of IgG2. Previously Baldwin et 
al (2000) reported that the majority of the IgG1 and IgG2 antibodies in pigeon fanciers are 
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specific for O-linked oligosaccharides of mucin molecules (Baldwin et al., 2000b). In 
addition, IgG2 may be more protective against polysaccharide antigens as it has been 
shown that IgG2 was the most active IgG subclass in the binding and opsonic activity 
against capsular polysaccharide of Haemaphilus influenza  type b and Streptococcus 
pneumoniae and was effective in reducing infections in patients with primary immune 
deficiency (Mikolajczyk et al., 2004).  
The results also showed that pigeon fanciers in groups A and B had a significant higher 
IgG, IgG1 and IgG2 responses against tested pigeon antigens as compared to groups C and 
D and control group (group E) (P ≤ 0.001). Symptomatic fanciers in group C had very low 
specific antibody titres which emphasises that the level of antibody may not predict the 
development of disease and other immunological pathways such as T cell responses and 
type IV hypersensitivity reaction may be involved in the pathogenesis of disease in these 
fanciers.  
The IgG, IgG1 and IgG2 titres against all tested pigeon antigens were also compared with 
the smoking status of pigeon fanciers by multiple regression, and there was a significant 
association between antibody titres and smoking status, with those fanciers who smoked 
having significantly lower antibody titres than non-smokers (P<0.05). This data supports 
previous studies (McSharry, Banham & Boyd, 1985; Baldwin et al., 1998b) that smoking 
inhibits antibody production in pigeon fanciers. This may be due to a number of reasons 
and it has previously been shown that smoking cigarettes may influence antigen 
presentation and antibody production (Al-Ghamdi & Anil, 2007), inhibit lymphocyte 
(Kalra et al., 2000) and fibroblast proliferation (Lahmouzi et al., 2000) and lead to a 
decrease in the secretion of IL-1, IL-6, IL-12, IFN-Ȗ and TNF-α (Matsunaga et al., 2001).  
Secondly, the avidity index (AI) of IgG1 and IgG2 against 6 pigeon antigens was 
determined in groups A and B by the use of a chaotrophic ELISA. Basically affinity is 
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defined as the strength of interaction between a monovalent antigen and a single antibody-
binding region, whilst avidity is the strength of the multivalent interaction between 
antibodies and their antigens which is an important characteristic of protective immune 
responses (Harris et al., 2007). It has been reported that the antibody avidity influences O2- 
production and the complement-fixing activity of immune complexes (Alves et al., 2004). 
Therefore, antibodies with a higher avidity will generally be more efficient in stimulating 
the respiratory burst of neutrophils and in the activation of complement by the classical and 
alternative pathway and the generation of large amounts of C3a and C5a which will cause 
more phagocytes to migrate into the alveoli (Alves et al., 2004). Several studies have 
previously reported that high avidity antibody against anti-glomerular basement 
membranes (GBM) may be important in the pathogenesis of anti-GBM disease (Cui & 
Zhao, 2005) and high avidity antibody has an important role in experimental neuropathy 
caused by anti-GM1 antibodies (Comin et al., 2006). This, therefore, highlights the 
important role that antibody avidity may have in the development of immune complex 
mediated diseases such as PFL. On the other hand, low avidity antibodies may have an 
important role in the pathogenesis of systemic disease with circulating immune complexes 
i.e. SLE with a kidney involvement (Nielsen, 1980). 
 Interestingly in this study, group A generally had higher AI for IgG1 against pigeon 
antigens as compared to group B, however, the differences were only significant for PDO 
(P=0.006). Group A also had higher AI for IgG2 against most of pigeon antigens tested 
with significant differences for IgG2 against PDO and PDF (P=0.00β and P≤0.001, 
respectively). The AI for IgG2 against PIM was higher in group B than group A, however, 
this difference was not significant. It has been suggested that the differences in IgG 
subclass profiles and the functional affinity of each isotype may affect the composition and 
properties of the immune complexes and consequently the development of disease 
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(Baldwin et al., 2000b). This is supported in this study as symptomatic fanciers in group A 
had higher IgG antibody avidities and therefore immune complexes in individuals with 
PFL may have a stronger composition and bonds and consequently they may be  harder to 
remove once deposited in the lung.  
As high avidity antibodies stimulate the respiratory burst of neutrophils and the 
complement system more effectively they may also, therefore, generate more alveolar 
damage in symptomatic pigeon fanciers (Alves et al., 2004; Cui & Zhao, 2005). This data, 
therefore, suggests that although the magnitude of the antibody responses cannot predict 
the development of disease, the level of AI may be a useful marker as asymptomatic 
pigeon fanciers in group B had higher IgG1 and IgG2 titres and lower antibody avidities as 
compared to symptomatic fanciers in group A.   
Furthermore, the efficiency of those mononuclear phagocytes responsible for removing the 
immune complexes depends on the functional capacity of the Fc ȖR that recognize the Fc 
portion of IgG and the receptors for complement (Zuniga et al., 2003). FcȖR 
polymorphisms and amino acid substitutions within extracellular domains of FcȖR are 
important in the binding avidity of IgG subclasses and may modulate the susceptibility to 
particular diseases such as SLE (Hepburn et al., 2006). Abnormal clearance of immune 
complexes by the phagocytic system is an important factor in the pathogenesis of SLE and 
R1γ1/H1γ1 polymorphism of FcȖRIIa may affect on the uptake of immune complexes. 
R131 is the low binding allele for human IgG2 and may contribute to the defect in removal 
of circulating immune complexes (Zuniga et al., 2003). Thus polymorphism in FcȖRIIa 
may be one of the reasons why fanciers with high levels of specific antibodies (group B) 
do not have respiratory symptoms following pigeon contact, whilst individuals with lower 
levels of specific antibodies do develop disease. 
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It has previously shown that immune complexes containing pigeon mucin and specific 
anti-mucin antibodies in symptomatic fanciers can activate complement more strongly than 
immune complexes generated with sera from asymptomatic fanciers (Khan, 1999). 
Originally it was suggested that this was due to high levels of IgG1 in the immune complex 
(Baldwin et al., 1998c) but it seems more likely from these results that high avidity 
antibodies in symptomatic fanciers may be involved in this enhanced ability to activate the 
respiratory burst of neutrophils and the complement system generating more tissue 
damages (Neale et al., 1993; Alves et al., 2004).   
Finally, the antibody avidity against PDO was determined in 20 pigeon fanciers from 
group A and B by isothermal calorimetry (ITC). PDO was used as the antigen in these 
experiments as it was shown that fanciers in group A have significantly higher AI for IgG1 
and IgG2 against PDO in comparison with group B (P=0.006 and P=0.002, respectively).  
During the experiments, the thermodynamics of the antigen-antibody reaction and the 
generated heat (H) were measured by the system (Sotriffer et al., 1999; Mosedale et al., 
2006).  
ITC has previously been used for the investigation of the pathogenesis of a number of 
different conditions and diseases eg Alzhimers Disease (Hoyer & Hard, 2008), Parkinsons 
Disease (Bharathi & Rao, 2007), ovarian cancer (Nikolopoulos et al., 2007), Wilsons 
disease (Wernimont, Yatsunyk & Rosenzweig, 2004), and Lyme disease (Raibaud et al., 
2005). It has also been used for identification of the antigenic determinants of an epitope 
presenting in lipopolysaccharide of gram negative bacteria causing septic shock such as 
Enterobacter (Muller-Loennies et al., 2003). There have been various studies about 
developing specific monoclonal antibodies against different microorganisms using ITC. 
For instance, the thermodynamic constants of reaction between the synthesized peptide 
sequence and staphylococcal enterotoxin B (SEB) causing food intoxication has been 
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determined by ITC in order to develop a peptide with the highest affinity to SEB (Soykut, 
Dudak & Boyaci, 2008). Muller-Loennies et al (2003) also studied Gram-negative bacteria 
causing septic shock in order to identify the antigenic determinants of an epitope which is 
present in enterobacterial lipopolysaccharide (LPS) and to recognize it by a cross-reactive 
monoclonal antibody obtained from Escherichia coli, Salmonella enterica, and E. Coli 
(Muller-Loennies, Lindner & Brade, 2003). Glycoform modification of immunoglobulin 
and its effect on antibody affinity has also been studied by ITC. Okazaki et al (2004) 
reported that the depletion of fucose from human IgG1 improves its affinity for FcȖRIIIa 
and exhibit higher ADCC suggesting that a glyco-engineering strategy can improve a 
glycoproteins affinity for its receptors (Okazaki et al., 2004). Previously monoclonal 
antibodies have been used in ITC experiments against one epitope in order to identify the 
structural details of different microorganisms, for instance the polysaccharides present in 
Mycobacterial cell wall (Rademacher et al., 2007). However, in this study antibody avidity 
which is the strength of the multivalent interaction between antibodies and their antigens 
has been determined.  
This is the first time that ITC has been used to determine the antibody avidity using whole 
sera in a clinical situation such as pigeon fanciers’ lung. The results showed that specific 
antibodies against PDO in pigeon fanciers in group A had higher ΔH than group B.  3 
arbitrary cut off points (>γ0, ≥γβ and ≥γ5) were selected for ∆H in order to compare 
pigeon fanciers in groups A and B. Only a ΔH ≥ γβ showed a significant difference 
(P=0.044) between groups A and B.  This data showed that the avidity of specific antibody 
in group A was higher than group B which confirms the results of the inhibition ELISA 
and emphasises the important role of high avidity antibody in the development of PFL. In 
addition to the clinical importance of these high avidity antibodies, ITC may be a novel 
way to evaluate the clinical status of pigeon fanciers by the measurement of ∆H. ITC is a 
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useful, easy and quick technique to predict the development of PFL. Although it does not 
have a high sensitivity and specificity (80% and 63%, respectively), further studies on 
larger groups of fanciers may help to further develop this technique as a diagnostic test. 
Furthermore, the potential use of ITC in other immune complex mediated diseases should 
be considered.  
Finally to summarise: 
i) Antibody titres against pigeon antigens containing PIM, PDO, PDF, PIS and TM 
were higher than PS and therefore these antigens seem to be more effective at 
stimulating B cells for the production of antibodies than PS. 
ii) Anti-avian IgG2 was the main IgG subclasses produced in both symptomatic and 
asymptomatic fanciers.  
iii) The magnitude of antibody response cannot predict the development of PFL. 
iv) Specific antibodies with high avidity against pigeon antigens may explain why 
some fanciers with low levels of antibodies develop disease.  
v) ITC is a novel and quick test to determine the avidity of specific antibodies in PFL. 
vi) Further development of ITC may provide a novel and quick practical test which 
may help in the diagnosis of PFL. 
vii) ITC may be a useful diagnostic tool in other immune complex mediated diseases. 
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5: T cell Responses in Pigeon Fanciers’ Lung 
 
5.1: Introduction: 
 
The pathogenesis of PFL has been suggested to be due to hypersensitivity reactions to 
pigeon antigens with disease progression being a complex process involving both arms of 
the immune response ((Kaltreider, 1993; Bourke et al., 2001; McSharry et al., 2002). After 
phagocytosis and processing of the antigen by antigen presenting cells (APCs) 
immunogenic epitopes of the antigen bind within the cleft of MHC class II on the surface 
of the APCs which can then activate CD4+ T  lymphocytes (Desombere et al., 2005). 
These CD4+ T cells can then differentiate into various T helper subsets which can either 
help in antibody production (Jenkins et al., 2001) or cell-mediated immune function.  
Both symptomatic and asymptomatic pigeon fanciers generate both B and T cell responses 
against pigeon antigens as both precipitating IgG antibodies and antigen specific T cells 
are detected in fanciers blood (Fink, 1992; Ohkawa et al., 2001). These anti-pigeon antigen 
antibodies, antigen specific lymphocytes and the development of lymphocytic alveolitis 
may be found in both symptomatic and asymptomatic pigeon fanciers (Fink, Tebo & 
Barboriak, 1969; Reynolds et al., 1989).  
The acute symptoms of PFL correlate with the development of a neutrophilic alveolitis 
(Fournier et al., 1985; McSharry et al., 2002) which gradually decreases and is replaced by 
a CD8+ T cell lymphocytic alveolitis (Reynolds et al., 1989; Murayama et al., 1993; 
McSharry et al., 2002). The proportion of CD4+ T cells then increases and alveolar 
macrophages are activated leading to the secretion of the pro-inflammatory cytokines 
TNF-, IL-1 and IL-8 which may lead to fibrosis (Calvert et al., 1999; Barrera et al., 
2008). It has been suggested that lung fibrosis in PFL is associated with CD4+ T cells 
(Murayama et al., 1993) with macrophages being activated directly by the formation of 
immune complexes or by T cells. Repeated macrophage activation may lead to 
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granulomata formation which, therefore, may be considered T cell-mediated (Hensley et 
al., 1969; Pepys, 1973; Kinet, 1999).  
Regulatory cytokines such as IL-10 may also be secreted and these may regulate and 
reduce inflammatory responses in the lung (Groux et al., 1997; Schuyler et al., 1997).  
 
 
 
 
5.1.1: Antigen Presenting Cells: 
T cells recognize processed antigen in the form of peptides or glycolipids bound to either 
MHC class I or II or CD1 (Rosat et al., 1999; Obukhanych & Nussenzweig, 2006; Barral 
& Brenner, 2007).  
      Exogenous protein and glycoprotein antigens are processed and converted into small 
peptide fragments in endosomes within APCs such as Dendritic cells (DCs) and 
macrophages (Machy et al., 2002). These fragments then bind to the cleft within the class 
II MHC molecules and are presented on the cell surface as a complex which can be 
recognized by CD4+ T cells (Engelhard, 1994; Obukhanych & Nussenzweig, 2006). 
Endogenous antigens are processed in the cytosol and then presented by class I MHC 
molecules (Grey, Sette & Buus, 1989; Machy et al., 2002).  
CD1 is a distinct family of antigen-presenting molecules (MHC-class-I like glycoproteins) 
encoded on chromosome one which present a range of lipid or glycolipid antigens to 
effector T cells which have roles in antimicrobial immune responses, antitomour immunity 
and regulation of tolerance (Sonoda et al., 2007; Terabe & Berzofsky, 2007). Five CD1 
isoforms are expressed in humans including CD1a, CD1b, CD1c, CD1d and CD1e (Barral 
& Brenner, 2007). CD1d molecules present mostly lipid and glycolipid antigens to NKT 
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cells (Gadola et al., 2002; Barral & Brenner, 2007). NKT cells are a distinct population of 
mature lymphocytes having a CD4+ or double negative CD4–CD8– phenotype (Wang et al., 
2002; Capone et al., 2003; Takagi et al., 2004). Upon activation NKT cells secrete 
inflammatory cytokines e.g. IFN-Land GM-CSF which increases the expression of 
CD1 on the APCs and consequently builds up immunity against micro-organisms such as 
mycobacterium and suppresses autoimmunity and graft rejection (Sieling et al., 2000; 
Ueda et al., 2006). NKT cells are also able to enhance CD8+ T cells proliferation through 
secreting IL-4 (Ueda et al., 2006). 
Among APCs, DCs function most effectively because they express high levels of class II 
MHC and the co-stimulatory B7 molecule which interacts with CD28 on T cells (Caux, 
Liu & Banchereau, 1995; Ndejembi et al., 2006). B cells also play an important role as 
APC (Chung et al., 2003). Resting B cells are not able to activate naïve T cells because 
they do not express the B7 molecules but following activation, B cells express higher level 
of class II MHC together with B7 molecules, which make them able to activate naïve T 
cells and memory cells (Hodgkin & Basten, 1995; Chung et al., 2003).  
 
 
 
5.1.2: T cell Differentiation:  
After maturation in the foetal liver and bone marrow pre- thymocytes then penetrate the 
vessels at the cortico-medullary junction and are found in the subcapsular region of the 
thymic outer cortex (Fu & Chen, 2004). Thymic cortical epithelial cells secrete stormal-
derived factor I (CXCL12 or SDF-I) which promotes the forward movement of the cells 
which is important for the differentiation of pre- thymocytes into early thymocytes which 
express the pre- T cell receptor (pre-TCR) and are double negative for CD4- CD8- (DN) 
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(Chen, 2004; Fu & Chen, 2004). In the outer cortex, TCR gene rearrangement influences 
on the development into double positive CD4+ CD8+ (DP).  As thymocytes move to the 
inner cortex, the thymus- expressed cytokine (CCL25 or TECK) and the related receptor 
(CCR9) play an important role in T cell transition from DN to double positive (DP) and as 
a consequence thymocytes express CD4 and CD8 which enhance the thymocyte/MHC 
interaction. The thymocytes at the cortico-medullary junction are a transient population 
which express CD69 and remain responsive to CCL25. In the third stage of maturation, the 
DP thymocytes develop into single positive TCR αȕ+ CD4+ (T helper) or TCR αȕ+ CD8+ 
(Cytotoxic) medullary thymocytes based on the engagement either with peptide/MHC II or 
peptide/MHC I complex, respectively. Finally in the thymic medulla the single positive 
cells develop further during an additional 2 weeks before they are released to the 
circulation (Anderson & Perlmutter, 1995; Chen, 2004; Fu & Chen, 2004).  
Upon contact with antigen, naive CD4+ Th cells may differentiate further to Th1, Th2, 
Th17 and regulatory T cells (Pflanz et al., 2002; Ferretti et al., 2003; Mangan et al., 2006; 
Oboki et al., 2008). This process can be influenced by antigen concentration, costimulatory 
molecules and cytokines (figure 5.1) (Pflanz et al., 2002).  
Th1 differentiation is initiated by signaling via the TCR and signal transducer and activator 
of transcription- 1 (STAT-1) - associated cytokine receptors (Anderson et al., 2003). 
STAT-1 signaling upregulates the transcription factor T-bet which stimulates the inducible 
chain of the IL-12 receptor (IL-1βRȕβ) on developing Th1 cells (Anderson et al., 2003). 
As a consequence, IL-12 signaling starts through STAT-4, which leads to IFN-Ȗ 
production by mature Th1 cells (Pflanz et al., 2002). IFN-Ȗ can reinforce the whole process 
through a positive and negative feedback on naive T cells. IFN-Ȗ induces STAT1 signaling 
and T-bet expression in naive CD4+ T cells leading to upregulation of the IL-12 receptor 
and suppression of GATA binding protein-3 (GATA-3) (Pflanz et al., 2002). Th1 cells 
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secreting IFN-Ȗ stimulate the immune response to eradicate intracellular pathogens 
(Anderson et al., 2003). 
Th2 differentiation, on the other hand, is initiated by TCR signaling together with IL-4 
receptor signaling via STAT-6 which upregulates the expression of the transcription factor 
GATA-3, a main regulator of Th2 differentiation (Anderson et al., 2003; Sun & Pearce, 
2007). In addition, GATA-3 suppresses STAT-4 and the IL-1βRȕβ chain which are critical 
to Th1 differentiation, whilst IL-4 produced by mature Th2 cells upregulates GATA-3 via 
STAT-6 and therefore blocks IL-1βRȕβ expression. Thβ cells are characterized by 
secretion of IL-4, IL-5, and IL-13 and they are important in fighting extracellular 
pathogens (Anderson et al., 2003).  
Furthermore, the naive precursor T cells can also be differentiated into Th17 cells in the 
absence of IFN-Ȗ and IL-4, independently of the transcription factors STAT-1, T-bet, 
STAT-4 and STAT-6 (Ferretti et al., 2003). It has been shown that the differentiation of 
Th17 cells is induced by the T regulatory cytokine, transforming growth factor- ȕ (TGF-ȕ), 
together with proinflammatory cytokines e.g. IL-23 and IL-6 (Mangan et al., 2006).  TGF-
ȕ is able to upregulate IL-23R expression and therefore responsiveness to IL-23. IL-17 and 
IL-23 secreted by Th17 is important in the clearance of several micro-organisms such as 
Toxoplasma gondii (Kelly et al., 2005) and Pneumocystis carinii (Rudner et al., 2007). T 
regulatory cells will be discussed in the following section separately. 
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Figure 5.1: Adopted figure about T cell differentiation in human; naive T cells 
differentiate into Th1 cells in the presence of IL-12, Th2 in the presence of IL-4, Th17 in 
the presence of IL-6 and IL-23, Th3 (induced regulatory T cells) in the presence of TGF-ȕ 
and IL-2. The mechanism of differentiation to type 1 T regulatory cells (Tr1) is still 
unclear (Oboki et al., 2008).  
 
 
 
 
 
 
 
 
        Naive CD4 + T cell 
       Th1       Th2      Th17        Tr1   Th3 
(iTreg) 
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5.1.3: Regulatory T Cells: 
      Regulatory T cells have a crucial role in the immune system and any defect or impairment 
in their function can cause autoimmune diseases and atopy (Itoh et al., 1999). They are 
essential in the down regulation of T cell responses to self and foreign antigens, and the 
maintenance of T cell homeostasis  (Tung et al., 1987; Sakaguchi et al., 1995; Thunberg et 
al., 2007).  
It has been suggested that regulatory T cells (Tregs) have 2 major classes within CD4+ T 
cells including: 
1. Natural populations or naturally occurring regulatory T cells (nTregs) are 
generated in the thymus through high affinity recognition of self antigens and 
express the forkhead-box transcription factor (Foxp3). These are CD4+ T cells 
which express surface markers such as  IL-2 receptor-α (CD25), the cytotoxic 
T-lymphocyte antigen-4 (CTLA-4) and the glucocorticoid-induced tumor 
necrosis factor receptor (GITR) and may constitute 10% of mature CD4+ T cells 
in the thymus (Maillard & Snapper, 2007; Maynard et al., 2007; Lehner, 2008). 
The suppressive function of nTregs initiates with cell-cell contact and depends 
on IL-10 and TGF - (Sakaguchi, 2000).  
2. Induced regulatory T cells (iTregs) or adaptive regulatory T cells (aTregs) are 
activated in the periphery and their functions are partly cytokine dependent and 
include: 
i. Type 1 T regulatory cells (Tr1) which produce regulatory 
cytokines such as IL-10. Tr1 cells arise in the periphery and their 
functions are IL-10 dependent (Strauss et al., 2007a; Strauss et 
al., 2007b). 
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ii. Th3 cells which secrete TGF -, have a suppressive function and 
are able to transfer tolerance (Maillard & Snapper, 2007; 
Lehner, 2008). 
 
It has been suggested that repetitive stimulation of naïve CD4+ T cells in the presence of 
IL-10 helps in the generation of Tr1 cells in vitro (Groux et al., 1997; Strauss et al., 
2007b). IL-10 is an anti-inflammatory cytokine that inhibits macrophages and DCs 
resulting in the inhibition of Th1 cell-mediated immunity. It also influence Th2 cells and 
inhibit cytokine production together with the down-regulation of eosinophil function, 
reduction of cytokine release by mast cells and suppression of IL-5 production by resting 
Th0 cells (Moore et al., 2001). 
TGF  secreted by Th3 cells, is also an immuno- suppressive cytokine which also helps in 
IgA production (Chen et al., 1994). Recent investigations on CD4+ CD57+ Germinal 
Centre (GC) T cells have revealed this subset may be a novel type of regulatory cell which 
suppresses effecter cells through cell-cell contact and by the secretion of cytokines 
including IL-10 and TGF-(Marinova, Han & Zheng, 2007). 
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5.1.4: B cell Activation: 
B cells may be activated by 2 different routes depending on the biochemical nature of the 
antigens that stimulate the responses (Jenkins et al., 2001; Lindroth et al., 2004; 
Obukhanych & Nussenzweig, 2006). These are: 
 Thymus dependent (TD) immune responses 
 Thymus independent (TI) immune responses 
 
5.1.4.1: Thymus Dependent Antigens: 
TD antigens are protein-based antigens and presented on MHC class II for recognition by 
Th cells (de Vinuesa et al., 2000; Obukhanych & Nussenzweig, 2006). After uptake of 
antigen by APC, class II MHC molecules are loaded and the MHC/peptide complexes are 
transported to the surface of the APC. The additional involvement of co-stimulatory 
molecules is required to promote the interaction between the DC and T cells (Caux, Liu & 
Banchereau, 1995; Hodgkin & Basten, 1995; Chung et al., 2003). TCR on Th cells interact 
with the MHC/peptide complexes resulting in Th cell activation. Activated Th cells will 
then produce cytokines such as IL-4, IL-5, IL-10 and IL-13 after interaction with B cells 
(Jenkins et al., 2001). As a result B cells start dividing and differentiate into plasma cells 
that secrete antibodies. Class switching for the immunoglubolin (Ig) isotypes is an antigen 
and T cell dependent process which involves class-switch recombination (CSR) and 
somatic hypermutation (SHM) as described previously in details in section 4.1.1.iii (Imai 
et al., 2003). In this type of response memory cells derived from B cells have proliferated 
and undergone affinity maturation in germinal centres (Armitage & Alderson, 1995; 
Jenkins et al., 2001; Obukhanych & Nussenzweig, 2006).  
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5.1.4.2: Thymus Independent Antigens: 
TI antigens are divided into 2 types: type 1 and type 2 (Cario et al., 2000; Obukhanych & 
Nussenzweig, 2006).  
Type I – TI (TI-1) antigens such as bacterial LPS are mitogenic stimuli which lead to 
polyclonal B cell activation via Toll-like receptors- 4 (TLR-4, as a transmembrane co-
receptors to CD14)  (Cario et al., 2000; Obukhanych & Nussenzweig, 2006). LPS signals 
via TLRs leading to NF- B activation (Cario et al., 2000). 
Type II – TI (TI-2) antigens are long polymers with repeating units such as bacterial cell 
wall polysaccharides which have repeating polysaccharide units. These antigens engage B 
cells by cross-linking surface immunoglobulin receptors (Armitage & Alderson, 1995; 
Cario et al., 2000; Obukhanych & Nussenzweig, 2006).  
 In both types of T cell activation there is a little or no class switching from IgM (Lindroth 
et al., 2004), although IgG2 may be produced, however, memory cells are not generated 
(Hsu et al., 2006). The mechanisms which control the TI antibody responses are still 
unclear although there are some suggestions including the necessity of complement 
receptor engagement in specific targeting of polysaccharide antigens (Guinamard et al., 
2000). 
 
 
5.2: Aims: 
The aim of this section was to generate the mucin-specific T cell clones from pigeon 
fanciers and to identify the T cell phenotype, cytokine profile and the antigen and epitope 
specificity of these cells.  
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5.3: Results: 
5.3.1: Generation of Mucin Specific T cell Clones: 
5.3.1.1: Isolation of Peripheral Blood Mononuclear Cells:  
Peripheral blood mononuclear cells were harvested onto Lympho-Prep as previously 
described in section 3.13 (Figure 5.2).  
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Figure 5.2: Universal bottle containing the heparinised peripheral blood and Lympho-Prep 
after centrifugation.  
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5.3.1.2: Generating of EBV Transformed B cell lines: 
5.3.1.2.i: EBV/ Cyclosporin Transformed B cell lines: 
After incubating PBMC with B958 supernatant containing EBV and cyclosporin  
B cells become infected with EBV. Cyclosporin suppresses cytotoxic T cell and natural 
killer cell activities. Small colonies of transformed cells were seen after a few weeks 
(Figure 5.3) and after about one month the colonies were transferred to a small culture 
flask. Finally some of the cells were stored in liquid nitrogen for future use. 
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Figure 5.3: Colonies of EBV transformed B cells after one week of incubation in RF10 
and cyclosporin. 
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5.3.1.2.ii: EBV/ Polymyxin B Transformed B cells: 
2.5 – 5 x 106  freshly separated PBMC were placed in 1.6 ml of transformation medium 
and the EBV containing supernatant of B958 cell cultures in the ratio of 4:1 (0.4 ml).  1 ml 
of that mixture was placed into 2 wells and incubated for 4-7 days until visible B cell lines 
were established (Figure 5.4). Every 3-4 days 1 ml from each well was replaced with a 
fresh mixture of RF 10. After about 3-4 weeks the cells were transferred to small flask to 
grow up. 
In this method the B cell lines were established in the first week of incubation which was 
faster, more efficient than cyclosporine method.  
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Figure 5.4: Colonies of EBV transformed B cells after one week of incubation in 
transformation medium. 
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5.3.1.3: T cell cloning for Generation of Trypsinised Mucin Specific Clones:  
Dilution cloning is the method of choice for T cell cloning and in this method cells are 
diluted until there is only one cell in the inoculum’s volume. PBMC isolated from an 
asymptomatic pigeon fancier were stimulated with trypsinised mucin for one week. T cell 
cultures were then restimulated with trypsinised mucin and the autologous EBV 
transformed B cell line (feeder cells) was added. Cells were diluted to a concentration of 1 
cell/ β0 ȝl and aliquated into Terasaki plates (GBO, UK). T cell clones were expanded by 
repeated stimulation with antigen. The first colonies were seen after 2 weeks incubation in 
Terasaki plates and then they were transferred into 96 well culture plates (Figure 5.5, 5.6 
and 5.7). Finally, after 4-6 months there were enough cells to store in liquid nitrogen and 
for future experiments. 
A large number of T cell clones were contaminated with stereptomyces spp (Figure 5.8). 
Finally 21 T cell clones were generated using trypsinised mucin and were later tested for 
their antigen specificity. One non-specific clone was also generated using PHA to 
stimulate cells. 
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                                   Figure 5.5: The colonies after the first 2 weeks incubation 
 
 
 
 
                                            
 
Figure 5.6: Colonies after transferring to 96 well culture plate.  
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                              Figure 5.7: T cell clones in the 96 well culture plate. 
 
 
 
 
                                  
 
                               
                         Figure 5.8: stereptomyces infection of T cell clones.  
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5.3.2: Proliferation Assay: 
A dividing lymphocyte requires DNA synthesis thus by the addition of an exogenous 
source of nucleosides (3H-thymidine) lymphocytes will transport them into the cell. Cell 
proliferation can then be determined by the incorporation of the 3H-thymidine into the 
dividing cells. Results are defined as stimulation index (SI), whereby the ratio of counts 
per minute of radioactivity in stimulated cells is divided by the counts per minute for 
unstimulated cells. In this study a SI of more than 3 was considered to be specific.  
Controls for these experiments were IL-2 and PHA which non-specifically stimulate T 
cells (Lord et al., 2000; Pearson et al., 2001).  IL-2 signals through a receptor complex 
consisting of IL-2Rα (CD25), IL-2Rȕ (CD122), and Ȗ chain and promotes proliferative 
signalling which is dependent to tyrosine kinase JAK3 and mediated by STAT-5 (Lord et 
al., 2000). PHA is a mitogen acting as a polyclonal T cell activator which triggers signal 
transduction pathway involving mitogen-activated protein kinase which results in mitosis 
(Pearson et al., 2001). 
The SI for the 21 clones generated after stimulation with trypsinised mucin and with the 
controls is shown in table 5.1. 
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T cell clones 
Day 4 
IL2  
(20ng/ml) 
 
 
PHA  
(10g/ml) 
 
 
TM 
(200g/ml) 
 
 
TM  
(50g/ml) 
 
 
TM 
 (10g/ml) 
 
 
01 
02 
03 
04 
05 
06 
10 
13 
14 
15 
16 
17 
18 
20 
21 
22 
23 
25 
30 
36 
42 
Control 
feeder cells 
37 
43 
51 
31 
20 
15 
50 
19 
8 
45 
12 
28 
12 
25 
20 
45 
20 
72 
23 
85 
28 
32 
negative 
 
29 
17 
42 
27 
10 
14 
49 
28 
5 
13 
10 
39 
8 
11 
21 
43 
27 
11 
36 
39 
8 
33 
2 
3.3 
2.9 
negative 
6.1 
2 
1.8 
4 
2.7 
1.7 
1.2 
1.8 
5 
5.6 
4.1 
3.2 
4.6 
5.1 
1.3 
4.2 
negative 
3 
negative 
negative 
2.6 
2.4 
1.25 
2.3 
1.4 
1.5 
3.3 
2.4 
1.2 
1.1 
2.1 
3.7 
3.5 
2.7 
2.1 
3.5 
3.1 
1.3 
3.7 
1.1 
3.5 
negative 
negative 
3.1 
3.1 
2.1 
3.8 
2.1 
2.6 
4 
2.7 
1.4 
1.4 
2.1 
4 
2.6 
2.1 
2.6 
3.8 
3.2 
1.7 
1.8 
1.3 
3 
1.1 
1.3 
 
Table 5.1: Stimulation Index (SI) of different T cell clones stimulated with different 
concentrations of t mucin. SI ≥ γ is shown in bold format. 
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The SI of T cell clones following stimulation with IL-2 ranged at 8 – 85 with a median of 
28. On the other hand, SI after stimulation with PHA ranged at 5 – 49 with a median of 21. 
Feeder cells did not show any response with IL-2, PHA and t mucin as expected. 8 
trypsinised specific T cell clones including 01, 02, 04, 10, 17, 22, 23 and 4β had SI ≥ γ 
with trypsinised mucin at 10ȝg/ml whilst 4 t mucin clones including 1κ, β0, β1 and γ0 only 
proliferated at very high levels of trypsinised mucin. Of these 12 clones only clones 04 and 
42 adapted to grow well in RPMI. 
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5.3.3: Cytokine Profile: 
T mucin specific and non-specific T cell clones were tested for their ability to produce 
cytokines in response to the non-specific stimulators (Ionomycin and PMA). Ionomycin is 
produced by bacterium Streptomyces conglobatus and increases the intracellular level of 
calcium, stimulating the intracellular production of the cytokines (Morgan & Jacob, 1994). 
PMA is a tumour promoter, activating the signal transduction enzyme protein kinase c 
(PKC) which stimulates macrophage functions including phagocytosis and the secretion of 
cytokines (Basta et al., 2001). 
2 x 105 of each T cell clone was incubated with and without the stimulators (Ionomycin 
and PMA) in triplicate at 37˚ C for 1, 2, 3, 4 or 5 days and the supernatant was collected. 
Results are shown in table 5.2 and t mucin specific clones are underlined.  
The detectable limit of each cytokine ELISA was as follows: 
IFN : 68.3 pg/ml, IL-2 and IL-4: 15.6 pg/ml, and IL-5, IL-6 and IL-10: 39 pg/ml.  
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Cytokines DAY Clone 01 Clone 04 Clone 09 Clone 11 Clone 13 
IFN (pg/ml) 1 
2 
3 
4 
6 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
544 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
544 
544 
2184 
<68.3 
<68.3 
600 
544 
<68.3 
IL2 (pg/ml) 1 
2 
3 
4 
6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
120.8 
IL4 (pg/ml) 1 
2 
3 
4 
6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
IL5 (pg/ml) 1 
2 
3 
4 
6 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
IL6 (pg/ml) 1 
2 
3 
4 
6 
<39 
<39 
<39 
156 
<39 
<39 
<39 
<39 
156 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
696 
IL10 (pg/ml) 1 
2 
3 
4 
6 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
94.8 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
 
Table 5.2:  The cytokine levels produced by different clones on different days of 
incubation period incubating with the stimulators (Ionomycin, PMA). Underlined clones 
are mucin-specific clones. The < values are below the detectable limit of the ELISA. 
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Cytokines DAY Clone 14 Clone 15 Clone 16 Clone 18 Clone 20 
IFN (pg/ml) 1 
2 
3 
4 
6 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
3352 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
IL2 (pg/ml) 1 
2 
3 
4 
6 
<15.6 
46 
<15.6 
<15.6 
167 
<15.6 
<15.6 
62 
<15.6 
852 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
135 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
IL4 (pg/ml) 1 
2 
3 
4 
6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
IL5 (pg/ml) 1 
2 
3 
4 
6 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
1094 
<39 
1094 
1113 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
IL6 (pg/ml) 1 
2 
3 
4 
6 
<39 
<39 
<39 
<39 
732 
78 
312 
558 
<39 
746 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
566 
IL10 (pg/ml) 1 
2 
3 
4 
6 
<39 
81 
<39 
93.6 
<39 
476.4 
<39 
<39 
94.8 
533.2 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
80 
<39 
<39 
<39 
<39 
<39 
<39 
 
Table 5.2:  Continued. 
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Cytokines DAY Clone 22 Feeder cells 
IFN (pg/ml) 1 
2 
3 
4 
6 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
<68.3 
IL2 (pg/ml) 1 
2 
3 
4 
6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
IL4 (pg/ml) 1 
2 
3 
4 
6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
<15.6 
IL5 (pg/ml) 1 
2 
3 
4 
6 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
IL6 (pg/ml) 1 
2 
3 
4 
6 
<39 
<39 
<39 
<39 
558 
<39 
<39 
<39 
<39 
586 
IL10 (pg/ml) 1 
2 
3 
4 
6 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
<39 
 
Table 5.2:  Continued. 
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Most previous studies have determined the cytokine profiles of the cells on single day 
(Gianfrani et al., 2006; Laughlin et al., 2007; Spaapen et al., 2007; Wolfl et al., 2007), 
whilst in this study the supernatant of T cell clones were collected after one to six days 
incubation in order to investigate whether there is a pattern in the production of cytokines 
by different clones. Clone 04 produced different cytokines in a high level only on day 4 of 
incubation, however, other T cell clones secreted different cytokines on different days.  
Among mucin specific T cell clones, clone 02, 10, 17, 21, 23, 30 and 42 also did not have 
cytokine study due to difficulty in T cell culture and occasional contaminations. 
The results showed that IFN- was produced in a significant level by clone 11 (on day 3, 4 
and 6), clone13 (on day 3 and 4), clone 04 (on day 4) and clone 15 (on day 6). IL-2 was 
produced significantly by clone 13, 14, 15 and 18 (on day 6), whilst clone 15 also secreted 
IL-2 on day 3. Clone 16 was the only clone that secreted IL-5 in significant amounts on 
day 1, 3 and 4. Although IL-6 was produced by the Feeder cells on day 6, the levels of IL-6 
produced by clone 13, 14 and 15 (on day 6) were higher. However, clone 15 (on day 1, 2 
and 3) and clones 01 and 04 (on day 4) also secreted significant amount of IL-6. In 
addition, IL-10 was secreted significantly by clone 15 (on day 1, 4 and 6), clone 14 (on day 
2 and 4) and clone 04 and 18 (on day 4). A summary of results is shown in table 5.3. 
Clones 11 and 13 therefore appear to be Th1 cells, whilst clones 14 and 16 are Th2 cells. 
On the other hand, clone 15 and 04 were capable of secreting IFN- , IL-2, IL-6 and IL-10 
and therefore look like Th0 cells, whilst clone 18 seems to be a regulatory T cell. Results 
show that a range of different mucin-specific T cell clones can be generated.  
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A 
Day 1 Clone   01     04      09     11      13      14      15     16      18       20      22        feeders 
IFN-γ 
IL-2 
IL-4 
IL-5 
IL-6 
IL-10 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         +      -          -         -              - 
               -        - 
           
-        -         -        -        +         -       -          -         -              - 
               -        - 
           
-        -         -        -        +         -       -          -         -              - 
 
B 
 Clone   01     04      09     11      13      14      15     16      18       20      22        feeders 
IFN-γ 
IL-2 
IL-4 
IL-5 
IL-6 
IL-10 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        +        -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         +        -       -          -         -              - 
               -        - 
           
-        -         -        +        -         -       -          -         -              - 
 
C 
Day 3 Clone   01     04      09     11      13      14      15     16      18       20      22        feeders 
IFN-γ 
IL-2 
IL-4 
IL-5 
IL-6 
IL-10 
               -        - 
           
-        +        +       -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         +         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         +      -          -         -              - 
               -        - 
           
-        -         -        -         +       -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
 
Table 5.3: Summary of the results of the cytokine profile of T cell clones and feeder cells; 
A: after one day of incubation, B: after 2 days of incubation, C: after 3 days of incubation, 
D: after 4 days of incubation, E: after 6 days of incubations. 
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D 
 
Day 4 Clone   01     04      09     11      13      14      15     16      18       20      22        feeders 
IFN-γ 
IL-2 
IL-4 
IL-5 
IL-6 
IL-10 
               -        +            -      +        +        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         +      -          -         -              - 
              +        +           -        -         -        -         -         -       -          -         -              - 
              -        +           -        -         -        +        +         -       +         -         -              - 
 
E 
Day 6 Clone   01     04      09     11      13      14      15     16      18       20      22        feeders 
IFN-γ 
IL-2 
IL-4 
IL-5 
IL-6 
IL-10 
               -        - 
           
-       +        -        -         +         -       -          -         -              - 
               -        - 
           
-        -       +        +         +         -      +         -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -         -        -         -         -       -          -         -              - 
               -        - 
           
-        -        +       +        +        -        -          +         +             + 
               -        - 
           
-        -         -        -        +        -        -          -         -              - 
 
 
Table 5.3: Continued. 
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5.3.4: Fluorescence- Activated Cell Sorting Analysis: 
 
Ten trypsinised mucin specific clones were tested for the cell surface expression of CD3, 
CD4 and CD8 by FACs analysis using FITC, PE- conjugated monoclonal antibodies. Data 
of clones 04, 18 and 42 are shown in figures 5.9, 5.10 and 5.11. Table 5.4 shows a 
summary of the results of FACs analysis. 
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Test tube 1: 
          
 
 
Test tube 2: 
   
 
     
 
Figure 5.9: FACs analysis results for clone 42; T cells are 98% CD3 + and of these 2% 
CD3+ CD4 +, 96% CD3+ CD4-, 52% CD3 + CD8+ and 46% CD3+ CD8-. 
 
 
CD4 
CD3 
CD8 
CD3 
213 
 
Test tube 1: 
 
     
 
Test tube 2: 
  
 
   
 
Figure 5.10: FACs analysis results for clone 04; T cells are 97% CD3 + and of these 1% 
CD3+ CD4 +, 96% CD3+ CD4-, 97% CD3 + CD8- and almost no CD3+ CD8+. It appears that 
clone 04 is a double negative T cell. 
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Test tube 1: 
   
    
 
 
Test tube 2: 
    
 
 
 
 
 
Figure 5.11: FACs analysis results for clone 18; T cells are 93% CD3 + and of these 45% 
CD3+ CD4 +, 48% CD3+ CD4-, 1% CD3 + CD8+ and 92% CD3+ CD8-.  
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Clone % CD3+ 
 
% CD3+ CD4+ 
 
% CD3+ CD8+ 
 
% CD3+ CD4- 
CD8- 
(double negative) 
 
01 
 
04 
 
17 
 
18 
 
20 
 
21 
 
22 
 
23 
 
30 
 
42 
 
89 
 
97 
 
98 
 
93 
 
73 
 
93 
 
96 
 
96 
 
97 
 
97 
 
 
18 
 
1 
 
2 
 
45 
 
26 
 
11 
 
4 
 
6 
 
23 
 
2 
 
4 
 
0 
 
28 
 
1 
 
2 
 
1 
 
0 
 
0 
 
1 
 
52 
 
67 
 
96 
 
70 
 
47 
 
45 
 
81 
 
92 
 
90 
 
74 
 
43 
 
Table 5.4: Summary of the results of FACs analysis for mucin-specific T cell clones.  
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Clones 04, 22 and 23 were probably true clones since 90 - 96% of the cells were CD3+ 
CD4- CD8- or double negative (DN). Clones 01, 18, 20, 21 and 30 were probably a mixture 
of CD3+ CD4+ and double negative T cells since a range of 11- 45% were CD3+ CD4+ and 
45 - 81% were double negative T cells and therefore not true clones. On the other hand, 
clone 17 and 42 were also a mixture of CD3+ CD8+ and double negative T cells since CD3+ 
CD8+ ranged 28 - 52% and double negative T cells ranged 43 – 70%.  
This is important as typically cloning technique have a tendency to produce Th1 and Th2 
CD4 + T cells (Jakobsen et al., 2006; Zuercher et al., 2006) and generating CD8+ or double 
negative T cells is rare. 
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5.4: Discussion:  
PFL progression is a complex process involving both the humoral and cellular pathways of 
the immune response (Kaltreider, 1993; Bourke et al., 2001; McSharry et al., 2002) and 
susceptibility to the causative antigens and host genetic factors are also involved in the 
pathogenesis of disease (Kurup, Zacharisen & Fink, 2006). The development of clinical 
symptoms 4-8 hours after antigen exposure and the presence of the precipitating antibodies 
in pigeon fanciers support the importance of type III hypersensitivity reactions in the 
development of disease. However, the lack of symptoms in some pigeon fanciers having 
precipitating antibodies and the absence of vasculitis in the lung biopsy of patients with HP 
suggest other mechanisms may be involved in the pathogenesis of disease (Kurup, 
Zacharisen & Fink, 2006). It has been suggested that T cells and inflammatory cytokines 
may have even greater roles to play in the pathogenesis of disease than immune complexes 
(Fink, Moore & Barboriak, 1975; Schuyler, Thigpen & Salvaggio, 1978; Curtis et al., 
1991; Ohkawa et al., 2001). One of the suggesting evidences is the predominance of 
neutrophils in BAL fluid in patients with acute HP which is followed by a lymphocytic 
alveolitis with an increase in CD8+ T cells and NK cells (Murayama et al., 1993; Kurup, 
Zacharisen & Fink, 2006) leading to a decrease in the ratio of CD4+ /CD8+ T cell to less 
than one. However, as the disease progresses to the chronic form, an increase in the ratio of 
CD4+ /CD8+  T cell is seen (Irifune et al., 2003; Kurup, Zacharisen & Fink, 2006; Barrera 
et al., 2008). It has also been suggested that pulmonary macrophages also play an 
important role in the pathogenesis of disease. They secrete IL-8, a chemotactic factor for 
neutrophils, and macrophage inflammatory protein (MIP)-1α which is a chemotactic factor 
for  CD8+ T cells and promotes further polarisation of CD4+ T cells to Th1 cells (Denis, 
1995; Kurup, Zacharisen & Fink, 2006). Activated macrophages also secrete IL-1 and 
TNF-α which can stimulate Th1 cells to produce IFN-Ȗ which is essential for the 
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development of disease (Gudmundsson & Hunninghake, 1997; Nance et al., 2005; 
Matsuno et al., 2007). Further evidence supporting the importance of Th1 cytokines 
includes the report of transferring experimental HP in mice by Th1 CD4+ cell lines 
(Schuyler & Cormier, 1997). Furthermore, NK cells present in BAL and lung tissue of 
patients with acute HP appear to provide a protective effect (Ratjen et al., 2003).  
On the other hand, it has previously been shown that anti-mucin IgG1 was higher in 
symptomatic fanciers and it was suggested that this response has an important role in the 
development of disease (Baldwin et al., 2000b). IgG1 is considered to be a T-dependent 
antibody and thus T cell responses to mucin may be important in the development of 
disease.  
Therefore this study aimed to understand the role of T cells in the pathogenesis of disease 
and was designed to generate mucin-specific T cell clones from pigeon fanciers and to 
identify the T cell phenotype, cytokine profile and the antigen and epitope specificity of 
these cells. This is the first study where T cell clones have been generated to the fully 
glycosylated mucin molecule. In this study 22 T cell clones were generated from an 
asymptomatic fancier from group B and 12 of these clones were found to be specific for t 
mucin. The proliferation assay showed that SI of T cell clones following incubation with 
IL-2 or PHA was very high (ranged at 5-85) in camparison to the SI of mucin-specific T 
cell clones after incubation with TM (SI: 3-6). These results suggest although TM is a 
specific antigen which can stimulate the pigeon fancier’s T cell clones to proliferate, it is 
not as strong as non-specific stimulators such as IL-2 or PHA. 
Previous studies reported a mixed Th1/Th2 systemic responses following contact with 
polysaccharide antigens such as pneumococcal polysaccharide (Jakobsen et al., 2006) and 
a Th1 response after immunization with O-polysaccharide-toxin A of P. Aeruginosa  
(Zuercher et al., 2006). A regulatory T cell expansion has also been described following 
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stimulation with ManLAM of Mycobacterium Tuberculosis (Garg et al., 2008) whilst a 
Th0 cytokine response develops after stimulation with Streptococcus pneumonia capsular 
polysaccharide (Mawas, Feavers & Corbel, 2000). Polysaccharide antigens induce 
endocytosis and delivery into endosomal pathway and it has been shown that mannosylated 
antigens enhance antigen-uptake and MHC class II antigen presentation by DCs (Tan et 
al., 1997). Mannan- conjugated tumour antigen mucin1 (MUC1) has also been shown to 
induce protective Th1/cytotoxic responses; however the Th2/antibody responses showed 
no protection (Apostolopoulos, Pietersz & McKenzie, 1996; Apostolopoulos et al., 2000). 
Furthermore, following contact with polysaccharide antigens APCs are activated via Toll-
like receptors (TLRs) resulting in activation of NF-țB (transcription factor) which is most 
often associated with the induction of Th1 responses (Thomas et al., 2005). 
Interestingly among the mucin-specific clones generated in this study, clones 04 and 18 
produced cytokines which had a Th0 and Treg profile. This shows that regulatory T cells 
can be generated from peripheral T cells of an asymptomatic pigeon fancier after 
stimulation with TM in vitro and these cells may play an important role in the prevention 
of disease in asymptomatic pigeon fanciers. Previously it has also been suggested that 
regulatory T cells are involved in the regulation of disease (Calvert et al., 1999) and 
regulatory cytokines such as IL-10 may reduce inflammatory responses in the lung (Groux 
et al., 1997; Schuyler et al., 1997). Kim et al also reported that glucocorticoid-induced 
TNF receptor (GITR) on NKT cells may provide costimulatory signals to CD4+CD25- and 
CD4+CD25+ T cells which modulate immune responses in HP and contributes to the 
regulation of disease (Kim et al., 2006).  
Unfortunately cytokine study was not done for t mucin-specific T cell clones 02, 10, 17, 
21, 23, 30 and 42 due to the contamination of the culture plate.  
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Furthermore, t mucin-specific T cell clones were analyzed by FACs. The results showed 
clones 04, 22 and 23 were probably true clones since 90 - 96% of the cells were CD4- CD8- 
double negative. The rest of the clones were a mixture of CD3+ CD4+ or CD3+ CD8+ and 
DN T cells. Recent studies about DN T cells indicates that they are the second most 
important sources of IFN-Ȗ in patients with infection such as cutaneous leishmaniasis and 
also have an immunoregulatory role to modulate the inflammation (Chen et al., 2004; 
Antonelli et al., 2006). 75% of DN T cells in healthy individuals may express TCR-Ȗį and 
the balance between the αȕ- DN T cells expressing proinflammatory cytokines with the Ȗį- 
DN T cells producing regulatory cytokines is important in formation of an effective 
cellular response (Antonelli et al., 2006). DN T cells may also have an antitumor role and 
are effective in prevention of GvHD by inhibiting donor T-cell activation (Young et al., 
2003). The FACs results suggest that the presence of DN T cells may be one of the 
mechanisms that T cells directly conduct to regulate the disease. These cells also may be a 
source of IFN-Ȗ as the cytokine profile of clone 04 showed high IFN-Ȗ production in day 4 
of incubation.  
Unfortunately in this study, the type of TCR on mucin-specific T cell clones was not 
studied due to contamination of the cultures. However, this data does indicate that t mucin-
specific T cell clones with double negative phenotype may have a crucial role in immune 
regulation in antibody positive asymptomatic fanciers (group B) and can be one of the 
reasons of why these individuals do not have any symptoms in spite of having high 
antibody responses.   
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6: Discussion: 
 
PFL is a complex disease involving both arms of the immune response (Kaltreider, 1993; 
Bourke et al., 2001; McSharry et al., 2002). Improvements in our understanding of the 
immunopathogenesis of disease depend on advances in our knowledge of the role of 
different cell types, cytokine profile and affinity of specific antibodies that contribute to 
protective immunity. In spite of the large number of individuals who have contact with the 
causative antigens, the prevalence and incidence of HP seems to be less than 10% in the 
population at risk (Bourke et al., 2003; Fink et al., 2005). Therefore, there may be a 
number of different defense mechanisms in asymptomatic pigeon fanciers such as i) low 
avidity antibodies against pigeon antigens and  ii) generation of double negative T cells 
which can prevent the development of symptoms. Therefore, this study was designed to 
investigate the importance of antibody and T cell responses in pigeon fanciers’ lung. 
6 pigeon antigens; PIM, TM, PS, PDO, PDF and PIS have been used to study the antibody 
responses in pigeon fanciers. This is the first time that TM, PDO, PDF and PIS have been 
studied in this way.  
In contrast to the majority of previous studies which investigated antibody responses to 
pigeon serum (Fink, Tebo & Barboriak, 1969; Rodriguez de Castro et al., 1993; Rodrigo et 
al., 2000; Aguilar Leon, Novelo Retana & Martinez-Cordero, 2003; McSharry et al., 
2006a; McSharry et al., 2006b), this study suggested that TM, PDO, PDF and PIS, which 
all contain the highly glycosylated mucin molecule, were more effective stimulators of B 
cells in producing antibodies as compared to PS (P ≤ 0.001).  
Previous studies have shown that anti-mucin IgG1 titres were significantly higher in 
symptomatic fanciers (Baldwin et al., 1998c; Baldwin et al., 2000b) as compared to 
asymptomatic fanciers. These results were not replicated in this study and this may be due 
to the fact that IgG1 may not be important in pathogenesis of the disease. The other factors 
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which can also be responsible are the size and method of classification of study 
populations, and the collection of serum samples at different times of the year. Further 
studies as to the role of mucin and IgG1 responses to mucin are urgently needed to clarify 
whether antibody responses to this antigen is important in the development of disease. 
Surprisingly, in this study group B had higher antibody titres against pigeon antigens than 
group A. This could be due to the different classification of the study group, for instance 
classifying all symptomatic fanciers regardless of their antibody levels in one group. Also 
this result together with the fact that some symptomatic fanciers have low levels of these 
specific antibodies may suggest that the magnitude of the antibody responses cannot 
determine the development of the disease.  
IgG2 titres against all tested pigeon antigens were higher than IgG1 in this study. As IgG2 
is generally a TI antibody and associated with responses to carbohydrate antigens 
(Hammarstrom & Smith, 1986; Obukhanych & Nussenzweig, 2006), it is tempting to 
suggest that these antibodies may be specific for carbohydrate parts of mucin or other 
highly glycosylated molecules.  
The biological activity and the strength of immune complexes depend on the IgG isotype 
response, the functional affinity of each isotype and the biochemical nature of related 
antigens (Baldwin et al., 1998c; 1999). In this study group A had higher avidity index for 
IgG2 against most pigeon antigens with significant differences for IgG2 against PDO and 
PDF (P=0.002 and P≤0.001, respectively). These results suggest the presence of high 
levels of IgG2 with high avidity against pigeon antigens containing mucin may influence 
the development of PFL in group A since they may have immune complexes with stronger 
composition which can be harder to remove. In addition antibodies with higher avidity will 
generally be more efficient in the activation of complement by the classical and alternative 
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pathway, generation of large amount of C3a and C5a and stimulating the respiratory burst 
of neutrophils resulting in large amount of damage to lung tissue (Alves et al., 2004).  
Other factors such as the functional capacity of FcȖR may also be important in the 
clearance of immune complexes and amino acid substitutions within the extracellular 
domains of FcȖR may influence the binding avidity of IgG subclasses (Zuniga et al., 
2003). This may be an important area of research in the future. 
The avidity of anti-PDO antibodies in some of the pigeon fanciers in groups A and B were 
determined by ITC. This is the first time that ITC has been used to determine antibody 
avidity in a clinical situation using whole serum as a source of antibodies. Group A had 
significantly higher ΔH than group B (P=0.044) when ΔH ≥ γβ was used as a cut off point.  
This confirms the results of the avidity index of mucin-specific antibodies determined by 
inhibition ELISA and also emphasizes the importance of antibody avidity in the 
pathogenesis of PFδ. It also indicates that the measurement of ΔH by ITC may be a 
practical, quick and novel test as part of routine investigations of PFL in clinics. Although 
it does not have a high sensitivity and specificity (80% and 63%, respectively), further 
studies on a larger group of fanciers may help to further develop this test. Furthermore, the 
potential use of ITC in other clinical situations such as immune complex mediated diseases 
should be emphasised.  
Furthermore, T cells and inflammatory cytokines may have even greater roles to play in 
the pathogenesis of disease than immune complexes (Fink, Moore & Barboriak, 1975; 
Schuyler, Thigpen & Salvaggio, 1978; Curtis et al., 1991; Ohkawa et al., 2001).  
In this study 22 T cell clones were generated from an asymptomatic fancier from group B 
in which 12 clones were specific for TM. The cytokine profile of these clones showed a 
range of different T cell subsets can be generated following stimulation with 
polysaccharide antigen (TM). Interestingly, clone 04 and 18 were a Th0 and a Treg cell. 
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This is the first time that the cytokine profile of mucin-specific T cell clones has been 
studied and it shows that regulatory T cells can be generated from peripheral T cells of an 
asymptomatic pigeon fancier after stimulation with TM and these cells may play an 
important role in the prevention of disease in asymptomatic pigeon fanciers. 
The phenotypes of t mucin-specific T cell clones were analyzed by FACs and these clones 
were shown to be DN T cells. This generation of DN T cells to t mucin is interesting since 
DN T cells have an immunoregulatory role and modulate inflammatory immune responses 
and they are the second most important sources of IFN-Ȗ (Antonelli et al., 2006). The 
cytokine profile of clone 04 showed a high level of IFN-Ȗ production on day 4. This data 
indicates that t mucin-specific T cell clones with a double negative phenotype may also 
have a crucial role in direct immune regulation in antibody positive asymptomatic fanciers 
(group B) and may explain why these individuals do not have symptoms in spite of having 
high antibody responses.  
In conclusion, the immunopathogenesis of PFL is complicated and involves both humoral 
and cell defense mechanisms. The data showed the presence of low avidity specific 
antibodies together with double negative mucin-specific T cells may be crucial in the 
prevention of disease development in asymptomatic pigeon fanciers in group B.  
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7: Future Work: 
Further studies may be conducted in order to investigate the role of following aspects in 
the development of PFL:  
1. To study the affinity of specific antibodies in PFL by ITC in more details 
and bigger study populations in order to optimize the method and to 
establish an easy and quick diagnostic test with high sensitivity and 
specificity.   
2. To study FcȖR polymorphisms and their roles in binding avidity of IgG 
subclasses in PFL. 
3. To study TCR properties of mucin-specific T cell clones and their role in 
the pathogenesis of PFL. 
4. To study the role of antigen presenting cells in presentation of mucin to T 
cells. 
5. To study the role of regulatory T cells in the pathogenesis of PFL. 
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Appendix I: List of Suppliers 
 
 Sigma Aldrich Company Ltd: Gillingham, UK 
 Pharmingen, BD Bioscience: Oxford, UK 
 Maxisorp, Nunc: Roskilde, Denmark 
 Dako cytomation: Glostrup, Denmark 
 Nycomed Pharma: Asker, Norway 
 Invitrogen, GIBCO: Paisley, UK 
 MicroCal LLC: Milton Keyne, UK 
 BDH: Bath, UK 
 Bio-Rad: Hempstead, UK 
 MicroCal LLC: Milton Keyne, UK 
 MDS Nordion: Ottawa, Canada  
 Packard Instrument Company: Meriden, CT, USA 
 NIBSC: Hertfordshire, UK 
 Bio-TEk Instruments: Vermont, USA 
 Fisher Scientific: Leicestershire, UK 
 Sandoz: Holzkirchen, Germany 
  Greiner Bio-One Co. Ltd (GBO): Business Park, Stone house, UK 
  Becton Dickinson UK Ltd:  Abingdon, UK 
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Appendix II: Buffers 
 
 Phosphate Buffer Saline PH =7.0 (PBS) 
NaCL: 8.17 g, Na2HPO4: 1.21 g, NaH2PO4.H2O: 0.22 g, Distilled H2O (dH2O): 1 
Litre. 
 PBS-Tween (PBS-T) for washing for ELISA 
PBS / 0.05% Tween 20 (PBS: 1 Litre, Tween: 0.5 ml). 
 Coating Buffer for ELISA 
0.1 M Sodium Phosphate, PH=7.0 (Na2HPO4: 8.7 g, NaH2PO4.H2O: 5.37 g, d H2O: 
1 Litre). 
 PBS-Tween- BSA (PBS-T-BSA) for blocking for ELISA 
PBS / 1% Bovine Serum Albumin (BSA) / 0.05% Tween 20 (PBS: 1 Litre, BSA: 
10 g, Tween: 0.5 ml). 
 Citrate Phosphate Buffer for ELISA 
Citric Acid: 5.1 g, Na2HPO4: 7.31 g, d H2O: 1 Litre. 
 Substrate Solution for ELISA 
Citrate Phosphate: 25 ml, Orthophenylenediamine (OPD): 400 l, H2O2: 25 l 
 EDTA PH=8.0 
Na2EDTA: 186.1 g, d H2O: 500 ml. 
Dissolve in approximately 400 ml d H2O, adjust PH to 8.0 with 10 N NaOH and 
make up to 1 litre final volume with d H2O. 
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Appendix III: Serial Dilution of Ammonium Thiocyanate 
 
 10 M Ammonium Thiocyanate: 10 ml PBS + 7.61 g Ammonium Thiocyanate 
 9 M Ammonium Thiocyanate: 10 ml PBS + 6.85 g Ammonium Thiocyanate 
 8 M Ammonium Thiocyanate: 10 ml PBS + 6 g Ammonium Thiocyanate 
 7 M Ammonium Thiocyanate: 10 ml PBS + 5.32 g Ammonium Thiocyanate 
 6 M Ammonium Thiocyanate: 10 ml PBS + 4.56 g Ammonium Thiocyanate 
 5 M Ammonium Thiocyanate: 10 ml PBS + 3.8 g Ammonium Thiocyanate 
 4 M Ammonium Thiocyanate: 10 ml PBS + 3 g Ammonium Thiocyanate 
 3 M Ammonium Thiocyanate: 10 ml PBS + 2.28 g Ammonium Thiocyanate 
 2 M Ammonium Thiocyanate: 10 ml PBS + 1.52 g Ammonium Thiocyanate 
 1 M Ammonium Thiocyanate: 10 ml PBS + 0.76 g Ammonium Thiocyanate  
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Appendix IV: Dilutions of Anti-Cytokine Antibodies for ELISA 
 
Anti-cytokine antibodies (Pharminogen, Oxford,UK) were diluted in coating buffer 
appropriately as below: 
 
IL-2 IL-4 IL-5 IL-6 IL-10 IFN- TNF- GM-CSF TGF- 
1/200 1/500 1/1000 1/4000 1/1000 1/500 1/1000 1/500 1/800 
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Appendix V: Final Concentration of Top Standards for ELISA 
 
Top standards (NIBSC, Hertfordshire, UK) were diluted in PBS-T-BSA and final 
concentration of each top standard is as following: 
 IL-2: 2000 pg/ml (stock concentration: 10 ng/ml) 
 IL-4: 2000 pg/ml (stock concentration: 20 ng/ml) 
 IL-5: 5000 pg/ml (stock concentration: 50 ng/ml) 
 IL-6: 5000 pg/ml (stock concentration: 200 ng/ml) 
 IL-10: 5000 pg/ml (stock concentration: 100 ng/ml) 
 IFN-: 8750 pg/ml (stock concentration: 175 ng/ml) 
 TNF-: 10000 pg/ml (stock concentration: 100 ng/ml) 
 GM-CSF: 10000 pg/ml (stock concentration: 10000 ng/ml) 
 TGF-: 250000 pg/ml (stock concentration: 5000 ng/ml) 
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Appendix VI: Dilutions of Biotinylated Anti-Cytokine Antibodies for   
ELISA 
 
Biotinylated anti-cytokine antibodies (Pharmingen, Oxford ,UK) were diluted in PBS-T-
BSA appropriately as below: 
 
IL-2 IL-4 IL-5 IL-6 IL-10 IFN- TNF- GM-CSF TGF- 
1/400 1/1000 1/1000 1/4000 1/1000 1/2000 1/1000 1/200 1/400 
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Glossary: 
 
  H: Heat generated by the antigen-antibody interactions 
 3H-thymidine: Tritiated thymidine  
 ADCC: Antibody-dependent cell mediated cytotoxicity 
 AI: Avidity index 
 AID: Activation-induced cytidine deaminase  
 APCs: Antigen presenting cells 
 AT: Ammonium thiocyanate 
 aTregs: Adaptive regulatory T cells  
 B: Factor B 
 BAL: Bronchoalveolar lavage 
 BCG: Bacille Calmette-Guerin 
 BDP: Beclomethasone dipropionate  
 BSA: Bovine serum albumin 
 CD40L or CD154: CD40 ligand  
 CDR: Complementary determining regions 
 CH: Constant domain on heavy chain 
 CHO: Carbohydrate 
 CIE: Counter current immunoelectrophoresis 
 CRP: Complement regulatory proteins 
 CsCL: Caesium chloride 
 CSR: Class-switch recombination 
 CTLA-4: Cytotoxic T-lymphocyte antigen-4 
 CXCL12 or SDF-I : Stormal-derived factor I 
 D: Factor D 
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 DAF: Decay accelerating factor 
 DCs: Dendritic cells 
 DMSO: Dimethyl Sulfoxide 
 DN T cell: Double negative T cell 
 DP T cell : Double positive T cell 
 DP: Differential power 
 EAA: Extrinsic allergic alveolitis   
 EBV: Epstein Barr Virus 
 ELLA: Enzyme-linked lectin assay  
 Fab: Antigen binding fragment 
 FACs: Fluorescence- Activated Cell Sorting 
 Fc: Crystalizable fragment 
 FCRs: FC receptors 
 FCS: Foetal calf serum 
 FcȖR μ IgG Fc receptors 
 FITC:  Fluorescein Isothiocyanate 
 Foxp3: Forkhead-box transcription factor 
 Fuc: Fucose 
 Gal: Galactose 
 GalNAc: N-acetyl galactosamine 
 GATA-3: GATA binding protein-3 
 GBM: Glomerular basement membrane 
 GC: Germinal centre 
 GITR: Glucocorticoid-induced tumor necrosis factor receptor  
 GlcNAc: N-acetyl glucosamine 
 H chain: Heavy chain 
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 HDI: Hexamethylene diisocyate 
 HFA: Hydrofluoroalkane-134a  
 HLA: Human leukocyte antigen 
 HP: Hypersensitivity pneumonitis 
 HRCT scan: High resolution computed tomographic  scan 
 IC : Immune complexes 
 IFN-Ȗ: Interferon- Ȗ  
 Ig: Immunoglubolin 
 IL: Interleukin 
 IL-12R: IL-12 receptor 
 ITAM : Immunoreceptor tyrosine-based activation motif 
 ITC: Isothermal microcalorimetry 
 ITIM: Immunoreceptor tyrosine-based inhibition motif 
 JAKs: Janus-associated kinases  
 L chain: Light chain 
 LN2: Liquid nitrogen 
 LPS: Lipopolysaccharide 
 MAC: Membrane attack complex  
 MASP-1: MBL-associated serine protease-1 
 MASP-2: MBL-associated serine protease-2 
 MASPs: Mannan-binding-protein-associated serine proteases  
 MBL: mannose-binding lectin 
 MDI: Methyenediphenyl diisocyate 
 MIP-1α : Macrophage inflammatory protein -1α 
 MMPs: Matrix metalloproteinases 
 NF-țB μ Nuclear factor inducing kinases 
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 NGF: Nerve growth factor 
 NK: Natural killer 
 NKT cell: Natural killer T cell 
 NO: Nitric oxide 
 NPV: Negative predictive value 
 nTregs: Naturally occurring regulatory T cells 
 OD: Optical density units 
 P: Properdin 
 PAS: Periodic acid schiffs 
 PBMC: peripheral blood mononuclear cells 
 PDF: Fresh pigeon droppings 
 PDO: Old pigeon droppings 
 PE: Phycoerythrin 
 PFL: Pigeon fanciers’ lung 
 PHA: Phytohaemagglutinin 
 PIM: Pigeon intestinal mucin 
 PIS: Pigeon intestinal scrapings 
 PMA: Phorbol 12 Myristate 13- Acetate 
 PMSF: Phenyl methyl sulfonyl fluride 
 PPV: Positive predictive value 
 Pre-TCR: Pre- T cell receptor 
 PS: Pigeon serum 
 RAG: Recombination activation gene 
 RF: Rheumatoid factor 
 SD: Standard deviation 
 SHIP: SH2-containing inositol polyphosphate 59-phosphatase  
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 SHM: Somatic hypermutation 
 SI: Stimulation index  
 S-S: Disulfydryl bonds 
 STAT-1 : Signal transducer and activator of transcription- 1 
 STAT: Signal transducers and activators of transcription  
 TCR: T cell  receptor T cell receptor 
 TD antibody: T-dependent antibody 
 TDI: Toluene diisocyate 
 TGF -: Transforming growth factor- ȕ 
 Th cell : T helper cell 
 Th3, iTreg: Induced regulatory T cells 
 TI: T-independent  
 TIMP-3: Tissue inhibitors of metalloproteinases 3 
 TL CO: Transferring of carbon monoxide 
 TLR-4: Toll-like receptors- 4 
 TM, t mucin: Trypsinised mucin 
 TMA: Trimelitic anhydride 
 TNF-αμ Tumor necrosis factor-α 
 Tr1: Type 1 T regulatory cell 
 TRAFs: TNF receptor-associated factors  
 Treg: Regulatory T cells 
 UNG: Uracil DNA glycosylase 
 VH: Variable domain on heavy chain 
 VL: Variable domain on light chain 
 VP-ITC : One of the latest models of isothermal microcalorimetry 
 αμ Alpha 
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 α-β, γ NeuNAc μ α-2, 3 N-acetyl neuraminic acid 
 Ȗμ Gamma 
 įμ Delta 
 İμ Epsilon 
 ȝμ Mu 
 țμ Kappa 
 Ȝμ δambda 
 
